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ABSTRACT

CYTOKINE DYNAMICS, DIAGNOSIS AND TREATMENT OF NEUROINFLAMMATION
IN CHRONIC CONSTRICTION INJURY RAT MODEL

By
Kiran Vasudeva
July 2015

Dissertation supervised by Dr. John A. Pollock
Chronic neuropathic pain is a serious, worldwide health problem leading to life-long
treatment and the possibility of significant disability. In this study, neuropathic pain was
modeled using the chronic constriction injury (CCI) in rats. The CCI rats exhibited
hypersensitivity (typical neuropathic pain symptom) to mechanical stimulation of the affected
paw 11 days post-surgery, at a time when sham surgery animals did not. It is known that immune
cells play a role in the development of neuropathic pain and to further explore the relationship
between neuropathic pain and immune cells, we hypothesized that the infiltration of immune
cells into the affected sciatic nerve can be monitored in vivo by optical imaging. To test this
hypothesis, an intravenous injection of a novel perfluorocarbon (PFC) nanoemulsion developed
by J. M. Janjic (PharmD, PhD) and co-workers was used. Post-injection, the nanoemulsion is
endocytosed by inflammatory cells (e.g. monocytes and macrophages) in a CCI rat. The
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nanoemulsion carried two distinct imaging agents, a near-infrared (NIR) lipophilic fluorescence
reporter (DiR) and a 19F magnetic resonance imaging (MRI) tracer (PFC). This study showed
that in live rats, NIR fluorescence was concentrated in the area of the affected sciatic nerve.
Furthermore, the 19F MRI signal was observed in the affected sciatic nerve in the perfusion fixed
rats. Histological examination of the CCI sciatic nerve sections revealed significant infiltration
of CD68 positive macrophages. These results demonstrate that the infiltration of immune cells
into the sciatic nerve can be visualized in live animals using these methods. Using the same
strategy, a theranostic nanoemulsion containing an anti-inflammatory drug, celecoxib, along with
NIR dye and 19F tracer, was used for the targeted delivery of the drug into the inflammatory cells
at the site of injury while at the same time providing the ability to track inflammation. A single
intravenous injection of the nanoemulsion carrying a low dose of celecoxib (0.24 mg/kg), a
normally highly insoluble drug, appears to have provided a direct delivery of the drug into the
inflammatory cells. Single dose intravenous injection of the theranostic nanoemulsion resulted in
significant relief from the hypersensitivity behavior (mechanical allodynia) that persisted for at
least four days post-injection. These findings demonstrated that celecoxib-containing theranostic
nanoemulsion based therapy is an effective tool for the simultaneous tracking and treatment of
the neuroinflammation in a CCI rat model. Inflammation is known to be associated with
peripheral neuropathy, however the interplay among cytokines, chemokines and neurons is still
unclear. We hypothesized that the neuroinflammatory interaction can be defined by using a
computational modeling approach, based on the dynamics of the protein expression of various
inflammatory mediators in the sciatic nerve of the CCI rats. Using Dynamic Bayesian Network
inference, we identified Interleukin (IL)-18 as a central node associated with neuropathic pain in
the CCI rat model. Immunofluorescence supported a role for inflammasome activation and
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induction of IL-18 at the site of injury. Combined in-vivo and in-silico approaches may thus
highlight novel molecular targets associated with peripheral neuropathy that can be the target of
future theranostic nanoemulsion-based therapy.

vi

DEDICATION

Dedicated to my family..........

vii

ACKNOWLEDGEMENT
I consider myself fortunate to get the opportunity to work under the excellent mentorship of Dr.
John A. Pollock. I pay my sincere gratitude for his incessant encouragement, support and
guidance throughout my PhD studies. He is one of the rare individuals who can easily strike the
balance of intellect and humility and can provide an inspiring and positive environment at the
workplace. Dr. Pollock’s scientific vision and positive attitude have helped me enjoy my PhD
journey and complete this study successfully. Under his guidance, I learnt to stay focused, use
resources skillfully, work in a collaborative environment, troubleshoot, and learn scientificwriting along with many other attributes that would help me throughout my career. I am
sincerely thankful to him for giving me the chance to flourish and move forward to achieve my
career goals. His positive influence will stay with me forever.
I am very thankful to our collaborator and my committee member Dr. Jelena M. Janjic for
generously providing the nanoemulsions used in this study and for her excellent supervision,
constructive remarks and guidance throughout this study.
I want to express my gratitude to Dr. Benedict Kolber for his meticulous suggestions, guidance
and encouragement throughout this study. I thank Dr. Becky Morrow for providing suggestions
and thoughtful insights especially from the clinical perspective.
I would like to pay my sincere thanks to Dr. David Somers, Dr. Richard Clemente and Karl
Andersen for providing training to perform CCI surgery and mechanical allodynia testing on
rats.
I am thankful to Dr. Denise Capozzi, Ms. Denise Butler-Buccilli and Christine for their help in
the animal care facility. I am thankful to Dr. Matthew Kostek, Dr. David Johnson and Dr.
Rehana Leak for sharing equipment in their laboratories. My sincere thanks to Dr. Armando
Knopps for providing training to perform intracardiac perfusion fixation in rats.
I would like to thank all of my colleagues in the department for their delightful company, with
special thanks to Andrea, Muz and Sravan for being very helpful and supportive colleagues and
good friends. I want to thank Brandi, an undergraduate student in the lab, for all her help during
the experiments. My sincere thanks to Amanda, Harsha, Natasha, Sanket, Sumedha, Tara and
Uma for their joyful company during this journey. I would also like to thank Rebecca for her
help to proofread this document and for her delightful company.
I am very thankful to Duquesne University for providing me with the opportunity to work as a
teaching assistant. I pay my sincere thanks to the ‘Center for Teaching Excellence’ staff for
executing excellent workshops and retreats. I learnt a lot while teaching at Duquesne University.
Thank you for providing me with this experience.
Many thanks are due to all the faculty members and staff in the department for their help in
several ways. I would also like to acknowledge Pam, Judy, Michele and Heather for their help
with the office matters throughout this time.

viii

Lastly, I am incredibly blessed to have the love and support of my parents Mrs. Veena Vasudeva
and Mr. Madan Vasudeva, brother Mr. Ravi Vasudeva (Sunny) and my husband Dr. Pawan Puri.
They have been a source of inspiration and strength in my life.

ix

TABLE OF CONTENTS
Page
Abstract ..............................................................................................................................iv
Dedication………………………………………………………………………….…….vii
Acknowledgement ...........................................................................................................viii
List of Tables ....................................................................................................................xv
List of Figures ...................................................................................................................xvi
Chapter 1: INTRODUCTION…………………………………………..…….................1
1.1 Nociceptive, Inflammatory and Neuropathic Pain…………………………………...1
1.2 Why Use The Chronic Constriction Injury (CCI) Rat Model?…………………….....3
1.3 CCI Causes Wallerian Degeneration and Neuroinflammation…………………….....4
1.4 Inflammatory Mediators During CCI………………………………………………...6
1.5 Dual Mode Nanoemulsion…………………………………………………………...9
1.6 Theranostic Nanoemulsion…………………………………………………………..9
1.7 Inflammasome…………………………………………………………………..........9
1.8 Computational Modeling…………………………………………………………….10
1.9 Non-steroidal anti-inflammatory drugs (NSAIDs)………………………………….11
1.10 Specific Aims……………………………………………………………………...........14
Chapter 2: IMAGING NEUROINFLAMMATION IN VIVO IN A NEUROPATHIC
PAIN RAT MODEL WITH NEAR-INFRARED FLUORESCENCE AND 19F
MAGNETIC RESONANCE……………….....……………………………………...…15
Chapter 2 Attributions…….………………………………………………………..….….15
2.1. Introduction…………………………………………………………………………..16

x

2.2 Materials and Methods………………………………………………………………..19
2.2.1 Ethics Statement……………………………………………………….……………19
2.2.2. Chronic Constriction Injury………………………………………………………..19
2.2.3 Behavioral Testing………………………………………………………………….20
2.2.4 Dorsal Root Ganglia Dissection………………………………….………………....21
2.2.5 RNA Isolation and qPCR Analysis………………………………………………....21
2.2.6 Immunohistochemistry and Confocal Microscopy……………………………...….23
2.2.7 NIR Labeled PFPE Nanoemulsion……………………………………………........25
2.2.8 Live Animal Imaging (NIR)……………………………………………...………...25
2.2.9 MRI (1H & 19F) Methods…………………………………………………………...26
2.3 Results………………………………………………………………………………...27
2.4 Discussion…………………………………………………………………………….47
2.5 Conclusion…………………………………………………………………................51
2.6 Acknowledgements…………………………………………………………………...52
Chapter 3: PAIN MANAGEMENT WITH LOW DOSE CELECOXIB
DELIVERED BY TARGETED NANOEMULSION…………………………………53
Chapter 3 Attributions…………………………………………………………………….53
3.1. Introduction…………………………………………………………………………..54
3.2. Methods……………………………………………………………………….……...56
3.2.1. Experimental Groups………………....…………………………....…………....….56
3.2.2. Chronic Constriction Injury……………………………………………………......56
3.2.3. Behavioral Testing………………………………………………………………....56
3.2.4. Theranostic Nanoemulsion………………………………………….......................57

xi

3.2.5. Live Animal Imaging (NIR)……………………………………………………......57
3.2.6. MRI (1H & 19F) Methods…………………………………………………….…....58
3.2.7. Histology and Confocal Microscopy……………………………………………….58
3.3. Results……………………………………………………………………..................58
3.3.1. Reduction in Mechanical Allodynia with Single Injection of Celecoxib
Containing Nanoemulsion………………………………………………………………..58
3.3.2. Reduction in Neuroinflammation Observed by Live Animal Imaging (NIRF)…...60
3.3.3. Reduction in Neuroinflammation Observed by 19F MRI………………..................64
3.3.4. Celecoxib-Loaded Nanoemulsion Reduces Macrophage Infiltration along with
Reduction in COX-2 and PGE2 Expression in Macrophages……………………………66
3.4. Discussion…………………………………………………………………………....70
3.5. Conclusion ………………………………………………………………..................73
Chapter 4: IN VIVO AND SYSTEMS BIOLOGY STUDIES IMPLICATE IL-18
AS A CENTRAL MEDIATOR IN CHRONIC PAIN………………………………...74
Chapter 4 Attributions……………………………………….………………………........74
4.1 Introduction…………………………………………………………………………...75
4.2 Materials And Methods……………………………………………………………….77
4.2.1 Animals…………………………………………………………………………......77
4.2.2 Surgery And Anesthesia……………………………………………………………78
4.2.3 Behavioral Analysis……………………………………………………...................78
4.2.4 Tissue Dissection………………………………………………………...................79
4.2.5 Histology And Confocal Microscopy………………………………………………79
4.2.6 Processing Of Rat Sciatic Nerves…………………………………………………..80

xii

4.2.7 Analysis Of Inflammatory Mediators……………………………………..…….….80
4.2.8 Dynamic Bayesian Network Inference………………………………......................81
4.3 Results………………………………………………………………………………...81
4.3.1Mechanical Allodynia And Inflammatory Mediators During CCI………………….81
4.3.2 Dynamic Bayesian Network (DBN) Inference…………………………..................86
4.3.3 Immunohistochemical Analysis…………………………………………………….88
4.4 Discussion…………………………………………………………………………….90
4.5 Conclusion……………………………………………………………………………93
4.6 Acknowledgements…………………………………………………………….……..94
Chapter 5: DISCUSSION………………………………………………………………95
5.1 In-Vivo Inflammation Imaging Using Near Infra Red (NIR) Fluorescence
And 19F Magnetic Resonance Imaging (MRI) In CCI Rat Model…………......................95
5.2 Imaging Reagents………………………………………………………......................96
5.3 Animal Model…………………………………………………………………….…..98
5.4 Nanoemulsion…………………………………………………………….…………..99
5.5 Reduced Hypersensitivity Using Celecoxib Containing Theranostic
Nanoemulsion In CCI Rat Model…………………………………………..……….…..105
5.6 In-Vivo Inflammation Imaging Using Near Infra Red (NIR) Fluorescence
And 19F Magnetic Resonance Imaging (MRI) In CCI Rat Model……………………....107
5.7 Dynamic Bayesian Network (DBN) Analysis…………………………….………...112
5.8 Future Directions……………………………………………………….…………...113
References………………………………………………………………….……….…...115
Appendix……………………………………………………………………...................126

xiii

A.1. Ethics Statement…………………………………………………………………....126
A.2 Animals………………………………………………………………………….….126
A.3 Chronic Constriction Injury (CCI)…………………………………...……………..126
A.4. Rat Preparation Before Surgery……………………………………..……………..127
A.5 CCI Surgery………………………………………………………………………...128
A.6. Sham Surgery…………………………………………………………....................129
A.7. Behavioral Testing (Mechanical Allodynia Testing)……………..…………....…..129
A.8. Rat Tail-Vein Injection…………………………………………….………….……130
A.9. LiCOR Pearl Imaging………………………………………………..…………......131
A.10. LiCOR Image Analysis………………………………………………...................133
A.11. Euthanasia………………………………………………………………………...133
A.12. Intracardiac Perfusion Fixation…………………………………………………...133
A.13. Sciatic Nerve And Femur Bone Dissection………………………………………135
A.14. Sciatic Nerve Collection In Live Rats……………………………………………136
A.15. Immunohistochemistry…………………………………………………………...136
A.16. Antigen Retrieval…………………………………………………………………139
A.17. Confocal Microscopy And Quantification………………………………………..139
A.18. Blinded Experiments……………………………………………………………...141
A.19. Statistical Analysis……………………………………………….……………….142

xiv

LIST OF TABLES
Page
Table 2-S1 List of primer sequences used………………………………..………………22
Table 2-S2 LiCOR total relative fluorescence for each ROI……………………………..40
Table 2-S3 One-way ANOVA of relative NIR fluorescence in live rats…………………41
Table 3-1 LiCOR relative NIR fluorescence for each ROI.................................................63
Table 4-1 Cytokine concentrations for 14 different mediators…………………………...83
Table A‐1: Mean fluorescence intensity of CD68 positive stained slides from CCI
rats injected with either theranostic nanoemulsion or vehicle nanoemulsion………143
Table A‐2: Mean fluorescence intensity of PGE2, CD68 and normalized PGE2
intensity (ratio of PGE2 MFI and CD68 MFI) for CCI rats injected with theranostic
and vehicle nanoemulsion………………………………………………………………………………....144
Table A‐3: Mean fluorescence intensity of COX‐2, CD68 and normalized COX‐2
intensity (ratio of COX‐2 MFI and CD68 MFI) for CCI rats injected with theranostic
and vehicle nanoemulsion………………………………………………………………………………....145

xv

LIST OF FIGURES
Page
Chapter 1
Figure 1-1. Inflammatory events following chronic constriction injury (CCI) in rats….…4
Chapter 2
Figure 2-1. Chronic Constriction Injury (CCI) affects behavior, as well as
mRNA and protein expression……………………………………………………………28
Figure 2-2. Near Infrared imaging (NIR) of live rats…………………………………......32
Figure 2-S3. Near Infrared imaging (NIR) of live rats merged with white light images
of their body, 2 days post-intravenous injection of labeled emulsion on day 11
post-surgery……………………………………………………………………………….34
Figure 2-3.1 Near Infrared imaging (NIR) of live rats…………………………………....36
Figure 2-3.2 Two-way ANOVA analysis of Near Infrared imaging (NIR) of live rats
merged with white light images of their body, 2 days post-intravenous injection of
labeled emulsion on day 11 post-surgery…………………………………………………38
Figure 2-S1. Near Infrared imaging (NIR) of live rats merged with white light images
with the Region of Interest (ROI) indicated……………………………………………....39
Figure 2-4. 1H and 19F MRI of the hind limbs……………………………………………43
Figure 2-S2. NMR 19F spectra for nanoemulsion in dissected CCI sciatic nerve………...45
Figure 2-5. Cryosection of sciatic nerve………………………………………………….46
Chapter 3
Figure 3-1. Mechanical allodynia testing ………………………………………………..59
Figure 3-2. Near infrared (NIR) imaging of live rats merged with white light images

xvi

of their body, 2 days post-intravenous injection of labeled emulsion on day 11
post-surgery……………………………………………………………………………….61
Figure 3-3. Near Infrared imaging (NIR) of live rats merged with white light images
with the Region of Interest (ROI) indicated…………………………………………..….62
Figure 3-4. 1H and 19F MRI overlay of the ipsilateral rat hind limbs…………………….65
Figure 3-5. Double immunofluorescence for COX-2 and PGE2 with CD68 positive
macrophages……………………………………………………………………………...67
Figure 3-6. Quantification of relative fluorescence ……………………………………...68
Chapter 4
Figure 4-1. Mechanical allodynia develops on ipsilateral hind paw post-CCI surgery…...82
Figure 4-2. Cytokine and chemokine protein levels at ipsilateral sciatic nerve suggest
sustained inflammasome activation in CCI rats…………………………………………..84
Figure 4-3. Dynamic Bayesian Network (DBN) inference suggests a central role for the
inflammasome in CCI…………………………………………………………………….87
Figure 4-4. Double immunofluorescence for macrophages and cytokines on ipsilateral
sciatic nerve cryosections suggests inflammasome activation in CCI rats……………….89

xvii

Chapter 1
INTRODUCTION
1.1 Nociceptive, Inflammatory And Neuropathic Pain
Pain is “an unpleasant sensory and emotional experience associated with actual or
potential tissue damage, or described in terms of such damage” [1]. Pain can be broadly
classified as nociceptive, inflammatory or pathological pain (neuropathic or dysfunctional pain).
Nociceptive pain is associated with a noxious stimulus and is a protective physiological warning
to avoid potential tissue damage [2]. Nociceptive pain is acute in nature, occurs only in the
presence of the stimulus and goes away in the absence of the stimulus. Examples of nociceptive
pain are pin pricking during an injection and transient intense mechanical pressure on skin. Both
nociceptive and physiological sensations such as heat, cold, touch and pain are felt via free nerve
endings of the afferent fibers of the somatosensory nervous system called receptors. The
receptors that respond specifically to a noxious stimulus are called as nociceptors. They can be
categorized based upon the type of stimuli they respond to, such as thermal nociceptors for
sensing heat. There are various types and subtypes of afferent nerve fibers that are responsive to
different sensations. Painful stimuli are normally felt via Aδ (myelinated) and C (unmyelinated)
type afferent fibers. These receptors are present on skin, muscles, joints, epithelial tissue and
internal organs. A stimulus can be innocuous or noxious depending upon the intensity. During
inflammatory or neuropathic pain, an innocuous stimulus could be perceived as noxious due to
the presence of inflammatory mediators along with changes in the expression of ion channels and
neurotransmitters that lead to amplified pain signals [3]. The nerve impulse generated via the
receptor is transmitted to the dorsal root ganglion (DRG) and the central nervous system (spinal
cord and brain) by the afferent fibers. The pain perception is not only based upon the neuronal
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changes in the peripheral nerves, but is greatly dependent upon the impulse transmission and
neural circuits in the spinal cord and brain [2]. Inflammatory pain, also known as adaptive pain,
typically occurs due to tissue injury and persists until the inflammation is resolved. Therefore,
inflammatory pain is protective in nature, as it restricts the movement of the inflamed region and
helps improve tissue healing. Inflammatory pain is associated with hypersensitivity due to
increased responsiveness of the nociceptors such as hypersensitivity to thermal stimuli (e.g.
thermal hyperalgesia). Neuropathic pain, on the other hand, is associated with pathology of the
neural tissue (i.e. associated with the somatosensory nervous system) [4], which may include
neuronal demyelination or axonal injury. It could also be defined as “pain arising as a direct
consequence of a lesion or disease affecting the somatosensory system” [5]. There can be
multiple etiologies for neuropathic pain, such as metabolic, ischemic, toxins, physical trauma and
infection. Neuropathic pain is also called maladaptive pain [6], because it is not a protective
response; rather it leads to amplified pain signals due to changes in neurons and neural circuits in
the peripheral and central nervous system. Axonal injury could be due to complete transection of
the neuron or changes in the metabolism/ transport of the axoplasm within the axon. Based upon
the location of the lesion in the nervous system, neuropathic pain could be categorized as
peripheral, if peripheral nerves are involved, and central, if the brain and/or spinal cord are
involved. Besides neuronal lesions, there is active participation of the immune cells and
inflammatory mediators within the nervous system to cause neuropathic pain through
neuroinflammation [7].
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1.2 Why Use The Chronic Constriction Injury (CCI) Rat Model?
There are various animal models available to study neuropathic pain. The majority of the
neuropathic pain conditions in humans involve partial damage to the nerve rather than complete
transection. CCI leads to partial damage to the nerve thus simulating commonly found
neuropathic conditions [8]. The CCI rat model is a well-established and well-characterized
model in the field of neuropathic pain [9]. CCI of the sciatic nerve is associated with
hypersensitivity behavior, which is indicative of spontaneous or evoked pain in rats. ‘Positive’
symptoms (i.e. hypersensitivity behavior) include spontaneous pain (pain arising without any
stimuli) and evoked pain such as allodynia or hyperalgesia. Allodynia is pain due to a stimulus
that is innocuous (i.e. does not normally cause pain). Hyperalgesia is increased response to a
stimulus that is normally painful [1]. Therefore, the hallmark of neuropathic pain, development
of hypersensitivity behavior, (i.e. spontaneous or evoked pain-like behaviors) can be studied by
using the CCI rat model [8] Spontaneous pain-like behavior in rats (post-CCI), is demonstrated
by paw licking, avoiding weight bearing on the affected limb, limping most likely due to the
ongoing pain and relatively less movement of the affected hind leg [10]. Evoked pain-like
behavior is demonstrated in rats by tactile allodynia after the CCI injury and persists for up to
two months post-CCI. Also, the common sciatic nerve is targeted in the CCI rat model, which is
easily located and manipulated due to its relatively large size.
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1.3 CCI Causes Wallerian Degeneration And Neuroinflammation

Figure 1-1 Inflammatory events following Chronic Constriction Injury (CCI)
in rats [11-20].
During CCI surgery, four sutures are loosely tied over the common sciatic nerve using 40 chromic gut suture. The chromic gut suture material causes chemotaxis of the immune cells at
the site of ligation [11] and the pressure applied to the nerve by the ligatures causes epineurial
edema. The nerve compression and ischemia that initiate axonal degradation distal to the site of
injury disrupt axon-Schwann cell organization, which activates Schwann cells that leads to
axonal fragmentation and hence myelin degradation. The beginning of myelin degradation
further directs the activation of mast cells, neutrophils, and macrophages and exacerbates the
cascade of inflammation at the site of injury [12, 13]. Additionally, activated Schwann cells are
an important source of inflammatory cytokines and attract hematogenous monocytes [13]. The
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resident macrophages become activated and also produce cytokines to attract hematogenous
monocytes. The macrophages begin to appear around day 3 post-injury and peak at about 2
weeks post-injury [13, 14]. The function of the macrophages is to remove the degenerating axons
and myelin debris and also help in axonal regeneration by removal of axon growth inhibitors
[13]. The accumulation of active immune cells helps to remove the degenerating axons and
produce inflammatory mediators to enhance the inflammatory cascade [13]. Although all types
of axons are damaged (i.e. large myelinated, small myelinated and unmyelinated), the majority
of the axons affected by CCI are large myelinated axons [15].
This sequence of events initiated due to axonal injury in the peripheral nervous system is
called Wallerian degeneration. The loss of large myelinated axons (i.e. axonal degeneration)
peaks around 7-10 days post nerve injury, followed by remyelination around 14-28 days post
nerve injury [13]. The degenerating axons produce a variety of inflammatory mediators that
sensitize the peripheral nerve endings by changing the expression of ion channels and
neurotransmitters [3]. These amplified peripheral nerve impulses are sensed by the DRGs, which
in turn lead to activation of spinal microglia and re-organization of synapses in the spinal cord
and brain [3]. Activated satellite glial cells produce nerve growth factor β (NGF-β), tumor
necrosis factor (TNF) and Interleukin 1β (IL-1β) [16]. In addition, reduced uptake of glutamate
(excitatory neurotransmitter) is found to occur in the activated glial cells in DRGs, contributing
to the hyperexcitability during neuropathic pain [16]. Another contributor towards the spread of
neuroinflammation in the DRGs is the increase in the expression of connexin-43 (Cx-43, gap
junction protein), which leads to easier trafficking of the inflammatory cytokines within the cells
[17]. These changes also lead to activation of astrocytes and microglia in the spinal cord and
brain, which in turn release cytokines that support inflammation and contribute to the
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maintenance of neuropathic pain [16]. Due to demyelination, axonopathy, and local
inflammatory response at the site of the lesion, there is an increase in ectopic firing of the
affected neurons, perceived by the corresponding DRGs, and leading to central sensitization. The
ectopic activity is observed in both Aδ and C fibers [18-20].
Wallerian degeneration, therefore, is caused by a combination of innate and adaptive
responses including both cellular and humoral components [16]. The innate immune response
includes activation of complement, Toll Like Receptors (TLR2, TLR3 and TLR4), and activation
of resident immune cells (i.e. mast cells, macrophages and neutrophils), whereas the adaptive
response includes the activation of T lymphocytes [16].

1.4 Inflammatory Mediators During CCI
Various inflammatory mediators are released during inflammation at the site of nerve
injury. Inflammatory mediators are in a dynamic state and under strict regulation to maintain a
balance between the cytokines and chemokines at any given time during the progression of
inflammation. As shown in figure 1-1 as well as described above, cyclooxygenase 2 (COX-2)
enzyme and prostaglandin E2 (PGE2) are not the only mediators contributing to the neuropathic
pain. As mentioned earlier, various types of immune cells participate in the production of
inflammatory mediators at the site of CCI. The first cells to respond to the injury are the resident
cells. Besides neurons, the resident cells around the peripheral nerve are the endothelial cells,
Schwann cells, fibroblasts, mast cells, macrophages and the dendritic cells. Following injury,
Danger Associated Molecular Patterns (DAMPs) such as ATP, proteins and lipids are released
outside the cells due to cell damage (neuronal damage). This leads to the activation of the ATP
receptors (purinergic receptors; P2X and P2Y) and TLRs that activate neurons and other resident
cells to produce inflammatory mediators such as TNF-α [3]. P2X receptors (ATP gated calcium
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ion channels) and P2Y receptors (G protein-coupled receptors) are found in the peripheral or
central nervous system [21]. Activated Schwann cells produce pro-inflammatory cytokines such
as TNF, IL-1β, IL-6, PGE2 and monocyte chemotactic protein 1 (MCP1) that promote the
neuroinflammation [16]. Besides these, Schwann cells also produce nerve growth factor β (NGFβ) that sensitizes the neurons to cause allodynia and hyperalgesia [22].
The underlying mechanism that activates the resident mast cells following nerve injury is
still unclear. However, it is known that the activated mast cells release various cytokines such
TNF-α, histamine, serotonin and prostaglandins. These mediators lead to sensitization of the
nociceptors and also lead to recruitment of hematogenous immune cells, such as neutrophils, to
the site of the lesion [16]. In response to the amplified nerve signals and the release of
inflammatory mediators in the peripheral nerve, cells in the DRG become activated. For
example, the satellite glial cells and the microglia become activated and exacerbate the
inflammatory cascade by producing pro-inflammatory mediators themselves [23]. In the spinal
nerve ligation (SNL) model of neuropathic pain, the satellite glial cell protein, glial fibrillary
acidic protein (GFAP), had elevated expression from day 1 up to day 10 post-SNL [24].
Activated satellite glial cells produce NGF-β, TNF and IL-1β [16]. TNF-α is the first cytokine
produced at the site of peripheral nerve injury from the mast cells [16]. TNF-α is upregulated
from 6 hours to 24 hours post-CCI in the injured sciatic nerve and day 1 to day 3 post-CCI in the
ipsilateral lumbar 4, 5 and 6 (L4, L5 and L6) DRGs [25]. Under the influence of the mediators
produced by the activated resident immune cells, neutrophils migrate to the site of injury and
reach their peak numbers at twenty-four hours post-injury [16]. Neutrophils produce cytokines
such as TNF, IL-1β, IL-2 and IL-6 that can lead to neuronal sensitization as well as neuronal
death due to the reactive oxygen species released as a result of oxidative burst in the neutrophils
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[16]. Infiltrating hematogenous macrophages are known to release TNF, IL-1β, IL-6, reactive
oxygen radicals, PGE2 and PGI2 [16]. T lymphocytes can be found at the affected sciatic nerve
on day 3 post-CCI and peak in numbers at the site of injury at 3 weeks post-CCI [26]. T
lymphocytes can be subdivided into helper T cells subtype 1 (Th1), helper T cells subtype 2
(Th2) or helper T cells subtype 17 (Th17). Th1 cells are known to produce pro-inflammatory
cytokines Interferon γ (IFN-γ) and TNF, whereas Th2 cells are known to produce antiinflammatory cytokines such as IL-4, IL-5, IL-10 and IL-13 [27]. Th17 cells produce proinflammatory cytokine IL-17 [28].
COX-2 enzyme is induced in the infiltrating (activated) macrophages at the site of the
neuronal injury. COX-2 activation leads to production of PGE2 and PGI2, which sensitize the
neurons [29]. Activated Schwann cells are also known to produce PGE2 [30]. Prostaglandins
play a central role during Wallerian degeneration and the maintenance of neuropathic pain [29,
31]. Following peripheral nerve injury, there is elevated production of prostaglandins that are
derived from arachidonic acid by the activation of COX-1 and COX-2 enzymes in the
infiltrating, activated macrophages [31]. For example, COX-2 enzyme and eicosanoid PGE2 are
involved in the pathogenesis of neuropathic pain, contributing to peripheral sensitization of the
nociceptors and elevated expression of P2X3 and TRPV1 receptors in the associated DRGs [29,
32, 33]. Local or systemic administration of selective COX-2 inhibitors such as ketorolac,
indomethacin, etodolac and celecoxib has been shown to be effective in reducing the
hypersensitivity during neuropathic pain [29, 33-36]. Celecoxib also resulted in improved
functional recovery after the sciatic nerve crush injury in a rat model [34]. However, sustained
high dose administration of non-steroidal anti-inflammatory drugs (NSAIDs) can exhibit a range
of adverse cardiovascular and gastrointestinal effects [29, 33-36].
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1.5 Dual Mode Nanoemulsion
A dual mode (NIR/19F MRI) nanoemulsion (V-Sense DM NIR) was designed and
developed by Dr. Jelena M. Janjic, Associate Professor of Pharmaceutics, Department of
Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University and Dr. Anthony
Balducci, PhD from Celsense Inc. Pittsburgh PA. Methodology for using this nanoemulsion for
imaging macrophages and inflammation was adapted from the earlier published work [37, 38].

1.6 Theranostic Nanoemulsion
‘Theranostics’ is a term used to describe the simultaneous diagnosis and therapy for an
illness [39]. A theranostic nanoemulsion was used in this study for simultaneous visualization
and treatment of neuropathic pain in a CCI rat model. The theranostic nanoemulsion used in this
study was originally designed and developed (by Dr. Jelena M. Janjic and Sravan K. Patel;
Graduate School of Pharmaceutical Sciences, Duquesne University), for the purpose of imaging
and inhibiting inflammation via targeted delivery of COX-2 inhibitors directly to the activated
macrophages, These agents were provided to us and were used in-vivo without further
modifications. Due to proprietary issues, the details of the theranostic nanoemulsion cannot be
included in this dissertation, while related nanoemulsion designs have been published earlier [4043].

1.7 Inflammasome
As previously mentioned, following tissue injury, DAMPs such as heat shock proteins,
ATP and DNA are released from the injured cells. After phagocytosis by the innate immune cells
(e.g. macrophages and neutrophils), the DAMPs act as ligands for intracellular nucleotidebinding oligomerization domain-like receptors (NLRs) that are found in the cytoplasm of the
innate immune cells [44]. The interaction of the ligand with the NLRs leads to assembly of
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various inflammasome proteins in the cytoplasm, which activate caspase-1, a pro-inflammatory
enzyme [44]. Caspase-1 causes maturation and release of IL-1β and IL-18 from the innate
immune cells via nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κB)
transcription factor activation. NF-κB activates the promoter region of IL-1β gene, and increases
the expression of pro-IL-1β. Active caspase-1 further leads to maturation of pro IL-1β and pro
IL-18 to active IL-1β and IL-18 and their subsequent release [45]. Caspase-1 itself is released
alongside active IL-1β and IL-18 outside the cells [44]. In this study, we demonstrate using a
CCI rat model that inflammasome activation may play an important role during peripheral
neuropathy.

1.8 Computational Modeling
The inflammatory diseases/syndromes have complex interactions among various
inflammatory mediators throughout the course of the disease [46]. It is important to recognize
that the same mediator can act as pro-inflammatory at one time point and anti-inflammatory at
another time point. Therefore, it is more relevant to study the associations among various
cytokines over the entire period of disease progression rather than at a single point in time [47].
Studying individual mediators at specific time points during the disease progression may not
provide an accurate representation of the inflammatory interactions [47]. To overcome this
problem, data driven computational modeling can be utilized, which is one of the methods used
to study complex interactions, such as cytokine interactions during inflammation. By using this
method, the data derived in a laboratory in a specific system (such as inflammation) can be
analyzed to predict the events during the disease progression in that system [48]. In the current
study, in collaboration with Dr. Yoram Vodovotz and his co-workers from University of
Pittsburgh, we have used the data driven computational modeling to identify dependent
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interactions among various inflammatory mediators/cytokines after the CCI surgery, based upon
the data derived in the laboratory (cytokine concentrations at the site of nerve injury at multiple
time points throughout the progression of CCI) as input for the Dynamic Bayesian Network
(DBN) inference. Similarly, network based models such as DBN have previously been shown to
reveal interactions among related variables [49]. However, the data driven computational
modeling provides information about the interactions among different variables and not the
mechanisms or steps leading to the disease progression [50]. Non-linear time series analysis was
performed in the current study due to the established fact that the cytokine levels change in a
non-linear fashion over time (i.e. dynamic/non-linearly) [51]. The cytokine level changes
occurring during inflammation are non-linear due to involvement of multiple mediators and their
regulation as multiple feedback loops operating in various directions [51]. Using this approach,
the concentrations of 14 different inflammatory mediators at various time points at the affected
sciatic nerve were used as input for the computer software algorithm to define the interactions
among various cytokines during the CCI induced inflammation progression over a period of 18
days post-injury. The limitations of the data driven computational approach are its dependence
on the data collected in the laboratory for a specific condition, data collection time points and the
parameters chosen, and the limitations of interpreting a small amount of data due to financial or
other constraints [50]. Also, the conclusion drawn through data driven computational modeling
is only a prediction based upon a given set of experiments and therefore needs to be biologically
tested in the laboratory [48].

1.9 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Anti-inflammatory drugs are broadly classified as steroidal or non-steroidal antiinflammatory drugs (NSAIDs). NSAIDs act by inhibiting the cyclooxygenase (COX) enzyme,
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which is required for the production of eicosanoid family of lipids including prostaglandins,
prostacyclins and thromboxanes, all derived from arachidonic acid (free fatty acid) [52]. Out of
these three compounds, only prostaglandins are involved in causing inflammation and pain.
Thromboxanes and prostacyclins have contrasting physiological functions and participate for or
against blood clotting respectively, by affecting the platelets to maintain homeostasis in the
circulatory system [53]. COX enzymes can be further subdivided into two isoforms; COX-1 and
COX-2. Both COX-1 and COX-2 lead to production of intermediate, highly unstable PGH2 from
arachidonic acid which is then converted into prostaglandins (PGs) (i.e. PGI2, PGD2, PGE2,
PGF2), thromboxane A2, and leukotriene products via various synthases [53]. Both COX-1 and
COX-2 are constitutively expressed differentially in various cell types [54] however COX-2 is
inducible and is up-regulated in the non-neuronal cells during inflammation, stress or
tumorigenesis and participates in causing fever, inflammation and pain via prostaglandin
synthesis [55-57]. Macrophages are the crucial immune cells participating during acute and
chronic peripheral nerve injury for the generation and maintenance of neuropathic pain [58, 59].
COX-2 is up-regulated in the activated macrophages in various types of peripheral nerve injury
rat models including CCI rat model where COX-2 up-regulation has been observed from around
two weeks to two months post-CCI, and for days to years in the human patients with acute or
chronic neuropathic pain [8, 29, 57]. COX-2 and prostaglandins, especially PGE2, have been
strongly implicated in the development and maintenance of neuropathic pain [29, 56, 60, 61].
After its release, PGE2 binds to its receptors (EP1, EP2, EP3 and EP4), which are G proteincoupled receptors expressed on immune cells and DRG neurons [60]. EP1 and EP4 have been
specifically reported to be of larger significance during neuropathic pain, contributing to
peripheral and central sensitization by reducing the threshold for depolarization in injured
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neurons and blocking glycine (inhibitory neurotransmitter) in the spinal cord [29, 62, 63].
Various non-selective COX inhibitors (i.e. ketorolac, ibuprofen) [29, 33, 64]; selective COX2
inhibitors (i.e. etodolac, celecoxib) [33, 35, 64] and PGE2 receptor antagonists can reduce
hypersensitivity associated with neuropathic pain [62]. It is well known that prolonged systemic
administration of non-selective COX inhibitors causes adverse effects such as gastric ulcers [65].
On the other hand, selective inhibition of COX-2 has been associated with significantly reduced
gastric ulcerations as compared to non-selective NSAIDs [65]. Based on these findings, in the
current study a selective COX-2 inhibitor, celecoxib was chosen for the CCI treatment group.
Even though, selective COX-2 inhibitors are effective in the pre-clinical neuropathic pain
animal models; their prolonged use at high therapeutic systemic doses has been associated with
serious side effect of thrombosis leading to adverse circulatory and cardiac sequelae [53]. High
systemic doses of celecoxib are required to achieve and maintain its therapeutic effects due to its
poor water solubility and low bioavailability [66]. Previously, nanoemulsions have been used as
an efficient drug delivery platform for the drugs with low water solubility such as doxorubicin,
flurbiprofen and celecoxib [40, 42, 67, 68]. Besides efficient and targeted drug delivery,
nanoemulsions also protect the drug from enzymatic degradation or hydrolysis during circulation
and reduce the therapeutic doses of the drugs, thus decreasing the side effects due to high doses
of the drug otherwise needed [68]. Therefore, in the current study, celecoxib was administered as
a nanoemulsion designed by Janjic and coworkers [42, 43] for the targeted drug delivery directly
into the macrophages with a goal to bypass the systemic side effects of the drug.
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1.10 Specific Aims
Aim 1: To visualize the in-vivo inflammatory changes associated with nerve injury in a CCI rat
model.
Hypothesis 1: Based on earlier studies [37, 38], we hypothesized that the neuroinflammation
will be visualized in-vivo by near infra-red (NIR) imaging and 19F magnetic resonance imaging
(MRI) by intravenous injection of a dual mode nanoemulsion containing NIR dye and 19F tracer
[40-43, 69-71].
Aim 2: To visualize and treat the neuroinflammation by earlier developed nanoemulsion for the
targeted delivery of celecoxib along with NIR dye and an MRI tracer [40-43] directly into the
inflammatory cells as a theranostic nanoemulsion in a CCI rat model.
Hypothesis 2: We hypothesized that the celecoxib-containing theranostic nanoemulsion [40-43]
will lead to a reduction in the hypersensitivity (mechanical allodynia) in a CCI rat model due to
COX-2 inhibition in the macrophages at the injured sciatic nerve, along with visualization of the
neuroinflammation in-vivo.
Aim 3: To identify a dynamic network of interactions among various inflammatory mediators
over a period of time and predicting the principle drivers of neuroinflammation by computational
modeling, based upon the dynamic changes in the cytokine levels at the site of injury in-vivo in a
CCI rat model over a period of 18 days.
Hypothesis 3: We hypothesized that the dynamic network of interactions among various
inflammatory mediators over a period of time and the principle drivers of neuroinflammation can
be predicted by computational modeling, based upon the dynamic changes in the cytokine levels
at the site of injury in-vivo in a CCI rat model over a period of 18 days.
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Chapter 2
Imaging Neuroinflammation In Vivo In A Neuropathic Pain Rat
Model With Near-Infrared Fluorescence And 19F Magnetic
Resonance
Kiran Vasudeva, Karl Andersen, Bree Zeyzus-Johns, T. Kevin Hitchens, Sravan Kumar
Patel, Anthony Balducci, Jelena M. Janjic, John A. Pollock
Reprinted from Vasudeva K, Andersen K, Zeyzus-Johns B, Hitchens K, Patel SK, et al. (2014)
Imaging Neuroinflammation In Vivo in a Neuropathic Pain Rat Model with Near-Infrared
Fluorescence and 19F Magnetic Resonance. PLoS ONE 9(2): e90589.
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2.1 Introduction
Pain is a public health problem that has deleterious effects on social, mental, physical and
economic health of its sufferers [72]. Pain caused by injury or disease associated with the
somatosensory nervous system is called neuropathic pain [4]. Recent studies have estimated that
at least 6 million Americans suffer from neuropathic pain [73]. Other studies indicate that
neuropathic pain is usually associated with nerve inflammation [20], which occurs when
leukocytes such as macrophages infiltrate the nerve. Understanding the role of key inflammatory
cytokines and immune cells involved in neuropathic pain could lead to a deeper understanding of
the signaling mechanisms involved in hypersensitivity as well as better diagnostic and treatment
strategies.
The chronic constriction injury (CCI) rat model [8] is a well-characterized example of
chronic peripheral neuropathic pain [74]. This model is widely used to simulate Complex
Regional Pain Syndrome type II observed in humans (CRPS II, earlier called causalgia) [8].
CRPS II develops when a major peripheral nerve is injured [75] and includes persistent pain and
mechanical allodynia [76].
Significant advances have been made in understanding the molecular basis of the diseases
and conditions of chronic pain and the hypersensitivity associated with CCI. In many cases,
hypersensitivity correlates with changes in the expression of specific ion channels [77]. Among
these are cation channel proteins including the Transient Receptor Potential (TRP), a superfamily
of receptors [78] that are known for being involved in a variety of sensory processes including
nociception and pain [79, 80]. In CCI, there is evidence that seven days after the CCI surgery,
TRPV1 protein, but not mRNA expression increases in the Dorsal Root Ganglia (DRG) [81, 82].
Furthermore, neuroinflammation has been associated with CCI-induced mechanical
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hypersensitivity. Clatworthy and coworkers [83] showed that inflammation plays a key role in
pathophysiology of neuropathic pain. Furthermore, macrophages have been shown to play a
central role in causing the inflammation that contributes to peripheral neuropathies [84]. It has
also been demonstrated that Wallerian degeneration occurs in CCI rat model [7]. During
Wallerian degeneration, resident macrophages and the Schwann cells are the first cells to
respond to the insult and together they initiate the axonal degeneration phase of the distal portion
of the damaged nerve. Within the first three days of nerve injury, acute inflammation is evident
with the infiltration of neutrophils reaching the site of injury via diapedesis [14]. The peak in
neutrophil infiltration is reached within 24 hours of injury. From day 4 to day 14 post injury,
hematogenous macrophages infiltrate the injured nerve area, reaching a peak around 1 week post
injury [14]. One of the roles of these macrophages is to remove the degenerating nerve tissue
debris and to cause inflammation [14]. The infiltration of these immune cells into damaged nerve
tissue is an important component of the inflammatory process. However, the role of
inflammatory cell infiltration into the site of neuronal injury and how that initiates chronic pain
is not well understood. Understanding this process will ultimately lead to the development of
new therapeutic agents and better pain management.
To study infiltrating immune cells in a rat chronic pain model, we used a novel NIR
(near-infrared) labeled perfluoro-15-crown-5 ether (PCE) nanoemulsion [37], shown to
preferentially label macrophages in culture and upon intravenous administration.
Perfluoropolyethers (PFPEs), including PCE, have been used for 19F MRI (magnetic resonance
imaging) in multiple animal models [85-88]. Specifically, PFPE nanoemulsions have become a
powerful tool for imaging inflammation in varied disease models, from acute organ rejection to
rheumatoid arthritis [89]. PFPE nanoemulsion droplets are taken up from the blood stream by
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phagocytic cells including monocytes and macrophages and carried by these cells to sites of
inflammation. PFPEs in the nanoemulsions are biologically and chemically inert, and are not
degraded by the phagocytic cells, which gives PFPEs advantage over other imaging modalities
[90]. The 19F MR signal remains unchanged during the lifetime of the labeled cell and can be
directly correlated to the immune cell number at the site of interest [91]. Further, 19F MR signal
is specific for the introduced nanoemulsion and provides an unambiguous signature of
monocytes and macrophages in vivo. In a recent study [37] we reported in vivo inflammation
imaging demonstrating that NIR and 19F MRI can be used as complementary imaging modalities
for identifying underlying cellular mechanisms in inflammation.
Previously, aspects of the role of inflammation in neuropathic pain have only been
established by ex vivo techniques [92-95]. To the best of our knowledge, there are no reports on
visualizing neuroinflammation in live animals using the CCI model of neuropathic pain. While
19

F MRI has been used previously to image in vivo neuroinflammation in the peripheral nervous

system [96], we are describing for the first time a novel method to visualize the in vivo
inflammation associated with nerve injury in the CCI rat. To achieve this, we are using a newly
developed nanoemulsion-based dual mode imaging probe [37]. We find that NIR and 19F MRI
can be used to monitor inflammation at the site of injury on the sciatic nerve. Using multiple ex
vivo imaging techniques (NIR, 19F MRI and histology), we demonstrate that macrophages have
infiltrated the sciatic nerve following CCI. We discuss the implication of a noninvasive
assessment of neuropathic pain for use in studying pain associated with the hypersensitivity
caused by CCI.
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2.2 Materials and Methods
2.2.1 Ethics Statement
This study was carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institute of Health, and the
Institutional Animal Care and Use Committee (IACUC) at Duquesne University approved the
animal protocol (Protocol 1109-10). All surgical procedures were performed under isoflurane
anesthesia. Male Sprague-Dawley rats weighing 250-350 g were used in this study (Hilltop Lab
Animals, Inc., Scottdale, PA). Rats were maintained on a 12:12 hour light-dark cycle and were
given ad libitum access to water and purified chow. Purified chow has been demonstrated to
reduce non-specific fluorescence caused by plant materials in basic chow in the LI-COR
Bioscience Application Note: In Vivo Animal Imaging Diet Consideration [97]

2.2.2. Chronic Constriction Injury
The chronic constriction injury (CCI) method developed by Bennett and Xie [8] was used
to induce neuropathic pain in the sciatic nerve of rats (Figure 2-1A). Animals were divided into
three groups; CCI, sham and naïve un-operated control. Briefly, under general anesthesia, the
common sciatic nerve of the CCI animals was exposed by making an incision through the skin
and carefully separating the muscles in the mid thigh region of right hind limb. Four ligatures
were tied around the common sciatic nerve using 4-0 chromic gut suture. Care was taken to
ensure that the ligatures were secured in place without restricting epineurial blood flow. The
muscle layer was closed using 4-0 chromic gut suture followed by skin closure using 9 mm
stainless steel wound clips. Sham rats underwent identical surgery except that the ligatures were
not tied around the nerve. Naïve control rats did not undergo any surgical procedures and are
referred to as un-operated controls.
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2.2.3 Behavioral Testing
On the day of surgery, prior to commencement of any surgical procedures, CCI, sham
and control rats underwent baseline assessment for mechanical sensitivity. Behavioral testing
was repeated on day 8 and day 11 post-surgery. Following previously established methods,
mechanical pain threshold was assessed by applying calibrated Semmes-Weinstein
monofilaments to the plantar surface of both the left and right hind paw, specifically in the
cutaneous region that is innervated exclusively by the sciatic nerve [98, 99].
A linear regression was used to estimate each rat’s 50% withdrawal threshold. As
previously described [98], rats were placed on a metal grid and covered with a Plexiglas cover.
The lowest-caliber filament (0.41g) was pushed onto the plantar surface of the right hind paw 5
times until the filament bent; 2 to 3 seconds separated each push. Five minutes later, the left paw
of the same rat was similarly assessed. Not less than 5 minutes after the left paw was assessed,
the entire procedure was repeated. In this way, the right and left paws were probed with the 0.41
g filament 10 times, and the number of withdrawals was recorded. In ascending order, each
filament was so tested until the rat withdrew from all 10 pushes of a single-sized filament or until
the largest-caliber filament was tested.
To estimate the force from which the rat withdrew 50% of the time, force (in grams) was
regressed on withdrawal frequency for all 5 filaments by using simple linear regression. The
force at which the rat withdrew a paw on 5 of 10 pushes (50% withdrawal threshold) was
predicted by using the regression equation. If the 50% withdrawal threshold so calculated was
greater than 15.13g, the highest-caliber filament used (15.13g) was recorded as the gram force. If
the rat failed to respond to any of the filaments, 15.13g was recorded as the 50% withdrawal
threshold. The same investigator always performed this test. Threshold levels were then
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expressed as a difference score between the pain threshold for the right and left hind paws.
These values were normalized to differences that existed between the 2 paws at baseline.
Statistics were performed using SPSS V12.0 software. We observed significant difference
between the CCI condition and the un-operated control rats (Kruskal-Wallis 1-way ANOVA by
ranks; P≤0.05). All behavioral testing was done by an experimenter blinded to the surgical
treatment. Rats used for the detailed behavioral testing consisted of a separate cohort from those
used for the DRG analysis and in vivo imaging. All CCI animals were observed to exhibit
guarding, paw licking and or paw lifting behaviors by day 8 post-surgery. However, only normal
grooming behaviors were seen in the sham and un-operated controls.

2.2.4 Dorsal Root Ganglia Dissection
Nine days post-surgery, bilateral L3, L4 and L5 DRG were dissected from CCI rats via
laminectomy. These ganglia were chosen because neurons within them provide the sensory
component of the sciatic nerve [100, 101]. Ganglia were rapidly removed and stored in RNA
later solution (Qiagen) for later use. Rats were sacrificed after completion of DRG extraction.

2.2.5 RNA Isolation And qPCR Analysis
Quantitative PCR (qPCR) and the comparative cycle threshold (CT) method [102] were
used to determine if the CCI altered the mRNA expression of TRPV1, Neuropeptide Y (NPY)
and Growth-associated Protein 43 (Gap43) relative to Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) in L5 DRG 12 days post-surgery (see Supplemental Table 2-S1 for
primers). GAPDH, an important enzyme in glycolysis, serves as a control transcript for
comparisons to transcripts from other genes expressed within the same tissue [103]. Tissue
samples were removed from the RNA later solution, processed over QiaShredder columns and
RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA). To prevent any genomic DNA
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contamination, each RNA sample was treated with DNase I (Invitrogen, Grand Island, NY).
Supplemental Table 2-S1. Primer Sequences used for this study.
GAPDH
Tm (C)
Forward
Reverse

55.4
54.7

GC content
(%)
55.0
55.0

Sequence (5’-3’)

Amplicon length

CACAGTCAAGGCTGAGAATGG
CGATGCCAAAGTTGTCATGG
300bp

TRPV1
Tm (C)
*Forward
*Reverse

56.2
55.0

GC content
(%)
55.0
55.0

Sequence

Amplicon length

GTGATCGCTTACAGCAGCAG
CGGTGACTCGGAAATAGTCC
238bp

NPY
Tm (C)
Forward
Reverse

49.6
48.9

GC content
(%)
47.4
47.4

Sequence

Amplicon length

GACAGAGATATGGCAAGAG
CTAGGAAAAGTCAGGAGAG
148bp

Gap43
Tm (C)
Forward
Reverse

51.0
49.7

GC content
(%)
50.0
44.0

Sequence

Amplicon length

CCTAAACAAGCCGATGTG
TTTGGCTTCATCTACAGC
150bp

* primer sequences acquired from Charrua A, Reguenga C, Paule CC, Nagy I, Cruz F, Avelino
A. (2008). Cystitis is associated with TRPV1b-downregulation in rat dorsal root ganglia.
Neuroreport 19(15): 1469-1472.
Using RNA as the template, one-step qPCR was performed with gene specific primers.
Reverse-transcription was performed on the StepOnePlus machine using the Power SYBR®
Green RNA-to-CT™ 1-Step Kit (Applied Biosystems). RNA extracted from each rat was
analyzed separately in triplicate. Analysis of amplified cDNA products by agarose gel and
subsequent DNA sequencing confirmed the identity of the intended PCR product. All statistical
tests were performed using SPSS software. Assumptions of ANOVA were met as indicated by
Mauchly’s Test of Sphericity and Levine’s Test for Equality of Variances. Significance of the F
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statistic was defined as p ≤ 0.05. TRPV1 mRNA levels in right (ipsilateral to the nerve injury)
DRG of CCI rats was compared to right DRG of control (pooled) rats by performing a 1-Way
ANOVA with treatment as the between-subjects factor.

2.2.6 Immunohistochemistry And Confocal Microscopy
Dorsal root ganglia from control and CCI rats were used for immunohistochemistry to
explore the protein expression levels of TRPV1. Under general anesthesia, prior to any surgical
procedures, the CCI and control rats were injected with DiD Dye (V-22887, Invitrogen,
Carlsbad, CA) in the plantar region of the right hind paw. DiD is a lipophilic retrograde tracer
that will stain all neuronal cells innervating the hind paw. Post-treatment, all DRGs were
removed and immediately fixed in 4% paraformaldehyde 1X Phosphate Buffer Saline (PBS)
solution. The tissue samples were cryoprotected in 30% sucrose 1X PBS solution for 4 hours.
After four hours of incubation, 1/3 of the cryoprotectant solution was replaced with Optimal
Cutting Temperature (OCT) compound (Sakura-Finetek, Torrance, CA) and incubated on a
rocking shaker overnight. After overnight incubation, samples were embedded in OCT and 20μm
thick sections were made on a cryostat. Sections were then fixed in 4% paraformaldehyde
solution 1X PBS, permeabilized with 0.3% Triton X-100 solution and stained with primary and
secondary antibodies. The following primary antibodies were used: 1:50 mouse anti-rat
Neurofilament-M (Neuromics, Edina, MN), 1:50 rabbit anti-rat TRPV1 (Santa Cruz
Biotechnology, Dallas, TX). The sections were then washed and incubated overnight with antimouse secondary antibodies conjugated to Alexa-546 (Invitrogen, Carlsbad, CA), and antirabbit-FITC (Santa Cruz Biotechnology, Dallas, TX), diluted 1:100 in PBS. Sections were
washed in 1X PBS and mounted in Prolong-Gold (Invitrogen, Carlsbad, CA). Relative
expression of TRPV1 was determined by comparing the fluorescence intensity for TRPV1 to the
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fluorescence intensity of DiD, whose fluorescence intensity is not affected by the CCI surgery.
This was done for labeled neurons from naïve control DRG and CCI DRG using the Leica TCS
SP2 software version 2.3. For a double-labeled cell, the overall TRPV1 mean amplitude was
divided by the overall mean DiD amplitude. The results of an unpaired t-test showed t= -6.45,
SD= 0.758E-01 degrees of freedom = 6. The probability of this result, assuming the null
hypothesis, is 0.0007. An experimenter blind to treatment did staining and quantification of
immunohistochemistry.
In separate immunohistochemical experiments using comparable protocols, the recovered
control, sham and CCI sciatic nerves were prepared for examination using mouse anti rat CD68
antibody (MCA341R, AbD Serotech, Raleigh, NC) and Alexa fluor-488 donkey anti-mouse
secondary antibody (A-21202, Invitrogen, Carlsbad, CA) to assess the presence of macrophages
that infiltrate the nerve.
Cellular uptake of nanoemulsion was performed in the mouse leukemic monocyte
macrophage cell line RAW 264.7 (ATCC, Manassas VA) as described by Patel et al [42].
Approximately, 0.3 million cells were seeded on cover slips in 6-well plates in 2 mL culture
medium per well and grown as adherent macrophages. After 48 h incubation at 37 °C and 5%
CO2, medium was aspirated and cells washed with 1X PBS. Cells were exposed to 2 mL of
either fresh culture medium alone or dispersed nanoemulsion-containing medium (10 µL/mL).
Following 5 h incubation, 1 mL medium was aspirated and cells fixed with 1 mL 4%
paraformaldehyde in 1X PBS. After 30 minutes at room temperature, the cells were washed with
1X PBS three times. Each coverslip with and without nanoemulsion labeled cells was
transferred to glass slides containing a drop of ProLong® Gold mounting medium. The
nanoemulsion labeled with DiR (Invitrogen, Carlsbad, CA) was detected with 633 nm laser
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excitation and emission window of 700 nm to 850 nm. Confocal microscopy was performed on a
Leica SP2 spectral Laser Scanning Confocal microscope. A transmission DIC image was
acquired with each confocal scan.

2.2.7 NIR Labeled PFPE Nanoemulsion
NIR labeled PFPE Nanoemulsion (V-Sense DM NIR) was produced and provided by
Celsense Inc (Pittsburgh, PA, USA) and was used without further modifications. Previous
studies have demonstrated that the nanoemulsion droplets are on the order of 180 - 200 nm in
size [37].

2.2.8 Live Animal Imaging (NIR)
To follow the localization of emulsion labeled circulating monocytes (monocytes in the
blood, macrophages in tissue), NIR imaging of the fluorescent label in live rats was performed
on a LiCOR® Pearl Impulse (LI-COR Biosciences, Lincoln, NE) small animal imaging system.
For the live animal imaging, rats were fed purified chow (D10012G Research Diets, Inc. New
Brunswick, NJ), which helps to reduce non-specific fluorescence in the abdominal and thoracic
region of the animal caused by certain foods. Tail-vein injection of 300 µL of V-Sense DM
nanoemulsion was performed 8 days after surgery under general anesthesia. Within minutes, the
injected animals were imaged in the LiCOR imager to establish that the intravenous injection
was successful and that the nanoemulsion was not leaking subcutaneously within the tail. On day
11 post surgery, maximum neuroinflammation was predicted based on previous results, and
another set of NIR imaging was performed under general anesthesia (xylazine, 7 mg/kg /
ketamine, 80 mg/kg) given intraperitoneally. Simultaneous image acquisition of white light
(body view) and 785 nm excitation for 820 nm emission were merged and processed in the
LiCOR Pearl Impulse Software (version 2.0) with linked look-up-tables (LUT). Relative
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fluorescence was measured from a region of the same size over the sciatic nerve for both left and
right legs for the naïve, sham and CCI conditions. This involved identifying a region of interest
(ROI) around the fluorescent signal evident in the CCI. That ROI perimeter was then copied to
the other legs for a given experiment. In this way, nearly the same number of pixels of area for
the signal is compared within a given paired experiment. The ROI images for each rat
(Supplemental Figure 2-S1) and the tabulation of relative fluorescence from the LiCOR Pearl
Impulse software (Table 2-S2) are shown in Supplemental Data. Prism software version 5.0 was
used to perform analysis of variance (ANOVA) for the entire set of conditions revealing a p
value < 0.0001 (Supplemental Table 2-S3). Furthermore, a t-test specifically comparing the
sham right leg to the CCI right leg reveals a p value <0.0001. Dissected sciatic nerves were
similarly imaged for NIR fluorescence on a flatbed LiCOR Odyssey Infrared Imaging system.
An experimenter blinded to experimental conditions did the analysis of NIR Pearl images.

2.2.9 MRI (1H & 19F) Methods
1

H and 19F MRI was performed on rat legs using a Bruker Biospec Avance III 7-T/21-cm

system (Bruker Biospin MRI, Billerica MA) and a 35-mm (1H/19F) double resonance birdcage
coil (Rapid MR International, Columbus OH). Following perfusion fixation, dissected legs were
placed in a 50 mL conical tube and positioned in the magnet. Following pilot scans, the
anatomical images were collected using a RARE (Rapid Acquisition with Relaxation
Enhancement) sequence with both axial and a double oblique (parallel to the femur/tibia plane)
coronal views. The following acquisition parameters were used: TR/TE 4000/7 ms, RARE
Factor = 8, NA = 4, 6 x 6 cm FOV, 256 x 256 matrix, 2-mm slice thickness, and 22 or 14
contiguous slices for axial or coronal views, respectively.
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F MRI was performed at 282 MHz

with the same slice geometry and the following parameters: TR/TE 3000/7 ms, RARE Factor =
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4, 6 x 6 cm FOV, 128 x 128 matrix, and NA= 256 or 384 for axial or coronal views, respectively.
Since the resonance frequencies were centered precisely on the water and the perfluorocarbon
resonances, 19F and 1H anatomical images were co-registered without additional image
processing.
19

F NMR spectra for the PFPE nanoemulsion in the dissected sciatic nerves were

acquired following standard protocols with trifluoroacetic acid (TFA) as the internal standard
[42]. Nerves were inserted into borosilicate NMR tubes (5 mm diameter) and spectra recorded
(Bruker, 470 MHz). 19F NMR peak around -92.5 ppm corresponding to fluorine nuclei was
measured with TFA (set at -76.0 ppm) as reference (Supplemental Figure 2-S2).

2.3 Results
In this study, we demonstrate that CCI rats exhibit symptoms of mechanical
hypersensitivity, which is a hallmark of chronic pain. We also show that dual mode PFPE
nanoemulsion can be used to reveal the focal point of neuroinflammation by both NIR imaging
and 19F MRI. Furthermore, we demonstrate that the NIR and 19F signal is arising from CD68
positive macrophage cells carrying the nanoemulsion that infiltrate the CCI injured nerve. Due
to anatomical barriers for free nanoemulsion delivery to the site of injury and considering the
supporting histological findings, the NIR and 19F MRI signal shown arise from infiltrating cells.
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Figure 2-1. Chronic Constriction Injury (CCI) affects behavior, as well as mRNA and
protein expression.
A. Sketch of the sciatic nerve with the chronic constriction injury sutures in place.
B. Mechanical hypersensitivity in the right hind paw. Bars represent the mean ± SEM
normalized 50% withdrawal threshold from calibrated Semmes-Weinstein monofilaments (g) for
each of the treatment groups; un-operated control (Con), sham-operated control (Sham), and
chronic constriction injury (CCI). The more negative a mean difference score, the lower the pain
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threshold in the right hind paw. *Significant difference from un-operated control rats (KruskalWallis 1-way ANOVA by ranks; P≤0.05). Un-operated and sham-operated control rats did not
differ in normalized pain thresholds at day 8 or day 11 post-operative. Sample size representing
each mean indicated on the graph.
C. Relative Expression of mRNA assessed by qPCR (one step direct priming of mRNA). mRNA
extracted from dissected L5 ipsilateral dorsal root ganglia for non-surgical control (Con), sham
and CCI were used to compare the expression levels of TRPV1, Growth associated protein 43
(Gap43) and Neuropeptide Y (NPY). All three genes exhibit elevated levels of transcript
expression in the CCI condition that were significantly different from control, indicating
peripheral nerve trauma and neuropathic pain. For TRPV1, these data show that the CCItreatment group was significantly different from the control groups (one-way ANVOA, p<0.05).
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t group was significantly different from the control groups (one-way ANOVA, p<0.05). The
sham-treatment group was not significantly different from the control group (one-way ANOVA,
p>0.05). For NPY, these data show that the CCI-treatment group was significantly different
from both the sham-treatment group and the control group (one-way ANOVA, p<0.001). Sample
D. DiD retrogradely labeled neurons from the right footpad of a CCI surgical animal. Cell
size representing each mean indicated on the graph.
bodies in the L5 dorsal root ganglia were processed for multi-stain confocal microscopy with
anti-TRPV1 and anti-Neurofilament antibodies. The results reveal that some neurons co-label
with TRPV1 and DiD, while other neurons identified with anti-Neurofilament antibody (*) lack
both DiD and TRPV1. Scale Bar = 80 µm.
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E. Using Leica confocal software, the relative fluorescence of TRPV1 to DiD in co-expressing
cells for representative CCI and comparably stained tissue sections from control DRG is shown.
Sample size representing each mean indicated on the graph. TRPV1 protein expression is
elevated in the CCI condition.
Figure 2-1 B illustrates that in the CCI rat, mechanical hypersensitivity is evident 11 days
post-surgery. Guarding behavior and other behaviors that are indicators of increased sensitivity
were evident in all CCI animals. We also demonstrate that under these conditions, the mRNA
expression levels of TRPV1, NPY and Gap43 are elevated on day 12 post-surgery (Figure 2-1
C). For TRPV1, the mean fold change values for the CCI-treatment, sham-treatment, and control
groups were 2.60±0.352, 2.06±0.30, and 1.11±0.18, respectively. These data show that the CCItreatment group was significantly different from the control groups (one-way ANOVA, p<0.05).
The CCI-treatment group was not significantly different from the sham group (one-way
ANOVA, p>0.05). For GAP43, the mean fold-change values for the CCI-treatment, shamtreatment, and control groups were 2.42±0.32, 1.52±0.51, and 1.00±0.07, respectively. These
data show that the CCI-treatment group was significantly different from the sham-treatment and
control groups (one-way ANOVA, p<0.05). The sham-treatment group was not significantly
different from the control group (one-way ANOVA, p>0.05). For NPY, the mean fold change
values for the CCI-treatment, sham-treatment, and control groups of 64.20±33.79, 6.49±6.21,
and 1.44±1.34, respectively. These data show that the CCI-treatment group was significantly
different from both the sham-treatment group and the control group (one-way ANOVA,
p<0.001).
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To demonstrate that the expression of the TRPV1 protein is similarly elevated in the L5
dorsal root ganglia of CCI animals as compared to control, we analyzed tissue sections with
antibodies against TRPV1 and Neurofilament-M (a neuronal marker). Additionally, the plantar
region of the right rear paw of each rat was injected with DiD, a retrograde fluorescent dye that
identifies the neurons innervating that specific region of the foot. Not all large diameter neurons
in the dorsal root ganglia were positive for the DiD retrograde tracer since only a discrete
number of neurons reach that region of the footpad. However, several DiD positive neurons are
found and of those, some co-express TRPV1 in both control and CCI tissue. In the control, the
immunofluorescent ratio of TRPV1/DiD is 0.787 indicating that under these conditions the DiD
signal is brighter than the TRPV1 signal. However, in the CCI the TRPV1/DiD ratio is 1.12
(Figure 2-1 E), indicative of elevated TRPV1 protein expression in these neurons of the dorsal
root ganglion.
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Figure 2-2. Near Infrared imaging (NIR) of live rats merged with white light images of
their body, 2 days post intravenous injection of labeled emulsion on day 11 post surgery.
All of these images were acquired on the LiCOR Pearl Live animal imager and processed in the
same experiment with linked look-up tables. The control (A, B, C) and sham (D, E, F) rats
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exhibit only autofluorescence over the thoracolumbar region, which is evident prior to injection
(A, D, G). The inset in F exhibits a ventral view of the wound, which lacks any fluorescent
signal. The CCI affected right leg (I) exhibits a clear band of fluorescent signal aligned with the
position of the sciatic nerve (arrow), which runs parallel to the femur. No signal is evident on
the CCI animal’s unaffected left leg (H). Note – supplemental data (Supplemental Figure 2-S3)
of a comparable experiment reveals only autofluorescence in sham and naïve controls, while
only the CCI exhibits extensive signal along the length of the thigh, parallel to the position of the
right sciatic nerve. Bar = 1 cm.
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Figure 2-S3. Near Infrared imaging (NIR) of live rats merged with white light images of
their body, 2 days post intravenous injection of labeled emulsion on day 11 post surgery.
All of these images were acquired on the LiCOR Pearl Live animal imager and processed in the
same experiment with linked look-up tables. The control, sham and CCI (A-F) exhibit auto
fluorescence over the thoracolumbar region, which is also evident prior to injection (Note Figure
2-2). The control animal (A) does not exhibit any fluorescence over the right leg. The sham (B)
similarly does not exhibit any fluorescence in the area of the surgical wound (surgical staples).
The CCI animal (C) exhibits a wide area of fluorescent signal over much of the thigh. The left
side of the control, sham and CCI (D, E, F) exhibit only the auto fluorescence in the
thoracolumbar region. Bar = 1 cm.
Figure 2-2 reveals that after the intravenous injection of the NIR labeled PFPE
nanoemulsion, CCI injured rats exhibits NIR fluorescence that is focally localized parallel to the
thigh (Figure 2-2 I) at 11 days post-CCI. This is in contrast to the autofluorescence evident in
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sham (Figure 2-2 F) and control (Figure 2-2 C) in the thoracolumbar regions, which is similar to
that seen prior to the nanoemulsion injection (Figure 2-2 A, D, G). In a separate experiment, the
surgical wound was occasionally found to exhibit low-level NIR fluorescence (Figure 2-3 B, C).
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Figure 2-3.1 Near Infrared imaging (NIR) of live rats merged with white light images of
their body, 2 days post-intravenous injection of labeled emulsion on day 11 post-surgery
compared to day 18 post-surgery. All of these images were acquired on the LiCOR Pearl Live
animal imager and processed in the same experiment with linked look-up tables. Bar = 1cm.
Bars in the graph represent Mean ± SEM. The sham surgical control (A, B, C) exhibits auto
fluorescence over the thoracolumbar region, which is also evident prior to injection. In the sham
animal, a superficial fluorescence signal is detected precisely on the surgical wound. That
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surgical wound signal is dramatically reduced by day 18 (C) in the same sham animal. The CCI
experimental animal (D, E, F) exhibits auto-fluorescence over the thoracolumbar region, which
is also evident prior to injection. The CCI affected right leg (E) exhibits a clear band of
fluorescent signal aligned with the position of the sciatic nerve (black arrow) along the entire
length of the thigh. No signal is evident on the CCI animal’s unaffected left leg (D). On day 18,
the signal in the Sham attributed to the wound has nearly completely resolved and no signal is
apparent along the sciatic nerve (C). The CCI sciatic nerve associated signal persists in at day 18
(F). Bar = 1 cm. G. The relative fluorescence of a region over the sciatic nerve is compared. For
each condition ROI measurements were made (Supplemental Figure 2-S1, Table 2-S2) for the 4
sets of data giving a sample number of 4 to 5. The results of the one-way ANOVA test
(Supplemental Table 2-S3) show that the relative fluorescence in the CCI right is significantly
different from the remainder of the samples with a p value <0.0001. Separately, a t-test analysis
of the Sham right versus the CCI right revealed a p value of <0.0001. Sciatic nerve dissected
from comparable animals imaged simultaneously in the same field of view for NIR fluorescence
on the LiCOR Odyssey Flatbed Imager (H, I). The CCI sciatic nerve (I) exhibits a strong
fluorescent signal in comparison to the sham sciatic nerve (H).
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Figure 2-3.2 Two-way ANOVA analysis of Near Infrared imaging (NIR) of live rats
merged with white light images of their body, 2 days post-intravenous injection of labeled
emulsion on day 11 post-surgery. The relative fluorescence of a region over the sciatic nerve is
compared. For each condition ROI measurements were made (Supplemental Figure 2-S1, Table
2-S2) for the 4 sets of data giving a sample number of 4 to 5. The results of the two-way
ANOVA test show that the relative fluorescence in the CCI right hind limb is significantly
different from the remainder of the samples with a p value <0.05 using Sidak’s multiple
comparison’s test. Separately, a t-test analysis of the sham right versus the CCI right revealed a p
value of <0.0001. Bars in the graph represent Mean ± SEM. There was a significant main effect
of rat condition (p = 0.0021) and hind limbs (p = 0.0012) with a significant interaction between
variables (p = 0.0023).
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Figure 2-S1. Near Infrared imaging (NIR) of live rats merged with white light images with
the Region of Interest (ROI) indicated. All of these images were acquired on the LiCOR Pearl
Live animal imager and processed in the same linked look-up tables. The ROI was set for the
right leg CCI condition and then copied to a similar relative position on each of other legs for
that experimental set. The LiCOR software tabulates the relative fluorescent signal and area
(note Table 2-S2).
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Table 2-S2. LiCOR total relative fluorescence for each ROI. The Mean (Total Relative

Experiment #4

Experiment #3

Experiment #2

Experiment #1

Fluorescence/Area) for each ROI is used for the analysis of variance (ANOVA) and t-test.

Image ID

Name

Polygon

Total

0000331_02
0000333_02
0000335_02
0000337_02
0000348_02
0000349_02
0000454_02
0000455_02
0000460_02
0000461_02
0000464_02
0000466_02
0000470_02
0000471_02
0000478_02
0000479_02
0000487_02
0000488_02
0000490_02
0000715_02
0000718_04
0000725_02
0000727_02
0000739_02
0000742_02

Ctr Right
Ctr Left
Sham Right
Sham Left
CCI Right
CCI Left
Ctr Right
Ctr Left
Sham Right
Sham Left
CCI Right
CCI Left
Ctr Right
Ctr Left
Sham Right
Sham Left
CCI Right
CCI Right
CCI Left
Ctr Left
Ctr Right
Sham Left
Sham Right
CCI Left
CCI Right

1
1
1
1
1
1
1
Ctr LF
ShamRT
ShamLF
CCI RT
CCI LF
Ctr RT
Ctr LF
ShamRT
ShamLF
CCI RT
CCI RT
CCI LF
Ctr LF
1
ShamLF
ShamRT
CCI LF
1

2.72E2
2.46E2
3.78E2
4.78E2
1.75E3
3.95E2
3.04E2
2.34E2
3.75E2
1.92E2
7.21E2
1.94E2
3.71E2
3.24E2
2.66E2
2.62E2
5.87E2
5.72E2
2.22E2
5.54E1
6.70E1
4.38E1
4.31E1
8.01E1
1.65E2

Mean
(total/area)
6.28E-3
5.67E-3
8.73E-3
1.10E-2
4.05E-2
9.10E-3
1.84E-2
1.42E-2
2.28E-2
1.17E-2
4.37E-2
1.18E-2
2.15E-2
1.88E-2
1.55E-2
1.52E-2
3.41E-2
3.32E-2
1.29E-2
8.08E-3
9.76E-3
6.39E-3
6.28E-3
1.17E-2
2.41E-2
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Std. Dev.

Min

Max

Area
(pixels)

2.02E-3
2.22E-3
4.22E-3
5.79E-3
1.18E-2
3.44E-3
4.78E-3
4.34E-3
8.34E-3
4.41E-3
6.77E-3
3.35E-3
4.24E-3
3.81E-3
4.73E-3
4.29E-3
8.07E-3
7.12E-3
2.44E-3
1.74E-3
1.92E-3
3.01E-3
1.45E-3
4.33E-3
7.35E-3

1.45E-3
1.05E-3
5.50E-4
1.95E-3
1.80E-3
1.30E-3
9.60E-3
6.00E-3
9.80E-3
5.10E-3
2.02E-2
4.65E-3
1.24E-2
9.85E-3
7.55E-3
8.00E-3
1.30E-2
1.30E-2
5.90E-3
3.20E-3
4.85E-3
7.50E-4
2.00E-3
4.05E-3
2.05E-3

1.95E-2
2.14E-2
3.31E-2
3.49E-2
7.41E-2
2.68E-2
4.14E-2
3.53E-2
5.91E-2
3.39E-2
6.43E-2
3.07E-2
3.88E-2
3.63E-2
4.25E-2
4.06E-2
6.74E-2
6.14E-2
2.31E-2
1.64E-2
1.91E-2
1.64E-2
1.22E-2
2.47E-2
4.40E-2

43369
43369
43369
43369
43369
43369
13271
12347
12653
13739
16486
11751
16498
16478
16798
16489
13708
17210
17210
6861
6861
6861
6861
6861
6861

Table 2-S3. One-Way ANOVA of Relative NIR Fluorescence in Live Rats.

Expt #1
Expt #2
Expt #3
Expt #4
n
Mean
Std.
Deviation
Std. Error

Naïve
Left
0.0057
0.0140
0.0190
0.0080

Naïve
Right
0.0063
0.0180
0.0220
0.0098

Sham
Left
0.0110
0.0120
0.0150
0.0064

Sham
Right
0.0087
0.0230
0.0160
0.0063

CCI
Left
0.0091
0.0120
0.0130
0.0120

***
CCI
Right
0.041
0.044
0.034 0.033
0.024

4
0.01168
0.0060

4
0.0140
0.0073

4
0.0111
0.0036

4
0.0135
0.0076

4
0.01153
0.0017

5
0.0352
0.0078

0.0030

0.0036

0.0018

0.0038

0.0008

0.0035
p <0.0001

t test of Sham Right versus CCI Right p value <0.0001
This indicated that there was some superficial inflammation at the surgical wound as
compared to the deeper sciatic nerve signal, which exhibits more scattering along the length of
the sciatic nerve Figure 2-3.1 (E, F). Using the Li-COR Pearl Impulse software version 2.0
image analysis tools, we identified regions of interest (ROI) over the affected sciatic nerve for
the CCI, sham and control animals (Supplemental Figure 2-S1 and Table 2-S2). By averaging
the normalized fluorescence (total relative fluorescence/total area) of the right and left legs, we
demonstrate in Figure 2-3.1 (G) and Figure 2-3.2, that the CCI fluorescence is significantly
brighter than the controls. Two-way ANOVA analysis of the entire data set comparing the
relative fluorescence detected in the naïve right and left legs, the sham right and left legs and the
CCI right and left legs reveals a difference for the CCI affected right leg with a p value < 0.05
using Sidak’s multiple comparison’s test (Figure 2-3.2 and Supplemental Table 2-S3). There
was a significant main effect of rat condition (p = 0.0021) and hind limbs (p = 0.0012) with a
significant interaction between variables (p = 0.0023). A t test specifically comparing the
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affected CCI right leg to the sham surgical right leg reveals a significant difference with a p
value < 0.0001 (Supplemental Table 2-S3). However, given that NIR imaging cannot
unequivocally provide spatial localization of the fluorescence, we continued the analysis by
assessing the fluorescence of the dissected sciatic nerve from the sham as compared to the CCI
animal Figure 2-3.1 (H, I). With CCI and sham nerves lying side-by-side and imaged
simultaneously on the flatbed LiCOR Odyssey imaging system, only the CCI shows positive
signal.
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Figure 2-4. 1H and 19F MRI of the hind limbs for the rats shown in Figure 2-2 F and 2-2 I.
Panel A shows an anatomical (1H) image of the leg for the animal shown in 2-2 I. The black
arrow indicates the sutures used for the chronic constriction injury. The long white arrows
indicate the position of the tibia, fibula and femur. The inset image shows the adjacent image
slice, giving a clearer view of the tibia (T) and the femur (F). The white arrow in inset panel A
points to the sciatic nerve, which appears as a white line. Panel B shows a composite 1H/19F
image. The 19F image is rendered in pseudo color (red) and is overlaid on the anatomical image
shown in A. A significant amount of 19F signal is observed at the sutured sciatic nerve. A small
amount of fluorine signal is also evident at the head of the tibia and slight in the femur. The
inset shows an axial view of the thigh revealing the femur in cross section. A small amount of
fluorine signal is observed at the surface aligning with the surgical wound, where minor
superficial inflammation is still evident (arrow head). The (F) indicates the femur in cross
sections with a low level of 19F signal. The white arrow indicates the sciatic nerve with 19F
signal. The asterisk (*) is near the femoral artery. Panel C shows a 1H/19F composite image of
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the sham right leg from the animal shown in Figure 2-2 F. No fluorine signal was observed at
the sciatic nerve, however a weak signal was observed in the femur, presumably in the bone
marrow (arrow). The inset shows an axial view at the level of the arrow near the head of the
femur (F) with 19F signal in the bone marrow. The black arrow points to the femur and the
asterisk (*) is near the femoral artery. Bar = 1 cm.
In preparation of the MRI analysis of the tissues, we assessed the NMR spectra of the
dissected sciatic nerves to ascertain that the only fluorine signature to be detected was arising
from the nanoemulsion and not any contribution that may come from natural sources or from
anesthesia. The NMR spectra (Supplemental Figure 2-S2) show that the only detectable fluorine
in the sciatic nerve arises from the PFPE nanoemulsion. Analysis of the same right legs as those
shown in Figure 2-2 F for the Sham and Figure 2-2 I for the CCI condition by proton and 19F
MRI show that the PFPE signal is coincident with the ligation of the sciatic nerve (Figure 2-4).
Figure 2-4 A shows that the four suture knots associated with the constriction injury are visible
by proton MRI along the sciatic nerve, which is running parallel to the femur. The sciatic nerve
(white arrow inset), tibia (T) and femur (F) are clearly visible in the adjacent image slice (Figure
2-4 A – inset). Fluorine signal is evident along the sciatic nerve in the region of the sutures
(Figure 2-4 B) as well as in the bone marrow of the proximal head of the tibia. Viewed in cross
section (Figure 2-4 B – inset), 19F signal is evident in the sciatic nerve, the femur as well as a
slight signal where some minor inflammation persists at the site of the surgical wound. The clips
had been removed on day 7 post-surgery. In the sham, a lower level of 19F signal is evident only
in the bone marrow near the head of the femur (Figure 2-4 C). A comparable experiment
revealed PFPE nanoemulsion labeled inflammation in the region of the CCI sciatic nerve
(Supplemental Figure 2-S3 C) as compared to control and sham.
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Figure 2-S2. NMR 19F spectra for nanoemulsion in dissected CCI sciatic nerve.
Exhibits 19F NMR spectrum of dissected right sciatic nerve from CCI animal. TFA (−76.00
ppm) reference standard is shown along with the tissue signal for the nanoemulsion in the sciatic
nerve (-92.5ppm).
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Figure 2-5. Cryosection of sciatic nerve. A, B show the affected right sciatic nerve from the
CCI leg shown in Figure 2-2 I stained with anti-CD68 antibody to reveal the presence of
macrophages infiltrating the nerve. C, D CD68 positive cells are not present in the left leg
(contralateral to surgery Figure 2-2 H) of the same CCI animal. E, F shows a nerve from a
separate CCI animal that also exhibits infiltration of CD68 positive cells. The boxed area is
enlarged to reveal the granular cytoplasm (black arrow) of the macrophages, indicative of the
presence of the nanoemulsion. Sham surgical sciatic nerve and non-surgical control sciatic nerve
do not exhibit any CD68 positive cells (G, H) and (I, J). The fluorescent images A, C, G, and I
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were all acquired at the same sitting with the exact same image acquisition parameters.
Macrophages grown in cell culture take up the nanoemulsion, exhibited as particles evident by
both confocal fluorescence emissions 700 – 850nm of NIR label (DiR) (K, M) as well as
transmitted light (L, N).
To confirm that the PFPE signal is localized to the site of neuroinflammation by
infiltration of macrophages into the actual nerve, we sectioned the recovered sciatic nerve from
the CCI right leg and the left leg of the same animal shown in Figure 2-2 H, I and Figure 2-4 A,
B and stained the nerve with anti-CD68 antibody (Figure 2-5 A-D). Similarly, the sciatic nerves
from the un-operated control and the sham were also recovered for analysis (Figure 2-5 G-J).
The results clearly demonstrate that macrophages have infiltrated into the CCI nerve, but not any
of the controls. In duplicate experiments, examination of the macrophages revealed that they
exhibit granular cytoplasm (Figure 2-5 E, F). The nanoemulsion droplets in these cells are
consistent with the nature of nanoemulsion droplets detected in macrophages grown in cell
culture, which measure at the limit of spatial resolution for the light microscope with a size of
200 – 300 nm (Figure 2-5 K, L, M, N), which is consistent with the analytic size measurement of
180-200 nm in diameter [37].

2.4 Discussion
Here we report the first live imaging of neuroinflammation in the CCI neuropathic pain
model with NIR and 19F labeled nanoemulsion taken up by circulating monocytes that infiltrate
into the damaged sciatic nerve and present as macrophages.
Chronic neuropathy in the CCI rat model leads to mechanical hypersensitivity [104].
Figure 2-1B demonstrates significant induction of mechanical hypersensitivity in ipsilateral hind
paw of CCI rat. We note that the role of TRPV1 as a nociceptor has been widely documented in

47

a variety of acute, chronic, and neuropathic pain models and diseases such as diabetic
neuropathy, chronic pancreatitis, cancer pain, osteoarthritis, and gastrointestinal diseases [105108]. NPY is a peptide neurotransmitter released by primary afferent neurons located in the
dorsal root ganglia and received by neurons located in the substantia gelatinosa region of the
spinal cord [109]. In animal models of neuropathic pain, NPY has been shown to be upregulated
[110, 111], and can be used as an indicator that trauma to the nerve has occurred. During
development, Gap43 is a growth-associated protein that is highly expressed in the growth cones
of elongating axons. Its expression decreases after the target has been innervated [112]. In
addition to its developmental role, Gap43 is also differently expressed following neuronal tissue
damage or inflammation, which has been demonstrated in several animal neuropathy models
[112-114] and can be used to verify that trauma has occurred in peripheral nerve tissue.
We have demonstrated that in the CCI pain model, changes in mRNA expression levels
of TRPV1 as well as NPY and Gap43 are evident in lumbar level five dorsal root ganglia using
one-step qPCR analysis (Figure 2-1 C). TRPV1 is known to play a role in inflammatory as well
as neuropathic pain models [115]. The increased expression of NPY, a neurotransmitter, is
known to play a role in modulating both innate and adaptive immune response [116], including
modulating the phagocytic uptake by neutrophils and macrophages [117]. Furthermore, NPY has
been shown to modulate neuronal signaling in acute pain, neuropathic pain and inflammatory
animal pain models and induces anti-nociceptive effects [109]. The increase in NPY expression
provides indirect evidence to support the interpretation that nerve trauma has been induced on
the sciatic nerve. We find that mRNA expression of TRPV1 was increased in the ipsilateral
dorsal root ganglia level 5 as compared to the control rat (Figure 2-1 C). Furthermore, neurons in
the dorsal root ganglia that are retrograde labeled with DiD from the plantar foot pad injection

48

exhibit a relative increase in TRPV1 protein expression in the CCI condition as compared to unoperated control rats (Figure 2-1 D, E). Collectively, these results demonstrate that CCI is
inducing a hypersensitivity associated with changes in gene expression for the nerves of the
affected DRG and sciatic nerve.
We also reported the in vivo imaging of neuroinflammation in the CCI sciatic nerve using
dual mode (NIR and 19F MRI) nanoemulsion. Both resident and hematogenous immune cells are
involved in causing neuroinflammation at the site of injury in CCI rat model [14]. The
infiltration of immune cells into the site of injury results in the release of inflammatory
mediators, which then cause changes in the gene expression profile of the affected neurons and
leads to peripheral sensitization [118]. In vivo imaging of granulomatous inflammation has been
previously reported via labeling of macrophages with fluorescent NIR dye [119]. However,
optical imaging is compromised due to the absorption and scattering of both the excitation and
emitted light [120]. 19F MRI has an advantage in that it is not limited by depth and has no
background noise in tissues [121]. 19F MRI has also been successfully used for in vivo imaging
and quantification of inflammation in various animal disease models [85, 96, 122]. Previously,
we demonstrated in vitro phagocytic uptake of a dual labeled nanoemulsion by macrophages in
culture [42]. Here, we again demonstrate that a perfluorocarbon nanoemulsion containing both
NIR dye and 19F [42] is taken up by macrophages in culture as an assessment of toxicity and
uptake as previously measured [37, 42], which gave us confidence that we could achieve
adequate sensitivity in vivo by both imaging modalities (Figure 2-5 K-N). This nanoemulsion is
then used in order that we might achieve maximum sensitivity and specificity in vivo, in the
analysis of neuroinflammation in CCI.
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On day 8 post-surgery, an intravenous injection of the nanoemulsion was given to the rats
followed immediately by NIR fluorescence assessment to ensure that the injection was not
inadvertently released subcutaneously. In the bloodstream, the phagocytic cells evidently engulf
these nanoemulsion droplets through a still undetermined mechanism. These labeled immune
cells naturally migrate to the site of injury to participate in the inflammatory response. NIR
fluorescence emission from the labeling was observed only on the ipsilateral side of the CCI rat
overlying the site of sciatic nerve ligation (Figure 2-2 I and Figure 2-3 E, F, I). Fluorescence was
absent on hind limbs of sham rat, control rat and the contralateral hind limb of CCI rat (Figure 22 B, C, E, F, Hand Figure 2-3 A-D). NIR imaging was used to reveal the accumulation of
immune cells at the site of sciatic nerve injury in live animals. Macrophages are the primary
immune cells that phagocytize perfluorocarbon nanoemulsion droplets and they represent the
majority of all the labeled cells [85]. The results from our in vivo NIR imaging suggest that the
fluorescence signal is associated with neuroinflammation at the site of sciatic nerve injury in CCI
rats. To confirm that the observed fluorescence originated in the sciatic nerve, ex vivo NIR
imaging of the recovered injured sciatic nerves was performed. Fluorescence emission for NIR
dye was observed only in the CCI ipsilateral sciatic nerve and not the ipsilateral nerve of the
sham animal (Figure 2-3 H, I). The results complement the findings from the in vivo imaging and
show that a fluorescence signal is present in the dissected nerve from the CCI rat, which is
indicative of the accumulation of labeled macrophages.
To confirm that the fluorescence signal at the site of CCI injury was due to accumulation
of nanoemulsion labeled macrophages, highly sensitive19F NMR spectroscopy and 19F MRI were
performed. NMR spectroscopy (supplemental data Figure 2-S2) demonstrates that in the
dissected sciatic nerve, the only fluorine signature arises from the 19F in the PFPE.
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The 19F signal localizes at the site of sciatic nerve injury in the CCI rats and no such
signal was observed in the sham rat (Figure 2-4). The presence of 19F signal was also observed
in the femur and tibia of CCI and sham rats. Complex regional pain syndrome has previously
been associated with osteoporotic changes in human subjects [123]. Furthermore, it has been
demonstrated that osteoporotic changes in the ipsilateral tibia bone occur after CCI surgery.
These changes are also associated with an increased number of osteoclasts in the bone [124].
Hence, the 19F signal we observed in the bone marrow (Figure 2-4) could be indicative of the
osteoporotic changes in the femur and tibia of CCI rats and is a result of the peripheral nerve
injury. It has also been shown that a subset of blood monocytes could serve as osteoclast
precursors [125]. Overall, our interpretation is that the 19F signal evident in the bone marrow is
due to migration of labeled monocytes to the bone.
Immunohistochemistry performed on the ipsilateral sciatic nerve of CCI rat clearly
demonstrates infiltration of macrophages in the sciatic nerve (Figure 2-5). No such infiltration
was observed for the left leg contralateral to the CCI, the ipsilateral sham and the control nerves
(Figure 2-5). Therefore, the 19F signal and the fluorescence observed during in vivo and ex vivo
NIR imaging is due to infiltration of labeled macrophages at the site of injury.

2.5 Conclusion
This study demonstrates that the infiltration of immune cells into the CCI affected sciatic
nerve can be monitored in live animals. Furthermore, the neuroinflammation caused by the CCI
surgery can be imaged using the dual mode nanoemulsion such that both live animal NIR
imaging and post-mortem perfluorocarbon 19F MRI generates complementary results
demonstrating that this neuroinflammation contributes to the pain associated with CCI surgery.
In rats, specifically targeting the immune cells in vivo may serve as a treatment for

51

neuroinflammation. The same technique could be used to monitor the effect of therapeutic drugs
by assessing the extent of inflammation at the site of injury and to diagnose neuroinflammation
without the need for surgical intervention involving a nerve biopsy.
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Chapter 3
Pain Management With Low Dose Celecoxib Delivered By Targeted
Nanoemulsion
Chapter 3 Attributions
I did all of the work in this chapter except those noted here:
Muzamil Saleem, graduate student in Dr. John A. Pollock’s laboratory, performed mechanical
allodynia testing using up-down method and contributed to Figure 3-1 in this chapter.
Muzamil Saleem and Kiran Vasudeva, performed CCI and sham surgeries and rats/tissue used
for Figure 3-5 and Figure 3-6 were compiled together, however the data was generated and
analyzed by Kiran Vasudeva.
T. Kevin Hitchens, Assistant Director, Pittsburgh NMR Center for Biomedical Research,
performed MRI, calculated 19F MRI signal, performed the image analysis and contributed to
Figure 3-4 in this chapter.
Jelena M. Janjic, Associate Professor of Pharmaceutics, Duquesne University, designed the
approach for COX-2 inhibiting nanoemulsion use in pain and inflammation, and provided the
theranostic drug-loaded nanoemulsion used in this study.
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3.1 Introduction
Neuropathic pain is caused by direct or indirect injury to the somatosensory nervous
system [4]. It affects millions of people globally and heavily impacts the physical, social, mental
and economic status of its sufferers [73]. Neuropathic pain is difficult to diagnose and is mostly
refractory to the prevailing treatment options [126]. It is now accepted that besides nerve injury,
neuropathic pain is almost always associated with inflammation due to nerve and tissue injury
[118]. Macrophages are the major effector cells that cause neuroinflammation and neuropathic
pain as a result of Wallerian degeneration following peripheral nerve injury [14]. Immediately
after the nerve injury, resident immune cells are activated and produce a variety of inflammatory
mediators to cause the migration and accumulation of hematogenous immune cells at the site of
injury. Although Schwann cells and resident immune cells participate during early phases of
nerve injury, major contribution towards inflammation and maintenance of neuropathic pain
come from the infiltrating macrophages at the site of nerve injury [127].
During neuroinflammation, prostaglandins are one of the mediators produced by the
macrophages and play an important role during Wallerian degeneration and maintenance of
neuropathic pain [29, 31]. Following peripheral nerve injury, there is elevated expression and
over production of prostaglandins that are derived from arachidonic acid by the activation of
cyclooxygenase (COX) enzymes COX-1 and COX-2 in the infiltrating macrophages [31]. COX2 enzyme and eicosanoid PGE2 are involved in the pathogenesis of neuropathic pain to cause
peripheral sensitization of the nociceptors and increased expression of P2X3 receptors in the
associated DRGs during peripheral nerve injury [29, 32, 33]. Previous studies have reported that
the systemic administration of selective COX-2 inhibitors such as celecoxib, ketorolac, and
indomethacin reduce hypersensitivity after the nerve injury. These same treatments can lead to
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improvement in functional recovery in various animal models of neuropathic pain. However,
COX-2 inhibitors have the limitation of causing adverse secondary effects due to sustained and
high dose systemic administration of non-steroidal anti-inflammatory drugs (NSAIDs) [29, 3336].
To study the neuroinflammatory pain, we used a well-established rat model of CCI
developed by Bennett and Xie in 1988 [8]. In our previous study, we had used a nanoemulsion
containing a near infrared (NIR) dye and a perfluorocarbon (PFC) tracer to label the
hematogenous immune cells in-vivo in the rats that underwent CCI. Subsequently, we could
successfully image the immune cell accumulation at the site of injury using NIR fluorescence in
live animals and also the 19F fluorine signal by magnetic fluorescence imaging (MRI) [128].
Previous studies using similar sized PFC nanoemulsions have revealed that majority of the
nanoemulsion is endocytosed by the circulating monocytes [38]. We have also demonstrated that
the theranostic nanoemulsion containing selective COX-2 inhibitor, celecoxib, was endocytosed
by the macrophages and significantly reduced the expression of PGE2 in the activated
macrophages during in-vitro cell culture [42].
In this study, we performed the in-vivo experiments to demonstrate that the new
theranostic nanoemulsion formulation can provide direct delivery of the celecoxib drug into the
macrophages in live rats, causing a reversal of mechanical allodynia (hypersensitivity) associated
with the CCI condition. We also demonstrate that the same drug loaded theranostic
nanoemulsion was useful to monitor the inflammation at the site of nerve injury and thus proving
true to its name (i.e. simultaneous therapy and diagnostics). Furthermore, immunohistological
analysis of the affected CCI sciatic nerve revealed that the drug loaded nanoemulsion resulted in
a statistically significant reduction (t test, p< 0.0001) in the relative number of activated
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macrophages along with a significant reduction in the COX-2 and PGE2 expression (t test, p<
0.0001) in the macrophages at the affected sciatic nerve.

3.2 Methods
3.2.1 Experimental Groups
CCI rats were divided into treated and untreated groups. These groups have also been
referred to as drug and no drug conditions. The treated CCI group received a single intravenous
injection of the theranostic nanoemulsion containing celecoxib drug on day 8 post-CCI. The
untreated CCI group was injected with the vehicle nanoemulsion, without containing the
celecoxib. The other controls used during this study were sham or naïve rats that were injected
with either the vehicle or the theranostic nanoemulsion.

3.2.2. Chronic Constriction Injury
Please refer to the appendix (Materials and methods)

3.2.3 Behavioral Testing (Up-down method, performed and analyzed by Muzamil
Saleem)
Mechanical allodynia testing was performed on the CCI rats injected with the
nanoemulsion containing celecoxib (with drug/theranostic nanoemulsion), CCI rats injected with
the vehicle nanoemulsion (without drug) and sham rats injected with the vehicle nanoemulsion.
Baseline behavior testing was performed on two consecutive days before the CCI/sham surgery
to obtain the baseline withdrawal threshold values for all the experimental groups. To prevent
any undue discomfort to the rats, the rats were rested and no behavior testing was performed for
two days (i.e. on the day of surgery and the day after). Beginning day 3 post-surgery, daily
behavioral testing was resumed for up to day 12 post-surgery. The behavior testing was
performed using the up-down method adapted from [129] on freely moving rats in a perspex
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chamber with a wire mesh floor that allowed access to the paws. During the light phase of their
circadian cycle, rats were allowed to acclimatize in the mechanical allodynia testing apparatus
for at least 15 minutes prior to the behavior testing, when there was an apparent decrease in their
cage exploration and grooming behavior. Tactile hypersensitivity was tested by applying von
Frey filaments to the plantar surface of their hind paw for duration of 3 seconds until there was a
flex of approximately 20 degrees. The gram forces of the filaments ranged from 1 g to 15 g.
Positive withdrawals were counted during or immediately following the stimulus. The thickness
of the von Frey filament was increased or decreased following a negative or positive response
respectively. At this point four more stimuli were applied and the responses recorded. There is a
latency of one minute between presentations of stimuli. The 50% paw withdrawal threshold was
calculated and treatment groups were analyzed by repeated-measures two-way ANOVA and the
Bonferney post-hoc test. Data are presented as mean ± SD.
Similarly, behavioral testing was carried out for two consecutive days preceding sham
surgery to establish a baseline withdrawal threshold. The rats were then allowed a day of rest and
then tested on consecutive days until 12 days post-surgery, at which point the rats were
euthanized and perfusion fixed.

3.2.4 Theranostic Nanoemulsion
The theranostic nanoemulsion was provided to us by Dr. Jelena M. Janjic, Associate
Professor, Department of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne
University, Pittsburgh. Due to proprietary issues, details of the theranostic nanoemulsion cannot
be included in the dissertation and will be included in the final publication.

3.2.5 Live Animal Imaging (NIR)
Please refer to the appendix (Materials and methods)
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3.2.6 MRI (1H & 19F) Methods
Performed by Dr. T. Kevin Hitchens, as described in Chapter 2.

3.2.7 Histology And Confocal Microscopy
Double immunofluorescence staining was performed for COX-2 and PGE2 along with
CD68 staining. For detailed methodology, please refer to the appendix (Materials and methods).

3.3. Results
3.3.1 Reduction In Mechanical Allodynia With Single Injection Of Celecoxib
Containing Nanoemulsion
To determine the effect of the drug-loaded nanoemulsion on the hypersensitivity
behavior, mechanical allodynia testing was performed on all the experimental groups of rats,
CCI injected with celecoxib-loaded theranostic nanoemulsion (with drug), CCI injected with
vehicle nanoemulsion (nanoemulsion without drug), and sham rats injected with vehicle
nanoemulsion only. Similar to our previous results [128], Figure 3-1 shows the development of
mechanical allodynia on the ipsilateral hind paw around day 7 post-CCI in both the CCI groups
(no injection given up to day 7 post-CCI). As expected, sham rats did not exhibit the
development of hypersensitivity throughout the period of study (Figure 3-1). However, after a
single intravenous injection of the celecoxib-loaded nanoemulsion (0.3 ml) on day 8 post-CCI,
the CCI group treated with the theranostic nanoemulsion exhibited reversal of mechanical
allodynia on day 9 post-CCI (i.e. 24 hours post injection), with a statistically significant (Twoway ANOVA and Bonferney post-hoc test) decline in mechanical allodynia on day 10 post-CCI
that persisted throughout the period of study up to day 12 post-CCI, as compared to the CCI
group injected with the vehicle nanoemulsion. There was a significant main effect of rat
condition (p < 0.0001) and time (p < 0.0001) with a significant interaction between variables (p
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< 0.0001) and a significant main effect of matching (p < 0.0001). Persistent mechanical allodynia
/ hypersensitivity was observed on the ipsilateral hind paw of the untreated CCI group (i.e.
injected with the vehicle nanoemulsion), (Figure 3-1) beginning around day 7 post-CCI until day
12 post-CCI. The contralateral hind paw did not reveal mechanical hypersensitivity in any of the
experimental groups (data not shown).

Figure 3-1. Mechanical allodynia testing. Mechanical allodynia develops on the ipsilateral
hind paw around day 7 post-CCI in both the CCI groups, treated with either the celecoxib
containing theranostic nanoemulsion (shown in blue) or the vehicle nanoemulsion (shown in
red). Significant reduction (matched two-way ANOVA and Bonferney post-hoc test, p <0.0001)
in mechanical allodynia is exhibited on the ipsilateral side of the CCI group treated with
celecoxib-loaded nanoemulsion on day 10 post-CCI (two days after the intravenous
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nanoemulsion injection) as compared to the ipsilateral side of the CCI group treated with vehicle
nanoemulsion. There was a significant main effect of rat condition (p < 0.0001) and time (p <
0.0001) with a significant interaction between variables (p < 0.0001) and a significant main
effect of matching (p < 0.0001). The decline in hypersensitivity on the ipsilateral side of the CCI
group treated with theranostic nanoemulsion, persists throughout the period of study (up to day
12 post-CCI). Sham rats do not exhibit development of mechanical allodynia on the ipsilateral
side of the sham surgery (shown in gray). The bars in the graph represent mean ± SD.

3.3.2 Reduction In Neuroinflammation Observed By Live Animal Imaging
(NIRF)
To determine the effect of the drug-loaded nanoemulsion on the near infrared (NIR)
fluorescent signal at the site of injury, that acts as an indirect indicator of neuroinflammation
[128], NIR fluorescence imaging was performed on all the experimental groups of rats. Similar
to our previous report [128], Figures 3-2 and 3-3 show NIR fluorescence band on the ipsilateral
thigh region of both the treated (i.e. injected with theranostic nanoemulsion) and the untreated
(i.e. injected with vehicle nanoemulsion) CCI groups on day 11 post-CCI (Figure 3-2 A, B;
Figure 3-3 A, B). Sham rats exhibited a low level fluorescence due to the wound caused by skin
and muscle incision during the sham surgery (Figure 3-2 C; Figure 3-3 C, D). For the
quantification of NIR fluorescent signal among four experimental groups (i.e. CCI injected with
celecoxib-loaded nanoemulsion, CCI injected with vehicle nanoemulsion, sham rats injected
with celecoxib-loaded nanoemulsion and sham rats injected with vehicle nanoemulsion),
normalized fluorescence (total fluorescence/total area) at the sciatic nerve region was compared
using LiCOR Pearl Impulse software version 2.0 link look-up tables.
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Figure 3-3 A, B, C, D displays the regions of interest (ROIs) chosen to compare the
relative NIR fluorescence among the various groups. The NIR imaging analysis did not reveal
any significant difference in the NIR fluorescence intensity among any of the three groups (i.e.
CCI injected with theranostic nanoemulsion, CCI injected with vehicle nanoemulsion and sham
rats injected with theranostic nanoemulsion) (Figure 3-3 E and Table 3-1) (One way ANOVA
and Tukey’s multiple comparisons test, p = 0.2346). However, a trend of decline in the NIR
fluorescence was apparent for the CCI group treated with the theranostic nanoemulsion as
compared to the CCI group treated with the vehicle nanoemulsion (Figure 3-3 E). Similar to our
previous observation [128], both the sham groups represent a reduced NIR fluorescence as
compared to both the CCI groups (Table 3-1). Sham rat without the drug was not included in the
one-way ANOVA analysis because only one rat was available in this group that received good
intravenous injection, and for ANOVA at least two rats were required in each group.
Nonetheless, the NIR fluorescence value for sham rat without the drug is included in the NIR
fluorescence data (Table 3-1).

A CCI without drug

B CCI with drug

C Sham without drug

Figure 3-2. Near infrared (NIR) imaging of live rats merged with white light images of their
body, 2 days post-intravenous injection of labeled emulsion on day 11 post-surgery.
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Images were acquired on the LiCOR Pearl Live animal imager and the acquired images were
processed in the same experiment with linked look-up tables. The CCI affected right legs (A, B)
exhibit a clear band of fluorescent signal aligned with the position of the sciatic nerve, which
runs parallel to the femur. Low-level fluorescent signal is evident on the sham rat right leg (C).
Autofluorescence in the thoracolumbar region is exhibited by all the experimental groups (A, B,
C).
CCI with drug

CCI no drug

A

B

Sham with drug
C

E
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Sham no drug
D

Figure 3-3. Near Infrared imaging (NIR) of live rats merged with white light images with
the Region of Interest (ROI) indicated. All of these images were acquired on the LiCOR Pearl
Live animal imager and processed in the same linked look-up tables. NIR fluorescence is
evident at the sciatic nerve region in all the experimental groups (A, B, C, D). However, the CCI
group treated with theranostic nanoemulsion (A) exhibits apparent reduction in the NIR
fluorescence at the sciatic nerve region as compared to the CCI group treated with the vehicle
nanoemulsion (B). Both the sham groups, treated with either the theranostic or vehicle
nanoemulsion (C, D) reveal low-level NIR fluorescence due to skin and muscle incision. The
ROI was set for the right leg CCI group treated with theranostic nanoemulsion (A) and the same
ROI was copied to a similar relative position on each of the other right hind legs of various
experimental groups (B, C, D). The LiCOR software tabulates the relative fluorescent signal and
the area (Table 3-1). A trend of reduced NIR fluorescence signal is revealed by the CCI group
treated with the theranostic nanoemulsion as compared to the CCI group treated with the vehicle
nanoemulsion, however, a statistically significant difference is not seen (E and Table 3-1) (Oneway ANOVA, p = 0.2346). Autofluorescence in thoracolumbar region is present in all the
experimental groups (A, B, C, D). Bars represent mean ± SEM.
Table 3-1. LiCOR relative NIR fluorescence for each ROI. The Mean (Total Relative
Fluorescence/Area) for each ROI is used for the analysis of variance (one-way ANOVA).
Name
CCI with drug
CCI with drug
CCI without drug
CCI without drug
Sham with drug
Sham with drug
Sham without drug

Image ID
0001792_02
0001851_02
0001799_02
0001845_02
0001805_02
0002009_02
0001812_02

Channel
800
800
800
800
800
800
800

Total
Mean (Total/Area)
2.10E+03
2.19E‐01
1.91E+03
2.00E‐01
1.96E+03
2.05E‐01
2.74E+03
2.88E‐01
1.74E+03
1.83E‐01
1.07E+03
1.12E‐01
7.63E+02
8.02E‐02
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Std. Dev.
1.28E‐01
1.19E‐01
1.28E‐01
1.86E‐01
9.17E‐02
5.02E‐02
4.52E‐02

Min
5.48E‐02
1.63E‐02
3.67E‐02
1.91E‐02
5.03E‐02
3.81E‐02
2.41E‐02

Max
Area (pixels)
7.25E‐01
5809
6.48E‐01
8744
8.44E‐01
8733
1.04E+00
7039
5.43E‐01
9514
3.76E‐01
8515
2.52E‐01
9514

Shape
Polygon
Polygon
Polygon
Polygon
Polygon
Polygon
Polygon

3.3.3. Reduction In Neuroinflammation Observed By 19F MRI
In a separate experiment, to see if there was any difference in the 19F signal in the treated
and untreated CCI groups at the site of injury, a highly specific and sensitive 19F MRI was
performed on the dissected ipsilateral hind limbs by Dr. Kevin Hitchens, similar to our previous
study along with regular 1H MRI [128]. Overlay of regular 1H MRI and 19F MRI images revealed
the presence of 19F signal at the sciatic nerve, parallel to the femur bone in both treated and
untreated CCI groups with a notable reduction in the 19F signal for the CCI rat treated with
celecoxib-containing nanoemulsion as compared to the untreated CCI rat injected with the
vehicle nanoemulsion (Figure 3-4 A, B). Comparative analysis for the 19F signal [86] in the
sciatic nerve was performed (by Dr. Kevin Hitchens) between the two CCI groups (with identical
parameters) and approximately 50% reduction in the 19F signal was observed in the sciatic nerve
retrieved from the CCI rat treated with the theranostic nanoemulsion (Figure 3-4 C). Statistical
analysis for 19F quantification could not be performed due to one rat in each CCI group. It was
not feasible to perform the highly expensive 19F MRI on a larger number of rats due to economic
constraints. Thus, the in-vivo 19F MRI results indicate a reduction in the neuroinflammation at
the site of injury in the CCI group treated with the theranostic nanoemulsion as compared to the
CCI group injected with the vehicle nanoemulsion. Similar to our previous study [128], the 19F
fluorine signal is also evident in the femur bones of both the CCI groups.
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A

B

With drug

Without drug

C

Figure 3-4. 1H and 19F MRI overlay of the ipsilateral rat hind limbs. A, B show an overlay of
an anatomical (1H) image of the leg (gray) and 19F MRI image (red). The white arrows indicate
the site of ligation of sutures at the sciatic nerve. The inset image shows the adjacent image slice,
giving a clearer view of the femur bone running parallel to the sciatic nerve, which appears as a
white line. 19F signal is observed at the sutured sciatic nerve in both the CCI groups (A, B).
Apparent reduction in the 19F signal is evident at the sciatic nerve of the CCI group treated with
the celecoxib-containing nanoemulsion (A) as compared to the CCI group injected with the
vehicle nanoemulsion (B). The comparative 19F signal at the sciatic nerve in both the CCI groups
is depicted graphically which shows approximately two-fold reduction in the 19F signal at the
ipsilateral sciatic nerve in the CCI rat treated with the celecoxib-loaded nanoemulsion (with
drug) as compared to the CCI rat treated with the vehicle nanoemulsion (no drug) (C).
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3.3.4 Celecoxib Loaded Nanoemulsion Reduces Macrophage Infiltration Along
With Reduction In COX-2 And PGE2 Expression In The Macrophages
Double immunofluorescence studies were performed to investigate whether the
differences in the 19F fluorine signals in the CCI treated and untreated groups were also
associated with changes in the macrophage infiltration and COX-2 or PGE2 expression changes
at the site of injury. Figure 3-5 A, B reveals expression of COX-2 and PGE2, along with the
presence of CD68 positive cells in both treated (B) and untreated (A) CCI groups. The
expression of COX-2 or PGE2 and infiltration of CD68 macrophages was not seen in the control
groups (i.e. contralateral sciatic nerves from CCI rat treated with vehicle nanoemulsion,
ipsilateral sciatic nerves from sham and naïve rats injected with vehicle nanoemulsion) (Figure
3-5 C, D, E).
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A

B

C

D

E

Figure 3-5. Double immunofluorescence for COX-2 and PGE2 along with CD68 positive
macrophages. A, B shows infiltration of CD68 positive macrophages along with COX-2 and
PGE2 expression in the ipsilateral sciatic nerve sections of the CCI group injected with the
vehicle nanoemulsion (A) and the CCI group injected with the theranostic nanoemulsion (B). An
apparent reduction in the expression of CD68, COX-2 and PGE2 is revealed in the CCI group
injected with the theranostic nanoemulsion (B). Ipsilateral sciatic nerve sections from the sham
(D) and naïve control rats (E) injected with the vehicle nanoemulsion and contralateral sciatic
nerve sections from the CCI rats injected with the vehicle nanoemulsion (C) do not exhibit
CD68, COX-2 and PGE2 expression. Double immunofluorescence staining for COX-2 and
CD68 macrophages was performed in the same experiment and confocal microscopy was
performed in the same sitting with the same image acquisition parameters. Similarly, double
immunofluorescence staining for PGE2 and CD68 macrophages was performed in the same
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experiment and confocal microscopy was performed in the same sitting with the same image
acquisition parameters. Bar = 150 µm

A

B

C

Figure 3-6. Quantification of relative fluorescence. Significant reduction in mean fluorescence
intensity per unit area was observed for CD68 macrophages (A), COX-2 expression in
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macrophages (B) and PGE2 expression in macrophages (C) in the CCI group treated with
celecoxib-containing nanoemulsion (t test, p<0.0001). n= total number of regions of interest
(ROIs) in (A) and number of macrophages chosen in (B, C) from a total of three rats in either of
the CCI groups. Bars represent Mean ± SEM.
To determine any differences in the relative number of macrophages in the treated
(injected with theranostic nanoemulsion) and untreated (injected with vehicle nanoemulsion)
CCI groups, mean fluorescence intensity of CD68 positive cells / area was compared. A
significant reduction (t-test, p<0.0001) in the mean fluorescence intensity of CD68 positive
macrophages per unit area was observed in the CCI group treated with a single dose of
celecoxib- containing nanoemulsion as compared to the CCI group injected with a single dose of
the vehicle nanoemulsion (Figure 3-6 A). CD68 fluorescence intensity of the individual
macrophages was not significantly different between the macrophages in the treated and
untreated CCI groups (data not displayed graphically, please see appendix for values, Table A-1,
A-2 and A-3). Therefore, significantly reduced CD68 fluorescence/area in the CCI group treated
with the theranostic nanoemulsion implies that there is relative reduction in the number of
macrophage infiltration in the CCI group treated with the theranostic nanoemulsion. Finally, to
see if a single dose of celecoxib-loaded nanoemulsion was effective enough to change COX-2 or
PGE2 expression in the macrophages, the normalized mean fluorescence intensity of COX-2 and
PGE2 (ratio of mean fluorescence intensity of COX-2 or PGE2 / CD68 fluorescence intensity,
please see the appendix for detailed methodology) was compared for both the CCI groups using
Leica SP2 spectral Laser Scanning Confocal microscope software analysis. A significant
reduction (t-test, p < 0.0001) in the relative expression of COX-2 and PGE2 was found in the
CCI group injected with the theranostic nanoemulsion as compared to the vehicle injected CCI
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group (Figure 3-6 B, C). These results show that a single dose of celecoxib-loaded nanoemulsion
was sufficient to significantly reduce the relative expression of COX-2 and PGE2 in the
infiltrating macrophages at the site of injury.

3.4 Discussion
As mentioned earlier, nerve injury leads to immunological activation of resident cells as
well as chemotaxis of hematogenous macrophages to the site of injury. The activated
macrophages at the site of injury release PGE2, a prostaglandin that contributes to the cause and
maintenance of neuropathic pain [60]. Furthermore, these activated immune cells release other
inflammatory mediators as described earlier in the introduction (Chapter 1). PGE2 is
predominantly produced via the COX-2 oxygenation of arachidonic acid to PGH2, which is
enzymatically metabolized to PGE2 during inflammatory conditions. Autoregulatory feedback
leads to an increase in COX-2 expression in the macrophages in the injured peripheral nerve
[60].
Released PGE2 binds to four EP (Prostaglandin E) receptors, EP1, EP2, EP3 and EP4
expressed on the injured afferent neurons [130]. The EP receptors are G protein coupled
receptors with seven transmembrane domains. Binding of PGE2 on EP1 receptor leads to
intracellular increase in calcium ions that mediates increased release of neurotransmitters at the
synapse in the spinal cord [131]. Binding of PGE2 to the EP2 and EP4 receptors on the afferent
neurons causes increase in cAMP concentrations intracellularly due to activation of adenylyl
cyclase. EP3 receptors cause anti-nociception by inhibiting the adenylyl cyclase activation in the
neurons [132]. Therefore, binding of PGE2 to its receptors on the primary afferent neurons
causes peripheral sensitization by reducing the activation threshold of tetradotoxin-resistant
sodium channels as well as inhibition of voltage-gated potassium currents [131]. Both these
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events are mediated by protein kinase A (PKA) signaling that causes an increase in the number
of action potentials per stimulus known as sensitization [131]. PGE2 also causes prolonged
action potential firing in the injured afferent neurons due to activation of voltage-gated calcium
channels that in turn leads to an increase in intracellular calcium and inhibition of the potassium
channels that ultimately contributes to the peripheral sensitization. Furthermore, PGE2
potentiates the transient receptor potential vanilloid type 1 (TRPV1) channel through EP1
receptor along with the bradykinin-induced release of substance P and CGRP in the DRG
neurons [60]. Increased intracellular calcium flow in the DRG neurons leads to enhanced release
of neurotransmitters (excitatory amino acids), such as glutamate and aspartate, excitatory
peptides, such as substance P and calcitonin gene-related peptide (CGRP) at the post-synaptic
neurons in the spinal cord [131]. The release of these excitatory molecules at the post-synaptic
neurons in the dorsal horn of spinal cord is the beginning of central sensitization [133] .
Central sensitization can be broadly divided into two phases, a transcription-independent
(i.e. phosphorylation-dependent) and a transcription-dependent phase. The phosphorylation
phase is the early phase of central sensitization that occurs due to binding of the excitatory
molecules (neurotransmitters) to their specific receptors on the post-synaptic neurons in the
spinal cord. Activation of glutamate receptors (i.e. amino-3-hydroxy-5-methyl-4-isoxazole
propionate (AMPA), N-methyl-D-aspartate (NMDA), kainate (KA) or mGluR metabotropic
receptor subtypes) and CGRP receptors lead to massive inflow of calcium ions, activation and
recruitment of PKA, protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II
(CAMKII) to cause strengthening of the excitatory synapse in the spinal cord [133]. Activation
of PKA, PKC and CAMKII causes phosphorylation of ERK 1/2 that further causes trafficking of
AMPA receptors at the posy-synaptic membranes in the spinal cord and phosphorylates
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potassium channel to further increase the membrane excitability [133]. In addition, ERK1/2
causes activation of various transcription factors, including CREB that leads to further
transcription of various genes such as COX-2 (as mentioned previously), and c-FOS among
others and therefore, begins the transcription-dependent long-lasting central sensitization phase
[133]. In this way, COX-2 and PGE2 are up regulated at the site of injury and in the spinal cord
in the CCI rat model of neuropathic pain [29]. For excellent illustrations of peripheral and central
sensitization, please refer to [133] and [134].
In this study, we have demonstrated a significant relief in mechanical allodynia behavior
upon injection with a single intravenous dose of the celecoxib-containing theranostic
nanoemulsion using the CCI rat model (Chapter 3, Figure 3-1, Two-way ANOVA, p< 0.0001).
The exact mechanism of action for this observation was not investigated in this study and further
experimentation is required. We have demonstrated a significant reduction in the relative
expression of COX-2 and PGE2 in the macrophages at the site of nerve injury (Chapter 3, Figure
3-6, t test, p< 0.0001). Based upon the literature described above, it is predicted that after the
release of celecoxib in the cytoplasm of the theranostic nanoemulsion-containing macrophages,
celecoxib selectively inhibits the COX-2 enzyme in the activated macrophages at the site of
nerve injury and therefore hampers the synthesis of PGE2 in the macrophages. Reduced PGE2
synthesis and thereby a decline in the PGE2 release at the site of injury is predicted to affect the
peripheral sensitization due to the reduced availability of PGE2 to bind to the EP receptors at the
injured afferent neurons. Reduced activation of EP receptors at the afferent neurons is predicted
to cause a decline in the release of neurotransmitters (i.e. glutamate, aspartate, substance P and
CGRP) at the post-synaptic neurons in the spinal cord. A decline in the peripheral sensitization is
predicted to indirectly affect the central sensitization and may prevent the transcription-
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dependent events responsible for long-term central sensitization. Therefore, the reversal of
mechanical allodynia demonstrated in this study could be due to a decline in the peripheral
sensitization or a reversal of both peripheral sensitization and transcription-independent
(phosphorylation-dependent) central sensitization events.
It is also known that prostaglandins are also produced by the injured neurons themselves,
referred to as neurogenic inflammation [60]. Prostaglandins released from the injured neurons,
bind to the EP4 receptors on the activated macrophages at the site of injury and mediate the
release of metalloproteases and CGRP from the macrophages [135]. It is predicted that the
theranostic nanoemulsion does not directly affect the neurogenic inflammation, as the
nanoemulsion is endocytosed by the inflammatory cells only and not the neurons. These are the
predictions based on the literature available. The actual mechanism of action of the theranostic
nanoemulsion to cause reversal of the mechanical allodynia in the CCI rat model needs to be
substantiated by further experimentation.

3.5 Conclusion
Significant reduction in mechanical allodynia was observed for at least three days (day 10
to day12 post-CCI) after the intravenous delivery of a single dose of celecoxib-loaded
theranostic nanoemulsion. This change in behavior occurs along with significant reduction in
inflammation as measured by in the number of infiltrating macrophages as well as a reduction in
the relative expression of COX-2 and PGE2 at the site of injury. These data show that the
successful delivery of low dose celecoxib in the activated macrophages leads to sustained pain
relief. Furthermore, the data exhibits the therapeutic potential of selective COX-2 inhibitors
injected as theranostic nanoemulsion to treat chronic neuropathic pain via delivery of the drug
directly into the macrophages.
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4.1 Introduction
Pain arises with multiple etiologies and when pain persists beyond the natural course of
tissue healing, it is considered to be chronic pain [1]. Chronic pain is now considered of public
health importance due to its wide impact on society. Chronic pain affects around 100 million
American adults and leads to economic loss of approximately $600 billion annually [73].
Neuropathic pain is one of the causes of chronic pain, and affects more than 6 million Americans
[73]. Neuropathic pain occurs in response to injury of the somatosensory nervous system [4], and
may cause pain in the joints, muscles, internal organs, or skin. Furthermore, neuropathic pain
may occur in the central or peripheral nervous system based upon the site of lesion.
Following nerve injury, Wallerian degeneration or anterograde degeneration of the
neurons occurs leading to disintegration of the myelin and the axons distal to the injury causing
inflammation and neuropathic pain [14]. This axonal degeneration causes disorientation of the
axon-Schwann cell organization, which initiates activation of the Schwann cells [136], as well
as resident immune cells including mast cells, and macrophages. Activated Schwann cells as
well as the immune cells secrete chemokines and cytokines that accelerate the recruitment of
other immune cells from the bloodstream. These recruited cells accumulate at the site of injury
and include neutrophils, monocytes, lymphocytes, and natural killer cells [12, 13, 137], likely in
an attempt to promote tissue healing [138]. However, this inflammatory response often becomes
self-sustaining and thus a deleterious part of the process of post-injury pain [139]. Indeed, due to
demyelination, axonopathy, and the local inflammatory responses at the lesion, neuronal firing
for the affected peripheral nerves is increased at the site of injury (peripheral sensitization). This
leads to hypersensitivity or reduced threshold to a given stimuli also known as allodynia [18-20].
In the past few years, various studies have been performed to explore the molecular dialogue
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during inflammation following peripheral nerve injury (neuroinflammation) [9, 16, 138, 140142] including chronic constriction injury (CCI) rat model as developed in the 1980’s [8];
however, details about the interaction among various inflammatory mediators and neurons
during neuroinflammation still need to be elucidated.
Numerous immune cells and inflammatory mediators are involved at different anatomical
levels in the pain axis, and hence various strategies targeting inflammation have been employed
to dampen neuropathic pain [16]. One strategy is to diminish the infiltration or activation of
immune cells such as mast cells, Schwann cells, neutrophils, macrophages, and microglia in an
effort to reduce the over-exuberant and self-sustaining production of inflammatory mediators
[16]. Even though this strategy has shown some success in limiting neuropathic pain associated
hypersensitivity in animal models, doing so poses a major side effect of causing a delay in the
nerve repair and regeneration [143-145]. An alternative strategy is to specifically target the pain
stimulating mediators from the immune cells without disrupting the beneficial functions of other
inflammatory mediators [13, 138]. In recent years, multiple studies have documented dynamic
changes in various inflammatory mediators post-CCI, including cytokines (TNF-α, IL-2, IL-6,
IL-1β, IL-4) and chemokines (MCP-1/CCL2 and KC/CXCL1). The expression of these
mediators is elevated in the sciatic nerve after CCI in rats, and induces peripheral
hypersensitivity post injury [16, 26, 137, 146-149]. Cytokines such as IL-1β and TNF-α
contribute to inflammation and pain during early stages of nerve injury, but later they exhibit a
beneficial role and are expressed during nerve repair/regeneration [46]. Therefore, studying the
complex interplay among various inflammatory mediators at different time points during the
disease progression is more relevant than studying the discrete mediators as singular products
functioning at one time point in the disease [47].

76

One method for studying the changes of complex pathophysiological responses in a time
series experiment is to employ data driven computational modeling. Such an approach does not
rely on an a priori understanding of the biological system, but rather only the input and the data
measured over time [48, 50]. Among several different approaches, network-centric models such
as Dynamic Bayesian Network (DBN) inference can be used to identify dependent interactions.
Furthermore, network-based models may reveal how related variables interact with one another
[48, 49]. For example, DBN inference has recently been used to study the interactions among
various inflammatory mediators in multiple clinical and pre-clinical settings [150-152].
In the present study, we utilized a combination of in vivo and DBN modeling approaches
to predict an inflammatory network that is active during chronic neuropathic pain as evident in
chronic constriction injury (CCI). The expression of 14 different cytokines/chemokines in the
CCI sciatic nerve was assayed using multiplex ELISA, over a period of 18 days post-surgery.
These protein expression levels were used to calculate the interplay of inflammatory mediators
based on DBN inference. Immunohistological examination of the CCI sciatic nerve for several
inflammasome markers supports the DBN prediction. To the best of our knowledge, this is the
first study to define an inflammatory target using computational modeling in the setting of
chronic neuropathic pain.

4.2 Materials and Methods
4.2.1 Animals
This study was carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institute of Health, and Institutional
Animal Care and Use Committee (IACUC) at Duquesne University approved the protocol (#
1109-10). Male Sprague-Dawley rats weighing 250-350 g were used in this study (Hilltop Lab
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Animals, Inc., Scottdale, PA). Rats were maintained on 12:12 hour light dark cycle and were
given ad libitum access to food and water.

4.2.2 Surgery And Anesthesia
Surgery was performed as described by Bennett and Xie [8, 128], which induces
neuropathic pain in rats. Rats were divided into three groups, CCI, sham controls and naïve nonsurgical control rats. Briefly, under isoflurane anesthesia, sciatic nerve was exposed via incision
through skin followed by muscle separation and then four ligatures approximately 1 mm apart
were tied around the common sciatic nerve of the CCI rat, using 4-0 chromic gut suture. The
ligatures were neither tight nor loose. The muscle layer was closed using 4-0 chromic gut suture
followed by skin closure using stainless steel wound clips. Sham rats underwent identical surgery
except that the ligatures were not applied to the sciatic nerve. Naïve control rats did not undergo
any surgical procedures and are referred to as non-surgical controls.

4.2.3 Behavioral Analysis
Naïve control, sham surgical control and CCI were tested for mechanical allodynia a day
before surgery and day 11post-surgery as described previously [128]. Briefly, the calibrated
Semmes-Weinstein monofilaments were applied to the plantar surface of the right hind paw in
the region of sciatic nerve innervation. The filaments were applied in the ascending order of
gram force ranging from 0.41-15.13 gram force. Each filament was applied 10 times and the
withdrawal responses were recorded. The force at which the rat withdrew a paw on 5 of 10
pushes (50% withdrawal threshold) was predicted by using the regression equation. Normalized
50% withdrawal threshold (WT) for the ipsilateral hind paw was calculated by using the formula:
Normalized 50% WT = Post-Surgery 50% WT– Baseline 50% WT. The normalized withdrawal
latencies were averaged for CCI, sham and naïve non-surgical controls, and their means were
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compared using Kruskal-Wallis 1-Way ANOVA by Ranks Test (Graphpad PRISM version
6.0c). Differences were considered significant at p≤ 0.05.

4.2.4 Tissue Dissection
The ipsilateral sciatic nerves were collected at the region of injury from CCI, sham and
naïve control rats. The tissue collection was performed at four time points spanned over the
period of 18 days post-surgery i.e. 2-3 hours post-surgery and day 8, 11 and 18 post surgery for
the CCI and sham rats, along with the naïve non-surgical control rats. Four rats were used for
every given time point. Immediately post-dissection, the tissue was preserved in RNA later
solution (AM7024, Ambion) and stored at 4°C for 24 hours and thereafter stored at
-20 °C freezer until further processing. For histology, the tissue was preserved in PBS buffered
(pH 7.4) 4% paraformaldehyde solution.

4.2.5 Histology And Confocal Microscopy
The fixed nerves from control, sham and CCI rats were sliced into 20 μm thick
longitudinal cryosections. Double immunofluorescence studies were performed to examine the
infiltration of macrophages (CD68) along with the presence of caspase-1, IL-18, IL-1β and IL-1α
using mouse anti-CD68, 1:100 (MCA341R, AbD Serotech), rabbit anti-caspse-1, 1:50 (caspse-1
p10 (M20) sc514, Santa Cruz Biotechnology), rabbit anti-IL-18, 1:100 (R1186, Acris
Antibodies), rabbit anti-IL-1β, 1:100 (ab9787, abcam) and goat anti-IL-1α, 1:100 (ab9875,
abcam) primary antibodies. The secondary antibodies used were Alexa fluor-488 donkey antimouse, 1:200 (A-21202, Invitrogen), Alexa fluor-546 donkey anti-goat, 1:200 (A-11056,
Invitrogen) and Alexa fluor-647 donkey anti-rabbit, 1:200 (A-31573, Invitrogen). All the
antibody dilutions were prepared using 1:20 normal donkey serum in 1X PBS, pH 7.4. Antigen
retrieval was performed using sodium citrate buffer (10 mM sodium citrate, 0.1% Tween 20, pH

79

6.0 and pH 8.5). Confocal microscopy was performed on a Leica SP2 spectral Laser Scanning
Confocal microscope.

4.2.6 Processing Of Rat Sciatic Nerve
Sciatic nerve sections were obtained from rats (Hilltop lab animals, Scottdale,
Pennsylvania) and immediately preserved in RNA later® solution (Ambion). Nerve tissue was
then homogenized in a 2X lysis buffer (Cell Signaling, Danvers, MA) with 1 mM PMSF using a
handheld homogenizer. Samples were then centrifuged at 12,000g for 10 min at 4°C. After
centrifugation, collected supernatant was measured for total protein concentration using a
Pierce™ BCA Protein Assay Kit (Pierce, Rockford, IL). Next, 100 g of total protein in a
volume of 100l per sample were subjected to analysis of rat cytokines and chemokines as
described below.

4.2.7 Analysis Of Inflammatory Mediators
Prepared nerve sample protein extracts were added to a Millipore (Rat
cytokine/chemokine 14-plex, cat. #RECYTMAG-25K (Billercia, MA) assay kit as per
manufacturer’s specifications, for use on a Luminex™ 100 instrument (Luminex Corp., Austin,
TX). Briefly, 14 cytokines and chemokines, granulocyte-macrophage colony stimulating factor
[GM-CSF], interferon [IFN]-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-18,
GRO/KC, monocyte chemotactic protein-1 [MCP-1], and TNF-α, were assessed using the
MiraiBio CT/QT multiplexing software platform (MiraiBio, Alameda, CA) as per
manufacturer’s specifications. Reported values in pg/ml were then normalized to pg analyte/mg
total protein. The cytokine concentrations obtained (pg/mg) were averaged for each group of rat
at a given time point and their means were compared among different groups at various time
points using Two- way ANOVA. Differences were considered significant at p≤ 0.05.
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4.2.8 Dynamic Bayesian Network Inference
It was assumed that the cytokine levels obtained at four different time points are the
result of ongoing neuroinflammation post CCI. The time course of cytokines/chemokines at four
different time points over a period of 18 days after CCI was first averaged across experimental
repeats and then used as input for a Dynamic Bayesian Network (DBN) inference algorithm,
implemented in Matlab® essentially as described previously [150-153]. Briefly, the algorithm
assumes the data to be drawn from a multivariate normal distribution, with interactions between
nodes modeled as piece-wise linear Gaussian distributions. Network structures were sampled
using a Gibbs sampling scheme and scored according to their fit with experimental data. The
Gibbs sampling procedure was run for 25 steps, and marginal posterior probabilities for each
edge were then averaged over these networks, and reported as an indicator of the confidence in
the inferred interactions. Only edges with marginal probabilities greater than 0.5 were included
in the reported network structure [154].

4.3. Results
4.3.1 Mechanical Allodynia And Inflammatory Mediators During CCI
Mechanical allodynia is one of the classic signs of neuropathic pain development [8]. In
the current study, an experimental paradigm of Chronic Constriction Injury (CCI) was used to
induce neuropathic pain in rats [8, 128]. Similar to prior reports [8, 128], CCI resulted in a
significant increase (Kruskal-Wallis one-way ANOVA and Tukey’s multiple comparisons test, p
< 0.0001) in tactile pain sensitivity (mechanical allodynia) during the second week after CCI
surgery as compared to sham and control rats (Figure 4-1, tactile sensitivity measured on day 11
post-surgery). The increased sensitivity to the tactile stimulus was observed only on the affected
ipsilateral side (right hind limb) of the rat and no such signs were observed on the unaffected
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contralateral side (left hind limb, data not shown). Animals subjected to CCI also exhibited
guarding behaviors for their right hind limbs. These findings confirmed the development of
hypersensitivity, which is an indication of neuropathic pain in the rats post-CCI.

FIGURE 4-1: Mechanical allodynia develops on ipsilateral hind paw post CCI surgery: The
mechanical allodynia is represented as normalized difference scores between the baseline values
before the surgery and day 11 post-surgery for three treatment groups; Naïve control, Sham
control and CCI rats. More negative scores represent higher mechanical sensitivity towards
Semmes-Weinstein filaments. CCI rats developed mechanical allodynia and were significantly
different from both sham and naïve control groups. Bars represent the mean ± SD and *
represents significant difference p < 0.0001 (Kruskal-Wallis 1-way ANOVA by ranks and
Tukey’s multiple comparisons test). Sample size for each treatment group is indicated on the
graph.
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As mentioned earlier, inflammation at the site of nerve lesion contributes to the
development of peripheral sensitization [128, 142]. To investigate the dynamics of
neuroinflammation in this animal model, fourteen different inflammatory mediators were
assayed simultaneously at multiple time points using Luminex™ assessment of protein extracts
from the dissected sciatic nerve (Extended Data Table 4-1).
Extended Data Table 4-1: Cytokine concentrations for 14 different inflammatory mediators in
three treatment groups; naïve control, sham control and CCI rats at four time points; day 0, day
8, day 11 and day 18 post surgery.

Sample$ID Sample
Baseline
Baseline?1&
Baseline?2
Baseline?3&
Baseline?4
Sham
Sham&&(0)1
Day&0
Sham&&(0)2
Sham&&(0)3
Sham&&(0)4
Sham
Sham&(8)1&
Day&8
Sham&(8)2
Sham&(8)3&
Sham&(8)4
Sham
Sham&(11)1&
Day&11
Sham&(11)2&
Sham&(11)3
Sham&(11)4&
Sham
Sham&(18)1&
Day&18
Sham&(18)2
Sham&(18)3&
Sham&(18)4&
CCI
CCI&(0)1
Day&0
CCI&(0)2
CCI&(0)3
CCI&(0)4
CCI
CCI&(8)1
Day&8
CCI&(8)2
CCI&(8)3
CCI&(8)4
CCI
CCI&(11)1
Day&11
CCI&(11)2
CCI&(11)3
CCI&(11)4
CCI
CCI&(18)1
Day&18
CCI&(18)2
CCI&(18)3
CCI&(18)4

Results$in$pg/mg$protein
Time$Point$of$tissue$
collection$(hrs.)
TNF?
IL?1
IFN?
IL?1
IL?5
MCP?1
IL?6
GM?CSF
GRO/KC
IL?10
IL?12p70 IL?18
IL?2
IL?4
0
26.02
86.8
6.06
272.13
164.04
10.58
8.16
277.18
31.72
38.32
32.29
207.14
114.97
174.14
0
20.86
129.14
1.11
164.04
214.59
0
4.76
422.55
18.06
5.08
31.04
176.91
86.98
50.51
0
23
208.26
14.95
264.41
333.79
11.85
30.12
543.56
28.39
30.89
33.52
249.61
121.2
44.38
0
19.73
86.8
1.11
189.08
214.59
9.3
9.82
298.79
37.44
3.46
31.04
132.45
126.58
22.82
2&hr.
21.95
2533.15
10.15
546.64
6841.53
14.35
901.84
243.7
19.83
20.07
28.45
203.36
107.94
49.64
2&hr.
19.73
1454.84
0
240.43
7285.84
3.9
3208.15
228.9
34.19
50.31
31.04
93.37
144.85
117.41
2&hr.
26.02
1490.07
6.83
530.11
5466.47
14.35
1658.14
392.1
21.57
61.76
32.29
262.91
117.19
47.04
2&hr.
20.86
2736.26
9.84
588.89
5485.88
8.65
1482.66
253.41
22.44
42.41
29.76
320.89
101.86
68.44
192&hr.
24.03
86.8
7.56
384.93
124.44
13.11
3.22
201.76
35.82
17.99
32.29
381.52
123.43
55.16
192&hr.
19.73
0
3.27
332.05
137.84
0
4.35
225.56
42.65
20.84
32.29
478.26
86.56
117.08
192&hr.
21.95
116.43
1.98
251.36
251.26
10.58
8.11
463.04
39.05
40.62
31.66
252.65
124.78
31.2
192&hr.
27.11
0.00
11.04
317.08
181.68
0.00
4.88
404.68
26.37
33.83
45.32
355.55
178.25
58.17
264&hr.
27.88
0.00
8.47
448.57
170.92
17.03
3.55
312.23
194.99
58.91
38.49
519.00
114.64
41.75
264&hr.
20.86
129.14
0
220.11
226.92
9.3
11.5
301.84
36.63
50.31
32.29
292.24
118.97
27.11
264&hr.
18.57
44.22
5.22
195.5
124.44
0
4.19
251.8
30.89
32.95
29.76
267.1
173.13
62.11
264&hr.
20.86
68.32
0
106.73
164.04
0
3.8
280.3
37.44
4.54
28.45
217.74
106.2
94.99
432&hr.
19.73
44.22
11.59
261.73
151.03
0
4.85
322.89
11.19
11.2
32.29
161.82
69.36
32.19
432&hr.
16.09
102.49
1.11
207.21
82.64
0
4.17
191.28
18.94
0
27.11
221.53
79.51
41.67
432&hr.
14.76
0
0
112.51
67.99
0
3.45
187.74
11.67
0
27.11
159.18
56.41
26.06
432&hr.
23
140.91
8.41
125.8
226.92
11.85
6.73
423.92
24.16
27.81
32.29
195.04
108.81
48.78
2&hr.
17.35
1159.21
0
405.17
9125.13
11.85
2300.08
201.76
71.41
34.74
25.74
64.85
36.82
17.04
2&hr.
18.57
841.11
0
189.95
3613.15
0
558.11
319.91
39.05
0
30.4
124.93
50.33
11.93
2&hr.
20.86
1633.73
0
501.66 15927.95
11.22 13484.15
167.87
29.23
65.57
31.04
105.38
34.72
10.54
2&hr.
18.57
1480.39
0
247.52
9016.66
6.66
2698.09
152.92
54.38
30.64
29.76
100.88
32.63
18.24
192&hr.
51.95
311.08
0
167.53
176.89
0
13.19
274.05
59.36
9.61
32.29
556
34.02
213.69
192&hr.
99.25
140.91
0
103.26
124.44
0
4.63
208.65
13.53
0
29.76
378.83
41.11
137.94
192&hr.
111.15
116.43
0
93.44
82.64
0
7.65
70.16
31.72
0
29.76
209.04
36.12
258.99
192&hr.
86.89
140.91
0
152.43
52.81
0
6.16
8.06
30.89
0
27.11
384.22
28.54
123.94
264&hr.
67.79
68.32
0
73.18
52.81
0
3.45
115.2
13.53
0
27.11
194.28
27.21
111.44
264&hr.
110.13
208.26
0
261.73
96.89
0
8.03
98.05
81.74
39.6
32.29
441
36.82
178.79
264&hr.
51.31
216.51
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FIGURE 4-2: Cytokine and chemokine protein levels at ipsilateral sciatic nerve suggest
sustained inflammasome activation in CCI rats. Protein concentration measured on ipsilateral
sciatic nerves by multiplex ELISA for three treatment groups; naïve control, sham-surgery
control and CCI rats at four time points; day 0 (2-3 hrs. post surgery), day 8, 11 and 18 post
surgery. a. IL-4 protein is elevated in a statistically significant manner (Tukey’s multiple
comparisons test) in the CCI condition as compared to sham and naïve rats from day 8 through
day 18 (Two-way ANOVA; there was a non-significant main effect of rat condition (p = 0.1723)
and a significant effect of time (p = 0.0119) with a significant interaction between variables (p =
0.0004). b. For CCI, IL-18 concentration increased from day 8 through day 18 and was
significantly different from day 0 values at all time points (Tukey’s multiple comparisons test).
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Significant difference between CCI & sham rats was observed on day 18 (Tukey’s multiple
comparisons test). Significant difference for CCI and naïve control rats was observed on day 8,
11 and 18 (Tukey’s multiple comparisons test). For sham rats, the IL-18 levels increased from
day 8 to day 11, however unlike CCI rats, the levels returned to baseline levels by day 18 postsurgery (Tukey’s multiple comparisons test). (Two-way ANOVA; there was a significant main
effect of rat condition (p = 0.0351) and time (p = 0.0315) with a significant interaction between
variables (p = 0.0139). c. MCP-1 protein is elevated in a statistically significant manner (Tukey’s
multiple comparisons test) similar to what was observed for IL-18 in the CCI condition as
compared to sham and naïve rats (Two-way ANOVA; there was a significant main effect of rat
condition (p = 0.0374) and time (p = 0.0084) with a significant interaction between variables (p
= 0.0334). d. IFN-γ protein drops in the CCI condition in a statistically significant manner
(Tukey’s multiple comparisons test) over the time course of the experiment as compared to sham
and naïve rats (Two-way ANOVA; there was a significant main effect of rat condition (p =
0.0171) and non-significant main effect of time (p = 0.1844) with a non-significant interaction
between variables (p = 0.5332). Bars represent the mean ± SD and * represents significant
difference at p ≤ 0.05 (Tukey’s multiple comparisons test). Four rats were used in each treatment
group at every given time point.
Inflammatory mediators whose expression was determined to be significantly different
between CCI and sham rats included IL-1β, IL-2, IL-4, IL-5, IL-6, IL-18, IFN-γ, TNF-α, MCP-1
and IL-12p70. Four mediators exhibited significant difference (Tukey’s multiple comparisons
test) across the entire time course of the experiment (Figure 4-2). For example, in CCI rats, the
expression of IL-4 was significantly elevated (Tukey’s multiple comparisons test) by day 8 and
high expression persisted through day 11 and day 18 as compared to both sham-surgery rats and
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the naïve control (Figure 4-2A). For IL-4, there was a non-significant main effect of rat condition
(p = 0.1723) and a significant main effect of time (p = 0.0119) with a significant interaction
between variables (p = 0.0004) using Tukey’s multiple comparisons test. In sham-surgery rats,
IL-18 expression was significantly higher (Tukey’s multiple comparisons test) than naïve control
from day 8 to day 11 post-surgery, followed by a return to baseline levels on day 18. In contrast,
the CCI rats exhibited IL-18 expression that was significantly higher (Tukey’s multiple
comparisons test) than normal on day 8 and that persisted at a significantly high level (Tukey’s
multiple comparisons test) through day 18 (Figure 4-2B). For IL-18, there was a significant main
effect of rat condition (p = 0.0351) and time (p = 0.0315) with a significant interaction between
variables (p = 0.0139) using Tukey’s multiple comparisons test. Similar to IL-18, MCP-1
expression was elevated at day 8 for both the sham-surgery and CCI rats. In contrast, at day 11
and day 18 MCP-1 expression trajectories of the sham and CCI animals diverged: MCP-1
expression in the sham animals returned to baseline levels, while MCP-1 expression in CCI
animals persisted at a significantly high level (Tukey’s multiple comparisons test) (Figure 4-2C).
For MCP-1, there was a significant main effect of rat condition (p = 0.0374) and time (p =
0.0084) with a significant interaction between variables (p = 0.0334) using Tukey’s multiple
comparisons test. IFN-γ levels were significantly lower in CCI rats (Tukey’s multiple
comparisons test) as compared to sham and naïve rats starting on day 8, and remained low
through day 18 (Figure 4-2D). For IFN-γ, there was a significant main effect of rat condition (p =
0.0171) and a non-significant main effect of time (p = 0.1844) with a non-significant interaction
between variables (p = 0.5332) using Tukey’s multiple comparisons test.

4.3.2 Dynamic Bayesian Network (DBN) Inference
Based on the tissue-level protein expression data (extended data Table 4-1), DBN
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inference [150-152] was utilized to calculate the most likely central nodes and regulatory
interactions (Figure 4-3).

FIGURE 4-3: Dynamic Bayesian Network (DBN) inference suggests a central role for the
inflammasome in CCI: Data on inflammatory mediators from CCI (A) and Sham (B) rats (see
Figure 4-2 & Extended Data Table 4-1) were used to carry out DBN inference. Inflammatory
mediators are represented as network nodes. The thickness of connections among nodes or to
themselves (edges) is based on how often they are represented in individual experiments. Nodes
with auto-regulatory feedback and connections to other nodes are considered central.
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This analysis suggested that elevated pain sensitivity in CCI rats occurs in parallel to
changes in the tissue expression of key inflammatory mediators. In CCI animals (Figure 4-3A),
this analysis suggested a network in which IL-18 serves as a central node exhibiting autoregulatory feedback. Furthermore, IL-18 was inferred to affect the expression of multiple
inflammatory mediators including IL-5, MCP-1, IL-1β, IL-6, IFN-γ, and IL-4. In sham-surgery
animals (Figure 4-3B), DBN inference suggested a network centered on IFN-γ, IL-1β, and IL-18,
with each exhibiting auto-regulation.

4.3.3 Immunohistochemical Analysis
Figure 4-3 raised the hypothesis that inflammasome activation – known to drive the posttranslational processing of pro-IL-18 and pro-IL-1 to IL-18 and IL-1, respectively [44, 155] –
occurred in the setting of CCI. To test this hypothesis, multi-target immunofluorescence was
performed on the ipsilateral sciatic nerve tissue sections from CCI, sham, and naïve control rats.
The analysis of CCI tissue sections demonstrated the elevated expression of prostaglandin E2
(PGE2), IL-18, IL-1β, IL-1α, and the inflammasome product caspase-1 in CCI, whereas these
proteins were not detected in sham or naïve control nerve sections (Figure 4-4).
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FIGURE 4-4: Double immunofluorescence for macrophages and cytokines on ipsilateral sciatic
nerve cryosections suggests inflammasome activation in CCI rats: IL-18 A shows infiltration of
CD68 positive macrophages and presence of IL-18 in CCI sciatic nerve. Sham and Naïve control
sciatic nerves did not exhibit presence of macrophages and IL-18 (B, C). IL-1α Ipsilateral CCI
sciatic nerves exhibit presence of macrophages and IL-1α (D), which are both absent from Sham
and Naïve control tissue (E, F). IL-1β Macrophages and IL-1β are evident in the affected sciatic
nerve (G), but are absent from Sham and Naïve control tissue (H, I). Caspase-1 Macrophages
and caspase-1 are evident in the CCI sciatic nerve (J), but are not evident in the Sham and Naïve
control tissue (K, L). PGE2 Macrophages and PGE2 are evident in the affected CCI sciatic
nerve (M). No macrophages or PGE2 expression are evident in the Sham and Naïve control
tissue (N, O). For each experiment group (A, B, C), (D, E, F), (G, H, I), (J, K, L) and (M, N,
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O), the confocal images were acquired in the same sitting with the same image acquisition
parameters. Bar = 150 µm.

4.4. Discussion
Within hours following the peripheral nerve injury, several physiological responses can be
observed including involvement of innate and adaptive immune responses [16]. Within days of
the peripheral nerve injury, the physiological changes become manifested as hyperexcitability of
nociceptive neurons in response to innocuous tactile stimuli. This phenomenon becomes evident
as mechanical allodynia, as described by Bennett and Xie in 1988. Similar to our previous report
[128], we have confirmed the development of mechanical allodynia in this study. Inflammation
begins at the site of injury, and later involves the dorsal root ganglia (DRG), spinal cord and
brain [16]. Conventional immune cells such as mast cells, neutrophils, macrophages and T
lymphocytes, along with other resident cells such as Schwann cells, microglia and astrocytes,
exhibit activated profiles of gene expression producing a variety of inflammatory mediators that
contribute to the initiation and maintenance of neuropathic pain [16, 23, 118, 136]. Based upon
previous studies, the cytokines that are consistently elevated in expression following peripheral
nerve injury are TNF-α, IL-1β, and IL-6 [3].
Neuroinflammation is a complex physiological response. While extensive research on
inflammatory mediators has led to some useful clinical therapies, satisfactory treatment of
neuropathic pain remains elusive [156]. Under experimental conditions of neuroinflammation,
neutralizing antibodies have been used to attack several inflammatory mediators including TNFα, IL-1β, IL-6, IL-15, IL-18, and MCP-1 resulting in limited success in reducing neuropathic
pain [16]. Furthermore, stimulation of nominally anti-inflammatory cytokines (IL-4, IL-10, TGFβ1) was reported to reduce hypersensitivity in various animal models of neuropathic pain [16].
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In the present study, we hypothesized that a better understanding of the dynamic
interconnections among tissue inflammatory mediators would facilitate the search for
inflammation-modulating therapies in the setting of neuropathic pain. In clinical settings,
neuropathic pain is mostly diagnosed in its chronic stages. Therefore, we determined the tissue
levels of inflammatory mediators at both acute (2-3 hours post-CCI) and subacute as well as
chronic stages (day 8 to day 18 post-CCI). Based on DBN inference carried out with these data,
we hypothesize key interactions among inflammatory mediators that are operant in CCI-induced
neuroinflammation, as well as the transition from acute to chronic pain. Specifically, we infer a
central role for IFN-, IL-1, and IL-18 following general tissue injury, since these mediators
appeared as central nodes (those which are feeding back on themselves as well as affecting the
expression of other mediators) in the sham surgical acute inflammatory network. In contrast, IL18 was inferred as the central node in the CCI animals, appearing to control its own expression
along with affecting other mediators involved in neuroinflammation. This IL-18-centered
network correlates with the maintenance of neuropathic pain (mechanical allodynia) throughout
the period of study.
The inflammasome is a caspase-activating complex that serves critical roles in innate
immunity [44, 155, 157-159]. It is known that inflammasome induction in macrophages leads to
secretion of IL-18 as well as IL-1. Both IL-18 and IL-1 are cleaved proteolytically from their
respective precursors via activation of caspase-1 enzyme. Both IL-18 and IL-1 can induce
cyclooxygenase and PGE2 [155, 160-164]. Both IL-18 and IL-1 are elevated in the spinal cord
(central nervous system) following CCI [9, 157]. Similarly, we found IL-18 expression to be
elevated consistently at the site of injury (peripheral nervous system) from day 8 to day18 postCCI. However, no consistent difference was found for IL-1 baseline and post-CCI protein
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levels at the site of injury (data not shown). Immunofluorescence analysis carried out on
ipsilateral sciatic nerve sections further confirmed the expression of IL-18, caspase-1, and PGE2
after the CCI surgery.
Among the many inflammatory pathways induced by inflammasome activation, the
cyclooxygenase pathway and attendant production of PGE2 play a key role in the setting of
inflammatory pain following peripheral nerve injuries [29, 118]. Separate studies have also
demonstrated that IL-18 can induce both cyclooxygenase and PGE2 from macrophages and
chondrocytes [160, 162]. Our immunohistological studies confirm the expression of IL-18 in the
sciatic nerve, supporting our Luminex™ data and supporting the hypothesis that inflammasome
activation occurs in damaged nerves in the setting of CCI.
DBN inference along with our other data suggests that as a consequence of CCI, besides
driving its own expression, IL-18 also drives the expression of IL-4 and MCP-1 along with the
down regulation of IFN-γ. In the context of nerve injury, IFN-γ has been shown to exhibit
elevated expression in the central nervous system, and contribute to central sensitization [148].
However in the present study, we observed a gradual decline in IFN-γ at the site of chronic
constriction injury on the sciatic nerve over the entire duration of the study. IFN-γ is induced in
macrophages either by the synergistic action of both IL-18 and IL-12 or in the presence of active
IL-12p70 homodimer [97, 165-168]. We did not observe an up regulation in the IL-12p70 levels
for the CCI rats. With regard to IL-4, this cytokine can play an anti-inflammatory role in many
settings of inflammation, as well as exerting anti-nociceptive properties in the setting of
neuropathic pain [169]. Moreover, IL-4 is a known inhibitor of IFN-γ production by the
macrophages [165]. Here, we observed a consistent up regulation of IL-4 in the CCI rats from
day 8 to day 18 post-CCI. Importantly, IL-18 is also known to perform other immune functions
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that are not directly related to the IFN-γ production. Furthermore, IFN-γ production is not
dependent entirely on IL-18 [170]. Therefore, even though IL-18 (which was initially named as
‘IFN-γ inducing factor’) is up regulated, this does not necessarily cause an up regulation of IFNγ in all circumstances.
Dynamic Bayesian Network inference also suggested that IL-18 might drive the
expression of the chemokine MCP-1/CCL2 during peripheral neuropathy. Consistent with
previous studies [171], we found elevated MCP-1 expression as a consequence of CCI, and it is
likely that MCP-1 expression also contributes to the development of mechanical allodynia. These
findings further support the activation of inflammasome pathways post-CCI injury, leading to
activation of caspase-1 and the production of IL-18 and IL-1β. Similar observations have been
made for neuropathic pain models and a model of complex regional pain syndrome [157, 172].

4.5. Conclusion
This study highlights the potential for computational modeling as a tool to infer key
interactions among inflammatory mediators at the tissue level in the context of chronic
neuropathic pain. The results of this combined in vivo / in silico study suggest a central role for
inflammasome activation and subsequent production of IL-18 in the induction and maintenance
of neuropathic pain during peripheral nerve injury. Furthermore, our analyses suggest that the
response to general tissue injury in this context involves interactions among IFN-γ, IL-1β and IL18. Recent studies have demonstrated that spinal blockade of IL-18 led to improvement in
mechanical allodynia and thermal hyperalgesia during CCI in rats [9]. Therefore, these results
raise the possibility that IL-18 or inflammasome inhibition may lead to significant neuropathic
pain relief; however, these studies must be extended and the exact underlying mechanisms still
need to be revealed. Finally, these studies demonstrate the power of combined in-vivo / in-silico
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studies in the setting of chronic neuropathic pain.
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Chapter 5
DISCUSSION
5.1 In-Vivo Inflammation Imaging Using Near Infra Red (NIR) Fluorescence
And 19F Magnetic Resonance Imaging (MRI) In CCI Rat Model
The accurate diagnosis of neuropathic pain associated neuroinflammation relies upon the
nerve biopsy, which is not feasible in all the cases of neuropathic pain [173]. In addition, the
procedure is invasive and the etiology may remain elusive even after the biopsy due to a
mismatch between the region of biopsy and the site of actual inflammation in the injured nerve.
Therefore, neuroinflammation imaging matched with an analysis of symptoms exhibited by the
patients may guide the clinicians to personalized and targeted treatment for a given set of
patients. Today, the focus is on mechanism-based treatment of neuropathic pain rather than
following a common regimen of treatment for various neuropathic pain disorders [156].
Therefore, it would be of great value if we can image neuroinflammation in-vivo using noninvasive techniques.
Multiple imaging modalities are available to image the structures and/or physiological
functions in the body. Examples of imaging modalities for medical purposes include plain
radiography (using X-rays only), fluoroscopy (using X-rays and contrast agents such as Barium
sulphate), computed tomography (CT scan using X-rays), magnetic resonance imaging (MRI
using radio frequency waves), positron emission tomography (PET using positron emitting
radionuclide tracers) and single photon emission computed tomography (SPECT using gamma
rays). Radionuclide based scans have limited resolution [174] and have to be combined with
MRI or CT to achieve the resolution of anatomic details [175]. These techniques have done
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wonders to guide clinicians in making accurate diagnoses. However, diagnosing early stages of
inflammation in soft tissues is still a bottleneck when using conventional imaging techniques
available, due to poor contrast between the inflamed and healthy tissue and low signal-to-noise
ratio [176]. In-vivo neuroinflammatory events are difficult to be captured by these conventional
imaging techniques, unless the inflammation is flared-up to the extent of causing morphological
changes in the nerve, such as a significant change in the diameter of the nerve due to edema or a
high contrast between the pathological and a healthy tissue.

5.2 Imaging Reagents
Contrast of MRI scan can be drastically improved with the use of contrast tracers such as
gadolinium, super paramagnetic iron-oxide particles and 19F tracers. Recently, iron-oxide
particles and 19F tracers have been successfully used in biomedical research in various animal
models, such as organ transplant rejection [38], experimental allergic encephalomyelitis [85],
inflammatory bowel disease [122], pulmonary inflammation [177], inflammation post cardiac
and cerebral ischemia [176], Staphylococcus aureus abscess [178], renal graft rejection [179],
and cardiac allograft rejection using iron-oxide particles [180]. Phase I clinical trial in humans
have employed a 19F tracer to track ex-vivo labeled dendritic cells, injected as dendritic cell
vaccine against colorectal adenocarcinoma in human patients [175]. 19F is a stable and a natural
isotope found in abundance. Also, 19F has a nuclear spin of ½ and is highly responsive to NMR
analysis providing a high signal-to-noise ratio with no background noise [42]. Even though iron
oxide labeling provides higher sensitivity as compared to a 19F tracer during MRI [38], 19F signal
directly correlates to the amount of labeled cells. On the other hand, metal ion-based MRI agents
indirectly change the relaxation times of water in their surroundings and therefore the alteration
in signal contrast (increase or decrease) is ambiguous and indirectly related to the amount of
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labeled cells present [38]. Also, 19F MRI has no background signal in the soft tissues and thus is
highly specific and more advantageous than metallic tracers [87]. Gadolinium, another metallic
labeling agent, labels the region of inflammation, due to its leakage through the leaky capillaries
with increased permeability due to the undergoing inflammatory events. Therefore, the
specificity can be compromised by other biological phenomena, such as a circulatory disease,
rather than due to the inflammatory disease under study [176].
Another advantage of 19F imaging is that both 1H and 19F MRI can be obtained with the
same scanner in one experiment and both the scans can be superimposed to precisely locate the
19

F signal within the anatomical structures. Natural fluorine found in the body (19F) is present in

bones and teeth. It stays fixed and moves negligibly and therefore the signal achieved elsewhere
due to 19F is highly sensitive of the tracer [181].
Our collaborator Jelena M. Janjic, Pharm D, PhD has designed a novel nanoemulsion
containing a NIR dye and a 19F tracer for tracking inflammation with dual imaging modalities of
optical imaging and 19F MRI. Previously, optical imaging and bioluminescence have been used
in animal models, such as cutaneous granuloma model using DiR dye labeled macrophages
[119]. Dyes with excitation wavelength below 700 nm are strongly absorbed and scattered by
hemoglobin in the body and the dyes with excitation wavelength above 820 nm are also strongly
absorbed as well as scattered by water molecules in the body. Thus, NIR dyes with excitation
window between 700 nm and 800 nm are best suited for optical imaging in animal tissues [97],
(LiCOR Biosciences http://biosupport.licor.com/docs/pearlBrochure2010.pdf). Therefore, in this
study, a NIR dye was used to label the circulating immune cells along with the 19F tracer,
formulated as a nanoemulsion. Even though NIR imaging has high sensitivity [42], it also has
tissue penetration depth limitations, due to scattering and absorption issues, which results in poor
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resolution, rendering NIR imaging only as a semi-quantitative technique [182]. To overcome this
limitation, MRI was performed along with NIR fluorescence imaging [42].
MRI has infinite tissue depth penetration with high resolution of 10-100 μm [38, 183].
Thus, the use of 19F tracer led to enhanced specificity and sensitivity of the inflammatory signal
detection. Therefore, the NIR dye and the 19F tracer containing dual mode nanoemulsion was
used in this study with the goal of imaging of neuroinflammation using dual imaging modalities
of NIR fluorescence and 19F MRI.

5.3 Animal Model
There are various animal models available to study neuropathic pain, such as the chronic
constriction injury rat model [8], spinal nerve ligation [184] and partial sciatic nerve ligation
[185]. A majority of the neuropathic pain conditions in human patients involve partial damage to
the nerve rather than a complete nerve transection. CCI in rats causes partial damage to the
sciatic nerve, thus simulating commonly found neuropathic conditions in humans [8]. CCI rat
model is a well-established and well-characterized rat model in the field of neuropathic pain [9].
The hallmarks of neuropathic pain include thermal hyperalgesia, cold allodynia and tactile
allodynia. These signs develop readily after the CCI injury and persist for about two months
post-CCI [8]. The common sciatic nerve is readily located and easily manipulated due to its
relatively larger size. Another advantage is that in this model, both spontaneous and evoked painlike behaviors can be studied. Spontaneous pain-like behavior is demonstrated by paw licking,
avoiding weight bearing, limping and relatively less movement of the affected limb [10]. Evoked
pain-like behavior is caused as a response to noxious or non-noxious external stimuli.
After about one week post-CCI, the signs of hypersensitivity develop that indicate the
onset of neuropathic pain in rats. Hypersensitivity is enhanced responsiveness to a normal

98

innocuous stimulus or an exaggerated response to a noxious stimulus [1]. We observed the
development of hypersensitivity to a normally innocuous mechanical stimulus, constituting
mechanical allodynia. Behaviorally, mechanical allodynia begins to develop in the ipsilateral
hind paw from day 8 post-CCI and persists for approximately 7 weeks post-CCI [186]. In the
current study, the development of neuropathic pain was confirmed by the presence of mechanical
allodynia on the ipsilateral hind paw, observed on day 11 post-CCI. Literature suggests that CCI
rats exhibit the signs of neuropathic pain-like behavior at least 2 months post-CCI surgery [8].

5.4 Nanoemulsion
Nanoemulsions are oil-in-water emulsions that are stabilized with surfactants or
emulsifiers. Nanoparticles can be of various sizes, and for biomedical purposes, the most
commonly used size ranges from 100-500 nm [187]. Most immune cells participating during
inflammation are known to be phagocytic, and can engulf the intravenously injected
nanoemulsion [90]. Given that during inflammation, the inflammatory cells migrate from blood
to the site of injury, one of the methods to track inflammation is to follow the migration of these
labeled immune cells (i.e. labeled with nanoemulsion) from blood to the site of injury [38, 188].
Hence, with the purpose of labeling the immune cells in-vivo, slow intravenous injection of the
nanoemulsion (0.3 ml) was given to the rats under general anesthesia on day 8 post-CCI. The
average size of the nanoemulsion droplets used in this study was around 180 nm [42].
It is important to recognize that the larger size nanoparticles (> 500 nm) are phagocytized
by the circulating phagocytic cells whereas the smaller size nanoparticles (<500 nm) are
engulfed by receptor mediated endocytosis or pinocytosis [189]. In-vitro studies have shown that
PFC nanoemulsions can be engulfed either by phagocytic or non-phagocytic cells via
endocytosis [69, 70, 190]. PFC based nanoemulsions can be phagocytized by phagocytic cells,
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such as monocytes, macrophages, neutrophils, dendritic cells and T lymphocytes [174, 191, 192].
Flogel and coworkers have shown that following the intravenous injection, the PFC containing
nanoemulsion droplets are engulfed preferentially by circulating monocytes/macrophages
(~80%), followed by B and T lymphocytes [176, 191]. During in-vitro characterization, it has
also been shown that the PFC nanoemulsion is non-toxic and does not affect the viability of
macrophages [40, 42, 71]. Post-intravenous injection blood clearance half-life of a similar PFC
nanoemulsion (~145 nm diameter) has been found to be approximately 9 hours [38]. In allograft
rejection rat model, it has been shown that the labeled immune cells reach the site of rejection
within 24 hours [38] and in another study, ex-vivo labeled dendritic cells took around 18 hours to
drain the regional lymph node in human subjects [175]. As mentioned earlier, we observed the
development of significant mechanical allodynia on day 11 post-CCI, which is an indirect
indicator of the development of neuroinflammation at the sciatic nerve [193]. Therefore, based
upon the given fact and the brief review of literature given above, in this study, the nanoemulsion
was injected on day 8 post-CCI and the NIR fluorescence imaging was performed on day 11
post-CCI. A time period of 72 hours between the time of injection and NIR imaging allowed for
the uptake of the nanoemulsion by the immune cells in circulation and their migration to the site
of injury (sciatic nerve).
Based upon the literature [37, 38, 40, 42, 69] and the size of the nanoparticles used in this
study (<160 nm, [42], it was predicted that after the intravenous injection of the nanoemulsion,
the nanoparticles containing NIR dye and 19F tracer would be endocytosed by the circulating
monocytes and then migrate to the sciatic nerve post-CCI, causing neuroinflammation. To
resolve a specific NIR signal above tissue background and to reveal that NIR fluorescence was
evident on the thoracolumbar region of the rats, NIR fluorescence images were acquired
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immediately before the injection of the nanoemulsion in all the experimental groups of rats
(Chapter 2, Figure 2-2). Pre-injection NIR fluorescence in the thoracolumbar region of the rats
suggested autofluorescence in the liver and abdominal areas, possibly due to rat diet contents in
the gastrointestinal tract (LiCOR Biosciences). Similar to hemoglobin and water, chlorophyll,
along with other components in a regular rat diet, absorbs NIR wavelength and scatters light invivo (LiCOR Biosciences). Therefore, purified diet (D10012G Research Diets, Inc. New
Brunswick, NJ) was used during NIR imaging because it significantly reduces autofluorescence
during in-vivo NIR fluorescence imaging (LiCOR Biosciences). Even though the use of purified
diet did lead to reduced autofluorescence, it was not completely eliminated and was consistently
observed before or after the nanoemulsion injection on day 8 post-CCI (Chapter 2, Figure 2-2, 23.1). To ensure the precise intravenous delivery of the nanoemulsion, all the rats were imaged on
the LiCOR imager immediately after the injection to observe a fluorescent spot on the tail that
represented the site of injection (Chapter 2, Figure 2-2 G). Slight leakage of the fluorescent
nanoemulsion at the injection site was inevitable due to puncture of the tail vein by the needle at
the injection site. However, the presence of a strong fluorescent signal from the site of injection
towards the base of the tail or a big clump of strong fluorescent signal localized in the tail
indicated a subcutaneous injection. The rats injected with unintentional subcutaneous delivery of
the nanoemulsion were excluded and only the rats injected with accurate intravenous delivery of
the nanoemulsion were included in this study. Overall, based upon the LiCOR imaging, the
success rate of intravenous injections in the lateral tail vein of young-adult rats was
approximately 70% in this study.
In the CCI rat, a sharp band of fluorescent signal visible on the ipsilateral thigh on day 11
post-CCI (Chapter 2, Figure 2-2 I) indicated presence of inflammation at the site of injury, which
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was significantly different (t test, one-way ANOVA, two-way ANOVA) from the contralateral
CCI hind limb and the naïve or sham conditions (Chapter 2, Figure 2-3.1 G, Figure 2-3.2). With
the goal of finding out the exact source of NIR fluorescence in the thigh region of the CCI rat,
LiCOR Pearl imaging was performed on a perfusion fixed rat on day 12 post-CCI. And it was
found that the NIR fluorescence at the ipsilateral thigh region of a CCI rat was contributed by the
regional lymph node and the femur bone in addition to the injured ipsilateral sciatic nerve (data
not included in the dissertation). On the contralateral hind limb, the NIR fluorescence was
observed only on the lymph node and the femur bone, however no fluorescence was visible on
the contralateral sciatic nerve. The presence of NIR fluorescence in the lymph node and femur
bone is possibly due to physiological circulation of the labeled immune cells through the
reticuloendothelial (RE) system. RE system is the other name for mononuclear-macrophage
system where the macrophages are scattered throughout the reticular connective tissue in liver,
spleen, lymph nodes, bone marrow and lungs. The clearance of PFC nanoemulsions is assumed
to occur via RE system and expiration through lungs [87, 90]. Sham rats exhibited a sharp NIR
fluorescence at the site of incision (Chapter 2, Figure 2-3.1 B) on day 11 post-surgery. Since the
fluorescence was not scattered and had very sharp boundaries, it indicated a superficial injury
due to the skin and muscle incision during sham surgery rather than a deep injury like in a CCI
rat that showed a scattering effect leading to an irregular band of fluorescence (Chapter 2, Figure
2-3.1 B). Also, on day 18 post-surgery, the fluorescent signal had almost disappeared in sham
rats, whereas it persisted in the CCI rats (Chapter 2, Figure 2-3.1 C,F). This confirmed that the
sham surgery was superficial and that the skin and muscle incisions had been nearly healed by
day 18 post-surgery, whereas CCI rats still exhibited a strong fluorescent signal on day 18 postCCI that indicated persistent inflammation on the injured sciatic nerve (Chapter 2, Figure 2-3.1
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C, F). To further confirm the origin of NIR fluorescence in the sciatic nerve, the ipsilateral
common sciatic nerve was dissected out from the CCI and the sham rats and was imaged on
LiCOR Odyssey imager. LiCOR Odyssey imager is a two dimensional scanner with 700 nm and
800 nm excitation lasers for ex-vivo NIR imaging (LiCOR Biosciences). A strong fluorescent
signal was observed for the CCI rat sciatic nerve that confirmed the presence of NIR dye in the
injured sciatic nerve and hence complemented the in-vivo NIR imaging data to suggest that the
NIR fluorescence in the sciatic nerve was indeed due to the presence of NIR dye containing
immune cells participating in the neuroinflammation at the injured sciatic nerve (Chapter 2,
Figure 2-3.1 H, I). Since the nanoemulsion labeled cells contained both NIR dye and a 19F tracer,
to trace the presence of 19F tracer in the sciatic nerve, 19F MRI was performed in the ipsilateral
hindleg of the perfusion fixed CCI and sham rats, along with 19F Nuclear Magnetic Resonance
NMR spectroscopy on the dissected ipsilateral and contralateral sciatic nerves. Superimposed 1H
and 19F scans of axial and coronal slices of the rat hind leg revealed the presence of 19F signal
(red) superimposed with the knots at the ipsilateral sciatic nerve of the CCI rat (Chapter 2, Figure
2-4). The 19F signal was not present at the ipsilateral sciatic nerve of the sham rat or the
contralateral sciatic nerve of the CCI rat. Hence, the in-vivo (LiCOR Pearl) and ex-vivo (19F MRI
and LiCOR Odyssey) imaging data strongly suggested the presence of inflammation at the
injured sciatic nerve in the CCI rats due to the accumulation of nanoemulsion labeled immune
cells at the site of injury. 19F NMR revealed the confirmatory peak of PFC nanoemulsion in the
ipsilateral sciatic nerve post-CCI and no 19F signal was evident in the contralateral sciatic nerve
of the CCI rats or the ipsilateral nerves from the sham or naive control rats (Chapter 2,
Supplementary Figure 2-S2). Besides the presence of 19F signal at the sciatic nerve, the 19F signal
was also observed in the ipsilateral femur and tibia bones of the CCI and sham rats (Chapter 2,
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Figure 2-4). 19F signal in the bones could be due to the fact that the PFC nanoparticles are
engulfed by the monocytes and macrophages and are cleared-up by the RE system of the bones
[189]. Suyama and coworkers showed the development of osteoporosis in the ipsilateral tibia
bone associated with the CCI of the common sciatic nerve in rats [124]. Similarly in humans,
patchy osteoporosis has been linked with complex regional pain syndrome [123]. Therefore,
another reason for the presence of 19F signal in the bones of CCI rats could be the inflammatory
changes associated with the regional peripheral nerve injury (i.e. common sciatic nerve). Since
the 19F signal was observed in both the CCI and sham rats, and apparently the intensity of the 19F
signal in the femur bone of the CCI rat was much higher than the femur bone of the sham rat
(Chapter 2, Figure 2-4), it is very likely that the 19F signal in the femur bone is due to a
combination of both physiological (clearing by the RE system of the femur bone) and
pathological reasons (osteoporosis of the ipsilateral femur bone). However, these interesting
findings need to be substantiated and further explored in future studies.
To validate the results obtained from the imaging techniques, immunofluorescence was
performed on thin cryosections of the fixed sciatic nerves to find out the infiltration of activated
macrophages in the sciatic nerve. In Chapter 2, Figure 2-5 showed the infiltration of CD68+
macrophages in the ipsilateral sciatic nerves of the CCI rats whereas no such infiltration was
apparent for the sham or naïve control rats. This finding confirmed that the NIR fluorescence
signal and 19F signal in the ipsilateral thigh of the CCI rats was indeed due to the presence of
nanoemulsion labeled macrophages at the site of injury. Therefore, the first hypothesis that
“neuroinflammation will be visualized in-vivo by NIR imaging and 19F MRI by intravenous
injection of a dual mode nanoemulsion containing NIR dye and 19F tracer” is accepted. We have
demonstrated that the NIR fluorescence imaging and the 19F MRI techniques were
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complementary to each other and that it was feasible to capture neuroinflammation with a
positive contrast signal and high resolution at the common sciatic nerve in a CCI rat model.
Following successful imaging of neuroinflammation in CCI rat model [128], the theranostic
nanoemulsion originally designed and developed by Dr. Jelena M. Janjic and Sravan K. Patel
[41, 42] was used to track the inflammation at the site of injury before and after the drug
administration. The goal of this study was to track the therapeutic effect of the theranostic
nanoemulsion [41, 42] on the CCI induced neuropathic pain by measuring mechanical allodynia
in rats along with tracking inflammation by using NIR fluorescence imaging and 19F MRI
techniques. The nanoemulsion injection with celecoxib (theranostic nanoemulsion) or
nanoemulsion without celecoxib (vehicle nanoemulsion) (0.3 ml each), was given on day 8 postsurgery. Similar to our previous study [128], and based upon the size of the nanoemulsion used
(< 160 nm, [42]), upon intravenous delivery, the nanoemulsion is engulfed by the circulating
monocytes and hence the anti-inflammatory drug (celecoxib) is delivered directly into the
monocytes in circulation. As mentioned earlier, nanoemulsion loaded monocytes then migrate
and accumulate at the site of injury to participate in the inflammation at the injured sciatic nerve
[128]. In-vitro drug kinetics and in-vivo pharmacodynamics and pharmacokinetics of the
theranostic nanoemulsion were beyond the scope of this dissertation and should be pursued in
future studies.

5.5 Reduced Hypersensitivity Using Celecoxib Containing Theranostic
Nanoemulsion In CCI Rat Model
As mentioned earlier, mechanical allodynia is one of the classic signs of neuropathic pain
[194]. Therefore, to observe the development of neuropathic pain-like behavior in rats,
mechanical allodynia was recorded everyday, up to day 12 post-CCI (performed and analyzed by
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Muzamil Saleem). Similar to our previous results, mechanical allodynia developed around day 7
post-CCI and persisted through the entire period of study, up to day 12 post-CCI for the CCI
group injected with the vehicle nanoemulsion (i.e. nanoemulsion without celecoxib) (Chapter 3,
Figure 3-1). Similar to the previous results and as expected, hypersensitivity development was
not observed for the sham or naïve control rats. Similar to our previous study [128], rats were
given the nanoemulsion injection (theranostic nanoemulsion or vehicle) on day 8 post-surgery.
For both the CCI groups, injected with theranostic or vehicle nanoemulsion, mechanical
allodynia profile was similar, up to the day of nanoemulsion injection (i.e. day 8 post-CCI).
Unlike the CCI rats injected with vehicle nanoemulsion, there was reversal of hypersensitivity
behavior (i.e. mechanical allodynia) in the CCI group injected with celecoxib-containing
nanoemulsion on day 9 post-CCI (the day following the theranostic nanoemulsion injection). A
statistically significant (Two-way ANOVA) reduction in the hypersensitivity behavior
(mechanical allodynia) was observed from day 10 post-CCI up to day 12 post-CCI (Chapter 3,
Figure 3-1). On the other hand, as mentioned earlier, the vehicle injected CCI group exhibited
persistent mechanical allodynia from around day 7 post-CCI up to day 12 post-CCI. COX-2 and
PGE2 are important contributors to the hypersensitivity associated with neuropathic pain [29, 56,
60-62]. In earlier studies, prolonged administration of celecoxib has been effective in reducing
the hypersensitivity in pre-clinical models of neuropathic pain [33, 35, 64]. Hypersensitivity in
neuropathic pain is majorly contributed by the macrophage infiltration, and also the subsequent
PGE2 release at the site of injury [62]. Therefore, a significant reduction in mechanical allodynia
in the treated CCI group (i.e. injected with theranostic nanoemulsion) indicated either a reduction
in macrophage infiltration and/or reduced COX-2 and PGE2 levels in the macrophages present at
the site of nerve injury. In-vitro characterization of the theranostic nanoemulsion, using an
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ELISA assay, has revealed a significant reduction in PGE2 levels in the activated macrophages
in cell-culture studies [42]. Based upon the previous in-vivo studies using PFC nanoemulsions of
similar size, the majority of the nanoemulsion is engulfed by the circulating monocytes and a
smaller proportion by other circulating immune cells [37, 38]. Possible molecular events for
reduced hypersensitivity upon injection of a single dose of celecoxib-containing theranostic
nanoemulsion have been discussed in Chapter 3, discussion. (Please refer to Chapter 3 for further
details).

5.6 In-Vivo Inflammation Imaging Using Near Infra Red (NIR) Fluorescence
And 19F Magnetic Resonance Imaging (MRI) In CCI Rat Model
Similar to our previous study [128] and as described earlier in Chapter 3, rats were
injected with the nanoemulsion on day 8 post-CCI, followed by NIR fluorescence imaging on
day 11 post-CCI. All the rats were also imaged immediately after the intravenous injection of the
nanoemulsion to ensure intravenous delivery of the nanoemulsion. NIR fluorescence imaging on
LiCOR Pearl imager revealed a clear difference between the rats injected via the intravenous
route and an erroneous subcutaneous injection. As mentioned earlier, a successful intravenous
tail-vein injection was evident as a small fluorescent spot at the site of injection and the vein was
cleared of the nanoemulsion immediately after the injection. On the other hand if the
nanoemulsion was erroneously injected into the subcutaneous tissue of the tail, a strong NIR
fluorescence was evident in an extended area from the site of injection towards the base of the
tail and the fluorescence persisted at the same spot in the tail throughout the period of study (up
to day 12 post-surgery). The nanoemulsion was always delivered based upon seeing a flash of
blood in the hub of the 24g x ¾ inch, over-the-needle catheter (Fisher Scientific), movement of
the syringe plunger without resistance and feel of the needle penetrating the vein. Even though
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every effort was made to deliver the nanoemulsion precisely into the vein, based upon the NIR
fluorescence imaging, the overall success rate of intravenous delivery of the nanoemulsion was
about 70% in this study. Therefore, in the current study, stringent screening of the rats was
performed and only those cases where the nanoemulsion injection was given successfully
through the intravenous route (based on the LiCOR Pearl imaging) were included in the data
analysis.
As described in our previous study [128], the presence of NIR fluorescence in the sciatic
nerve region is an indicator of macrophage accumulation at the site of nerve injury. Similar to
our previous study [128], Chapter 3, Figures 3-2, 3-3 depicted NIR fluorescence signal in the
ipsilateral thigh of the CCI and sham rats injected with either theranostic or vehicle
nanoemulsion. The fluorescence signal appeared due to the presence of NIR dye at the site of
injury in both CCI and sham groups (Chapter 3, Figure 3-2). Even though the NIR fluorescence
signal was present in both CCI and sham groups, unlike CCI rats, the sham rats revealed a lowlevel NIR signal at the site of surgery (Chapter 3, Table 3-1). Based upon the NIR fluorescence
quantification analysis, it was determined that there was a trend of reduced NIR fluorescence in
the CCI group injected with the theranostic nanoemulsion, in comparison to the untreated CCI or
sham groups (Chapter 3, Figure 3-3 E). Since the NIR fluorescence was not significantly
different (One-way ANOVA) among any of the rat groups (Chapter 3, Figure 3-3 E), based on
the previous study [128], it was predicted that there may not be any significant difference in the
macrophage infiltration at the site of injury for the treated or untreated CCI groups. However, the
trend of reduced NIR fluorescence in the treated CCI group (i.e. injected with theranostic
nanoemulsion) indicated reduced infiltration of NIR dye labeled macrophages at the site of nerve
injury. And as mentioned earlier, it is not advisable to completely rely on the NIR fluorescence,
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due to its tissue penetration depth issues [182], which make it a semi-quantitative technique and
therefore less sensitive to subtle differences in the NIR fluorescence intensity. Besides the tissue
penetration depth issues, the NIR autofluorescence signal was also evident at the thoracolumbar
region of rats in all the experimental groups, irrespective of the nanoemulsion injection (i.e.
before as well as after the injection). We made the same observation in our previous study [128],
and the autofluorescence was due to rat diet components in the gastrointestinal tract of the rats
(LiCOR Biosciences). Autofluorescence could not be resolved completely, even though rats
were fed a purified diet as per the LiCOR diet recommendations to reduce autofluorescence
(LiCOR Biosciences).
Therefore, to overcome the limitations of NIR fluorescence imaging, complementary 19F
MRI was performed (by Dr. Kevin Hitchens). As described earlier, 19F signal is highly specific
due to absence of background noise in the animal tissue. The 19F MRI was performed on the
perfusion fixed ipsilateral hind legs of the CCI rats injected with theranostic or vehicle
nanoemulsion and 19F signal differences were recorded precisely in both the treated and
untreated CCI groups. Superimposed scans of 1H and 19F MRI revealed a clear 19F signal at the
ligatures that were tied over the common sciatic nerve in both the CCI groups (Chapter 3, Figure
3-4). The presence of 19F signal at the sciatic nerve confirmed the presence of PFC nanoparticles
at the site of injury (Chapter 3, Figure 3-4). 19F quantification performed (by Dr. Kevin Hitchens)
on 19F MRI scans for the treated and untreated CCI groups, revealed approximately two-fold
reduction in the 19F signal for the CCI group treated with celecoxib-containing theranostic
nanoemulsion (Chapter 3, Figure 3-4). 19F MRI quantification (performed by Dr. Kevin
Hitchens) was based upon the number of 19F nuclei spins per voxel, using trifluoroacetic acid
(TFA) as a standard reference with known number of 19F nuclei [86]. Statistical analysis could
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not be performed for the 19F MRI scans because one rat was used per condition (due to economic
constraints). Similar to our previous findings (Chapter 2, Figure 2-4), besides the presence of 19F
signal in the sciatic nerve, the 19F signal was also evident in the femur bone of both the CCI
groups, which could be attributed to both physiological and pathological reasons as described
earlier in discussion. It is well known that inflammatory mediators cause vasodilation of the
capillaries at the site of inflammation, leading to their enhanced permeability. Hence, some
nanoparticles in circulation (after intravenous delivery of the nanoemulsion) may bypass
endocytosis by the circulating immune cells and pass directly through the leaky capillaries at the
site of the injured sciatic nerve (also known as blood-nerve barrier dysfunction, [195]) and
accumulate at the site of injury, thus contributing to NIR fluorescence and 19F signal. These
nanoparticles may continue to reside at the site of injury or later on, may get engulfed by the
resident immune cells at the site of injury. Based upon the previous study [128], reduced 19F
signal in the CCI rat sciatic nerve, treated with the celecoxib-loaded nanoemulsion, was
predicted to be due to a lower number of nanoemulsion labeled macrophages at the site of injury.
Therefore, to determine the actual differences in the infiltration of activated macrophages and
expression levels of COX-2 and PGE2, double immunofluorescence was performed on the
ipsilateral sciatic nerves of the treated and untreated CCI groups. The CD68 positive macrophage
infiltration was observed in both treated and untreated CCI groups, thus revealing the presence of
inflammation at the sciatic nerve in both the CCI groups (Chapter 3, Figure 3-5). The CD68
fluorescence intensity was not different in individual macrophages, either in the treated or
untreated CCI rat groups. Therefore, a significant reduction in the mean fluorescence intensity of
CD68 expression (Chapter 3, Figure 3-6; t test, p<0.0001) was considered as an indirect measure
of reduced number of the macrophages in the sciatic nerve of the CCI group treated with
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theranostic nanoemulsion (i.e. containing celecoxib), as compared to the CCI group treated with
vehicle nanoemulsion (i.e. without celecoxib), and hence the fluorescence differences can-not be
attributed merely to the staining artifacts. Similarly, there was a significant relative reduction in
the COX-2 and PGE2 expression (t test, p<0.0001) in discrete macrophages for the CCI group
treated with theranostic nanoemulsion (i.e. containing celecoxib) as compared to the CCI group
treated with vehicle nanoemulsion (i.e. without celecoxib) (Chapter 3, Figure 3-5, 3-6). Since the
CD68 expression in discrete macrophages did not change in both the groups, the ratio of COX-2
fluorescence intensity to CD68 fluorescence intensity and the ratio of PGE2 fluorescence
intensity to CD68 fluorescence intensity revealed the relative differences in the expression
profiles of COX-2 and PGE2 between the two CCI groups. The reduced relative expression of
COX-2 and PGE2 in the treated CCI group appeared to be due to reduced infiltration of the
macrophages at the site of injury, as compared to the CCI group injected with the vehicle
nanoemulsion. Besides reduced macrophage infiltration, the reduced relative expression of PGE2
in the treated CCI group could also be due to inhibition of COX-2 in the macrophages present at
the site of injury. Celecoxib has been shown to reduce macrophage infiltration and PGE2
synthesis during pulmonary inflammation in mice [196]. Hematogenous macrophage recruitment
at the site of nerve injury occurs due to the release of macrophage inflammatory protein (MIP)1α and interleukin (IL)-1β [197]. Therefore, it is feasible that celecoxib affects the
synthesis/release of cytokines and/or chemokines from the activated macrophages; to impede the
ongoing macrophage infiltration at the site of sciatic nerve injury, however further
experimentation is required to test this hypothesis in the CCI rat model of neuropathic pain.
Possible caveats in this study are that the precise type and number of immune cells that
endocytose the nanoemulsion and the mechanism of drug release in-vivo, remains elusive. Also,
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activated macrophages are in a dynamic state at the site of inflammation and some macrophages
may die at the site of injury and the 19F PFC may get transferred to a new phagocytic cell [175].
Hence, further experimentation is required to study the pharmacodynamics and pharmacokinetics
of the nanoemulsion in-vivo, in the future studies.
In conclusion, in the current study, we have described the successful implementation of
celecoxib-containing theranostic nanoemulsion [41, 42] to reduce the hypersensitivity behavior
due to neuropathic pain in CCI rat model and simultaneously visualize and quantify the
inflammation in-vivo, with a single dose intravenous injection of celecoxib-containing
theranostic nanoemulsion in comparison with the CCI rats injected with vehicle nanoemulsion
without celecoxib that served as a negative control. To the best of our knowledge, this is the first
study to use theranostic nanoparticles in the setting of neuropathic pain. Recently, PFC labeled
dendritic cells have been tracked in human colorectal adenocarcinoma patients with no apparent
side effects noted [175]. Flurbiprofen axetil (NSAID)-containing drug delivery nanoemulsion is
commercially available along with many other drugs formulated as nanoemulsion [68]. The
theranostic nanoemulsion used in this study, designed by Dr. Jelena M. Janjic and Sravan K.
Patel, allowed not only the targeted delivery of celecoxib in the macrophages but also
simultaneous in-vivo therapeutic evaluation by tracking inflammation at the site of injury.

5.7 Dynamic Bayesian Network (DBN) Analysis
As mentioned earlier in Chapter 1 and Chapter 4, various inflammatory mediators are
involved during neuroinflammation. IL-18 and IL-1β undergo expression, maturation, and
release via inflammasome assembly and caspase-1 activation by innate immune system [44].
Based upon the DBN analysis of the inflammatory mediators at the site of nerve injury in CCI rat
model of neuropathic pain, the central drivers of inflammation were IL-18 and IL-1β (Chapter 4,
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Figure 4-3). Both of these mediators, along with their activator enzyme caspase-1, were
expressed at the site of the nerve injury as determined in the immunofluorescence studies
(Chapter 4, Figure 4-4). Persistent up regulation of IL-18 has been shown earlier in the spinal
cord from day 1 to day 18 post-CCI [9]. Potential intervention of these two inflammatory
mediators by using monoclonal antibodies, IL-18 and IL-1β receptor antagonists or IL-18 and
IL-1β inhibitors may prove an efficient therapy to manage chronic neuropathic pain. It is for the
first time that the computational modeling tool has been used in the field of neuropathic pain
using CCI rat model with a comprehensive analysis of fourteen different inflammatory mediators
in the same experimental set up. However, IL-18 and IL-1β as principle drivers of peripheral
neuropathic pain is only a prediction and needs to be tested in the future studies.

5.8 Future Directions
During 19F MRI, besides the presence of the 19F signal at the injured sciatic nerve, the 19F
signal was also observed in the femur and tibia bones of the CCI and sham rats (Chapter 2,
Figure 2-4; Chapter 3, Figure 3-4). The 19F signal intensity was less in the ipsilateral femur bones
of the sham rats as compared to the CCI ipsilateral femur bones (Data not included). As
mentioned earlier, the presence of 19F signal is an indirect evidence of infiltration of phagocytic
immune cells (especially monocytes/macrophages). Previously it has been shown that there are
pathological changes, such as reduction in the bone mineral density (BMD) due to increased
bone resorption (osteoporosis) induced by a peripheral nerve injury in the vicinity of the bone
[123, 124]. It is also known that specialized osteoclast cells, which are produced from
monocyte/macrophage cell lineage precursor cells in bone marrow, cause the bone resorption.
These precursor cells enter into blood circulation before they differentiate into osteoclasts, and
the migration of monocytes into bone marrow and their differentiation into osteoclasts is
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dependent upon the rate of bone resorption [125, 198]. This indicates higher bone resorption
activity in the CCI femur and tibia bones as compared to the sham rats. Since the 19F signal is
also found in the femur bones of sham rats, there is a possibility that besides osteoporotic
changes in the bones of CCI affected rats, the signal is also caused by physiological circulation
of labeled monocytes through the bone marrow in both sham and CCI rats. Both ipsilateral and
contralateral femur bones of CCI, sham, and naïve rats (~ 30 total) were collected during the
tissue dissection from perfusion fixed rats (please refer to appendix) and have been stored in
0.4% paraformaldehyde solution at 4° C for future studies. I hypothesize that the 19F signal in
the femur bones of CCI is caused by osteoporotic (pathological) changes associated with chronic
constriction injury, along with physiological contribution by the circulating monocytes through
the bone marrow. Further experiments, especially tissue histology, need to be performed on the
collected femur bones to substantiate this interesting finding.
In addition experiments to determine the long-term effects of celecoxib-containing
nanoemulsion could be performed for longer duration post-CCI. Also, biological
experimentation is required to verify the conclusions drawn from the computational modeling
analysis performed in this study. IL-18 and IL-1β inhibitors may be tested in future studies to
reveal any changes in the hypersensitivity using CCI rat model. Theranostic nanoemulsions
containing new drugs or different drug combinations may be tried to see their therapeutic effect
for the treatment of chronic neuropathic pain.

114

References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.

IASP, International Association for the Study of Pain. Pain, 2003. XI(2): p. 1‐4.
Woolf, C.J., What is this thing called pain? J Clin Invest, 2010. 120(11): p. 3742‐4.
Sacerdote, P., et al., Cytokine modulation is necessary for efficacious treatment of
experimental neuropathic pain. J Neuroimmune Pharmacol, 2013. 8(1): p. 202‐11.
Jensen, T.S., et al., A new definition of neuropathic pain. Pain, 2011. 152(10): p. 2204‐
5.
Treede, R.D., et al., Neuropathic pain: redefinition and a grading system for clinical
and research purposes. Neurology, 2008. 70(18): p. 1630‐5.
Woolf, C.J. and R.J. Mannion, Neuropathic pain: aetiology, symptoms, mechanisms, and
management. Lancet, 1999. 353(9168): p. 1959‐64.
Myers, R.R., H.M. Heckman, and M. Rodriguez, Reduced hyperalgesia in nerve‐injured
WLD mice: relationship to nerve fiber phagocytosis, axonal degeneration, and
regeneration in normal mice. Exp Neurol, 1996. 141(1): p. 94‐101.
Bennett, G.J. and Y.K. Xie, A peripheral mononeuropathy in rat that produces disorders
of pain sensation like those seen in man. Pain, 1988. 33(1): p. 87‐107.
Zhang, Y.K., et al., WNT signaling underlies the pathogenesis of neuropathic pain in
rodents. J Clin Invest, 2013. 123(5): p. 2268‐86.
Zimmermann, M., Pathobiology of neuropathic pain. Eur J Pharmacol, 2001. 429(1‐
3): p. 23‐37.
Maves, T.J., et al., Possible chemical contribution from chromic gut sutures produces
disorders of pain sensation like those seen in man. Pain, 1993. 54(1): p. 57‐69.
Monk, K.R., et al., Mast cells can contribute to axon‐glial dissociation and fibrosis in
peripheral nerve. Neuron Glia Biol, 2007. 3(3): p. 233‐44.
Dubovy, P., Wallerian degeneration and peripheral nerve conditions for both axonal
regeneration and neuropathic pain induction. Ann Anat, 2011. 193(4): p. 267‐75.
Gaudet, A.D., P.G. Popovich, and M.S. Ramer, Wallerian degeneration: gaining
perspective on inflammatory events after peripheral nerve injury. J
Neuroinflammation, 2011. 8: p. 110.
Coggeshall, R.E., et al., Is large myelinated fiber loss associated with hyperalgesia in a
model of experimental peripheral neuropathy in the rat? Pain, 1993. 52(2): p. 233‐42.
Austin, P.J. and G. Moalem‐Taylor, The neuro‐immune balance in neuropathic pain:
involvement of inflammatory immune cells, immune‐like glial cells and cytokines. J
Neuroimmunol, 2010. 229(1‐2): p. 26‐50.
Ohara, P.T., et al., Evidence for a role of connexin 43 in trigeminal pain using RNA
interference in vivo. J Neurophysiol, 2008. 100(6): p. 3064‐73.
Chen, Y. and M. Devor, Ectopic mechanosensitivity in injured sensory axons arises
from the site of spontaneous electrogenesis. Eur J Pain, 1998. 2(2): p. 165‐178.
Kajander, K.C., S. Wakisaka, and G.J. Bennett, Spontaneous discharge originates in the
dorsal root ganglion at the onset of a painful peripheral neuropathy in the rat.
Neurosci Lett, 1992. 138(2): p. 225‐8.
Tal, M. and E. Eliav, Abnormal discharge originates at the site of nerve injury in
experimental constriction neuropathy (CCI) in the rat. Pain, 1996. 64(3): p. 511‐8.

115

21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.

Ando, R.D., et al., A comparative analysis of the activity of ligands acting at P2X and
P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br J
Pharmacol, 2010. 159(5): p. 1106‐17.
Wild, K.D., et al., Antibodies to nerve growth factor reverse established tactile
allodynia in rodent models of neuropathic pain without tolerance. J Pharmacol Exp
Ther, 2007. 322(1): p. 282‐7.
Scholz, J. and C.J. Woolf, The neuropathic pain triad: neurons, immune cells and glia.
Nat Neurosci, 2007. 10(11): p. 1361‐8.
Xie, W., J.A. Strong, and J.M. Zhang, Early blockade of injured primary sensory
afferents reduces glial cell activation in two rat neuropathic pain models.
Neuroscience, 2009. 160(4): p. 847‐57.
Sacerdote, P., et al., Transient early expression of TNF‐alpha in sciatic nerve and
dorsal root ganglia in a mouse model of painful peripheral neuropathy. Neurosci Lett,
2008. 436(2): p. 210‐3.
Moalem, G., K. Xu, and L. Yu, T lymphocytes play a role in neuropathic pain following
peripheral nerve injury in rats. Neuroscience, 2004. 129(3): p. 767‐77.
Mosmann, T.R. and S. Sad, The expanding universe of T‐cell subsets: Th1, Th2 and
more. Immunol Today, 1996. 17(3): p. 138‐46.
Kleinschnitz, C., et al., T cell infiltration after chronic constriction injury of mouse
sciatic nerve is associated with interleukin‐17 expression. Exp Neurol, 2006. 200(2):
p. 480‐5.
Ma, W. and J.C. Eisenach, Cyclooxygenase 2 in infiltrating inflammatory cells in injured
nerve is universally up‐regulated following various types of peripheral nerve injury.
Neuroscience, 2003. 121(3): p. 691‐704.
Muja, N. and G.H. DeVries, Prostaglandin E(2) and 6‐keto‐prostaglandin F(1alpha)
production is elevated following traumatic injury to sciatic nerve. Glia, 2004. 46(2): p.
116‐29.
Camara‐Lemarroy, C.R., et al., Arachidonic acid derivatives and their role in peripheral
nerve degeneration and regeneration. ScientificWorldJournal, 2012. 2012: p.
168953.
Ma, W. and J.C. Eisenach, Morphological and pharmacological evidence for the role of
peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci,
2002. 15(6): p. 1037‐47.
Wang, Y., et al., Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors
in the DRG and attenuate hyperalgesia following chronic constriction injury in rats.
Neurosci Lett, 2010. 478(2): p. 77‐81.
Camara‐Lemarroy, C.R., et al., Celecoxib accelerates functional recovery after sciatic
nerve crush in the rat. J Brachial Plex Peripher Nerve Inj, 2008. 3: p. 25.
Suyama, H., et al., Effect of etodolac, a COX‐2 inhibitor, on neuropathic pain in a rat
model. Brain Res, 2004. 1010(1‐2): p. 144‐50.
Schafers, M., et al., Cyclooxygenase inhibition in nerve‐injury‐ and TNF‐induced
hyperalgesia in the rat. Exp Neurol, 2004. 185(1): p. 160‐8.
Balducci, A., et al., A novel probe for the non‐invasive detection of tumor‐associated
inflammation. Oncoimmunology, 2013. 2(2): p. e23034.
Hitchens, T.K., et al., 19F MRI detection of acute allograft rejection with in vivo
perfluorocarbon labeling of immune cells. Magn Reson Med, 2011. 65(4): p. 1144‐53.

116

39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.

Jeelani, S., et al., Theranostics: A treasured tailor for tomorrow. J Pharm Bioallied Sci,
2014. 6(Suppl 1): p. S6‐8.
O'Hanlon, C.E., et al., NIR‐labeled perfluoropolyether nanoemulsions for drug delivery
and imaging. J Fluor Chem, 2012. 137: p. 27‐33.
Patel, S.K., et al., Two‐color fluorescent (near‐infrared and visible) triphasic
perfluorocarbon nanoemuslions. J Biomed Opt, 2013. 18(10): p. 101312.
Patel, S.K., et al., Cyclooxgenase‐2 inhibiting perfluoropoly (ethylene glycol) ether
theranostic nanoemulsions‐in vitro study. PLoS One, 2013. 8(2): p. e55802.
Jelena M. Janjic, S.K.P., Michael J. Patrick, John A. Pollock, Erin DiVito, Michael Cascio,
Suppressing inflammation from inside out with novel NIR visible perfluorocarbon
nanotheranostics. Proceedings of SPIE, 2013. 8596.
Schroder, K. and J. Tschopp, The inflammasomes. Cell, 2010. 140(6): p. 821‐32.
Sollberger, G., et al., Caspase‐1: the inflammasome and beyond. Innate Immun, 2014.
20(2): p. 115‐25.
Nadeau, S., et al., Functional recovery after peripheral nerve injury is dependent on the
pro‐inflammatory cytokines IL‐1beta and TNF: implications for neuropathic pain. J
Neurosci, 2011. 31(35): p. 12533‐42.
Vodovotz, Y., Deciphering the complexity of acute inflammation using mathematical
models. Immunol Res, 2006. 36(1‐3): p. 237‐45.
Aerts, J.M., et al., From data patterns to mechanistic models in acute critical illness. J
Crit Care, 2014. 29(4): p. 604‐10.
Mi, Q., et al., A dynamic view of trauma/hemorrhage‐induced inflammation in mice:
principal drivers and networks. PLoS One, 2011. 6(5): p. e19424.
Vodovotz, Y. and T.R. Billiar, In silico modeling: methods and applications to trauma
and sepsis. Crit Care Med, 2013. 41(8): p. 2008‐14.
An, G., G. Nieman, and Y. Vodovotz, Toward computational identification of multiscale
"tipping points" in acute inflammation and multiple organ failure. Ann Biomed Eng,
2012. 40(11): p. 2414‐24.
Dubois, R.N., et al., Cyclooxygenase in biology and disease. FASEB J, 1998. 12(12): p.
1063‐73.
Grosser, T., Y. Yu, and G.A. Fitzgerald, Emotion recollected in tranquility: lessons
learned from the COX‐2 saga. Annu Rev Med, 2010. 61: p. 17‐33.
O'Neill, G.P. and A.W. Ford‐Hutchinson, Expression of mRNA for cyclooxygenase‐1 and
cyclooxygenase‐2 in human tissues. FEBS Lett, 1993. 330(2): p. 156‐60.
Beiche, F., et al., Up‐regulation of cyclooxygenase‐2 mRNA in the rat spinal cord
following peripheral inflammation. FEBS Lett, 1996. 390(2): p. 165‐9.
Smyth, E.M., et al., Prostanoids in health and disease. J Lipid Res, 2009. 50 Suppl: p.
S423‐8.
Durrenberger, P.F., et al., Prostanoid receptor EP1 and Cox‐2 in injured human nerves
and a rat model of nerve injury: a time‐course study. BMC Neurol, 2006. 6: p. 1.
Abbadie, C., et al., Impaired neuropathic pain responses in mice lacking the chemokine
receptor CCR2. Proc Natl Acad Sci U S A, 2003. 100(13): p. 7947‐52.
Liu, T., N. van Rooijen, and D.J. Tracey, Depletion of macrophages reduces axonal
degeneration and hyperalgesia following nerve injury. Pain, 2000. 86(1‐2): p. 25‐32.
Ma, W. and R. Quirion, Does COX2‐dependent PGE2 play a role in neuropathic pain?
Neurosci Lett, 2008. 437(3): p. 165‐9.

117

61.
62.
63.
64.

65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.

Minami, T., et al., Characterization of EP receptor subtypes responsible for
prostaglandin E2‐induced pain responses by use of EP1 and EP3 receptor knockout
mice. Br J Pharmacol, 2001. 133(3): p. 438‐44.
St‐Jacques, B. and W. Ma, Peripheral prostaglandin E2 prolongs the sensitization of
nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and
anterograde axonal trafficking of EP4 receptors. Exp Neurol, 2014. 261: p. 354‐66.
Ahmadi, S., et al., PGE(2) selectively blocks inhibitory glycinergic neurotransmission
onto rat superficial dorsal horn neurons. Nat Neurosci, 2002. 5(1): p. 34‐40.
Yaksh, T.L., et al., The acute antihyperalgesic action of nonsteroidal, anti‐
inflammatory drugs and release of spinal prostaglandin E2 is mediated by the
inhibition of constitutive spinal cyclooxygenase‐2 (COX‐2) but not COX‐1. J Neurosci,
2001. 21(16): p. 5847‐53.
Wallace, J.L., et al., NSAID‐induced gastric damage in rats: requirement for inhibition
of both cyclooxygenase 1 and 2. Gastroenterology, 2000. 119(3): p. 706‐14.
Homayouni, A., et al., Comparing various techniques to produce micro/nanoparticles
for enhancing the dissolution of celecoxib containing PVP. Eur J Pharm Biopharm,
2014. 88(1): p. 261‐74.
Gianella, A., et al., Multifunctional nanoemulsion platform for imaging guided therapy
evaluated in experimental cancer. ACS Nano, 2011. 5(6): p. 4422‐33.
Ganta, S., et al., Nanoemulsions in translational research‐opportunities and challenges
in targeted cancer therapy. AAPS PharmSciTech, 2014. 15(3): p. 694‐708.
Janjic, J.M., et al., Self‐delivering nanoemulsions for dual fluorine‐19 MRI and
fluorescence detection. J Am Chem Soc, 2008. 130(9): p. 2832‐41.
Patrick, M.J., et al., Intracellular pH measurements using perfluorocarbon
nanoemulsions. J Am Chem Soc, 2013. 135(49): p. 18445‐57.
Janjic, J.M., et al., Perfluorocarbon nanoemulsions with fluorescent, colloidal and
magnetic properties. Biomaterials, 2014. 35(18): p. 4958‐68.
von Hehn, C.A., R. Baron, and C.J. Woolf, Deconstructing the neuropathic pain
phenotype to reveal neural mechanisms. Neuron, 2012. 73(4): p. 638‐52.
IOM, Institute of Medicine, Relieving Pain in America: A Blueprint for Transforming
Prevention, Care, Education, and Research. Washington, DC: The National Academies
Press. 2011.
Wang, L.X. and Z.J. Wang, Animal and cellular models of chronic pain. Adv Drug Deliv
Rev, 2003. 55(8): p. 949‐65.
Stanton‐Hicks, M., et al., Reflex sympathetic dystrophy: changing concepts and
taxonomy. Pain, 1995. 63(1): p. 127‐33.
Baron, R. and G. Wasner, Complex regional pain syndromes. Curr Pain Headache Rep,
2001. 5(2): p. 114‐23.
Woolf, C.J. and Q. Ma, Nociceptors‐‐noxious stimulus detectors. Neuron, 2007. 55(3):
p. 353‐64.
Montell, C., The TRP superfamily of cation channels. Sci STKE, 2005. 2005(272): p.
re3.
Voets, T., et al., Sensing with TRP channels. Nat Chem Biol, 2005. 1(2): p. 85‐92.
Damann, N., T. Voets, and B. Nilius, TRPs in our senses. Curr Biol, 2008. 18(18): p.
R880‐9.

118

81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.

Cortright, D.N. and A. Szallasi, TRP channels and pain. Curr Pharm Des, 2009. 15(15):
p. 1736‐49.
Stucky, C.L., et al., Roles of transient receptor potential channels in pain. Brain Res
Rev, 2009. 60(1): p. 2‐23.
Clatworthy, A.L., et al., Role of peri‐axonal inflammation in the development of
thermal hyperalgesia and guarding behavior in a rat model of neuropathic pain.
Neurosci Lett, 1995. 184(1): p. 5‐8.
Thacker, M.A., et al., Pathophysiology of peripheral neuropathic pain: immune cells
and molecules. Anesth Analg, 2007. 105(3): p. 838‐47.
Ahrens, E.T., et al., Rapid quantification of inflammation in tissue samples using
perfluorocarbon emulsion and fluorine‐19 nuclear magnetic resonance.
Biotechniques, 2011. 50(4): p. 229‐34.
Srinivas, M., et al., Fluorine‐19 MRI for visualization and quantification of cell
migration in a diabetes model. Magn Reson Med, 2007. 58(4): p. 725‐34.
Srinivas, M., et al., In vivo cytometry of antigen‐specific t cells using 19F MRI. Magn
Reson Med, 2009. 62(3): p. 747‐53.
Boehm‐Sturm, P., et al., In vivo tracking of human neural stem cells with 19F magnetic
resonance imaging. PLoS One, 2011. 6(12): p. e29040.
Temme, S., et al., 19F magnetic resonance imaging of endogenous macrophages in
inflammation. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2012. 4(3): p. 329‐
43.
Janjic, J.M. and E.T. Ahrens, Fluorine‐containing nanoemulsions for MRI cell tracking.
Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2009. 1(5): p. 492‐501.
Chen, J., G.M. Lanza, and S.A. Wickline, Quantitative magnetic resonance fluorine
imaging: today and tomorrow. Wiley Interdiscip Rev Nanomed Nanobiotechnol,
2010. 2(4): p. 431‐40.
Hu, P. and E.M. McLachlan, Macrophage and lymphocyte invasion of dorsal root
ganglia after peripheral nerve lesions in the rat. Neuroscience, 2002. 112(1): p. 23‐
38.
Ma, W. and R. Quirion, Up‐regulation of interleukin‐6 induced by prostaglandin E from
invading macrophages following nerve injury: an in vivo and in vitro study. J
Neurochem, 2005. 93(3): p. 664‐73.
Morin, N., et al., Neutrophils invade lumbar dorsal root ganglia after chronic
constriction injury of the sciatic nerve. J Neuroimmunol, 2007. 184(1‐2): p. 164‐71.
Di Cesare Mannelli, L., et al., Palmitoylethanolamide is a disease‐modifying agent in
peripheral neuropathy: pain relief and neuroprotection share a PPAR‐alpha‐mediated
mechanism. Mediators Inflamm, 2013. 2013: p. 328797.
Weise, G., et al., In vivo imaging of stepwise vessel occlusion in cerebral
photothrombosis of mice by 19F MRI. PLoS One, 2011. 6(12): p. e28143.
(http://biosupport.licor.com/docs/InVivoDiet‐Considerations.pdf).
Somers, D.L. and F.R. Clemente, The relationship between dorsal horn
neurotransmitter content and allodynia in neuropathic rats treated with high‐
frequency transcutaneous electric nerve stimulation. Arch Phys Med Rehabil, 2003.
84(11): p. 1575‐83.

119

99.
100.
101.
102.
103.
104.
105.
106.
107.
108.

109.
110.
111.
112.
113.
114.

Swett, J.E. and C.J. Woolf, The somatotopic organization of primary afferent terminals
in the superficial laminae of the dorsal horn of the rat spinal cord. J Comp Neurol,
1985. 231(1): p. 66‐77.
Swett, J.E., et al., Sensory neurons of the rat sciatic nerve. Exp Neurol, 1991. 114(1): p.
82‐103.
Ji, R.R., et al., MAPK activation by NGF in primary sensory neurons after inflammation
increases TRPV1 levels and maintains heat hyperalgesia. Neuron, 2002. 36(1): p. 57‐
68.
Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real‐
time quantitative PCR and the 2(‐Delta Delta C(T)) Method. Methods, 2001. 25(4): p.
402‐8.
Barber, R.D., et al., GAPDH as a housekeeping gene: analysis of GAPDH mRNA
expression in a panel of 72 human tissues. Physiol Genomics, 2005. 21(3): p. 389‐95.
Field, M.J., et al., Detection of static and dynamic components of mechanical allodynia
in rat models of neuropathic pain: are they signalled by distinct primary sensory
neurones? Pain, 1999. 83(2): p. 303‐11.
Hong, S., et al., The TRPV1 receptor is associated with preferential stress in large
dorsal root ganglion neurons in early diabetic sensory neuropathy. J Neurochem,
2008. 105(4): p. 1212‐22.
Xu, G.Y., et al., Transient receptor potential vanilloid 1 mediates hyperalgesia and is
up‐regulated in rats with chronic pancreatitis. Gastroenterology, 2007. 133(4): p.
1282‐92.
Szabo, A., et al., Role of transient receptor potential vanilloid 1 receptors in adjuvant‐
induced chronic arthritis: in vivo study using gene‐deficient mice. J Pharmacol Exp
Ther, 2005. 314(1): p. 111‐9.
Jones, R.C., 3rd, L. Xu, and G.F. Gebhart, The mechanosensitivity of mouse colon
afferent fibers and their sensitization by inflammatory mediators require transient
receptor potential vanilloid 1 and acid‐sensing ion channel 3. J Neurosci, 2005.
25(47): p. 10981‐9.
Smith, P.A., et al., Spinal mechanisms of NPY analgesia. Peptides, 2007. 28(2): p. 464‐
74.
Moran, T.D., W.F. Colmers, and P.A. Smith, Opioid‐like actions of neuropeptide Y in rat
substantia gelatinosa: Y1 suppression of inhibition and Y2 suppression of excitation. J
Neurophysiol, 2004. 92(6): p. 3266‐75.
Staaf, S., et al., Differential regulation of TRP channels in a rat model of neuropathic
pain. Pain, 2009. 144(1‐2): p. 187‐99.
Leslie, T.A., et al., Nerve growth factor contributes to the up‐regulation of growth‐
associated protein 43 and preprotachykinin A messenger RNAs in primary sensory
neurons following peripheral inflammation. Neuroscience, 1995. 67(3): p. 753‐61.
Van der Zee, C.E., et al., Expression of growth‐associated protein B‐50 (GAP43) in
dorsal root ganglia and sciatic nerve during regenerative sprouting. J Neurosci, 1989.
9(10): p. 3505‐12.
Andersen, L.B. and D.J. Schreyer, Constitutive expression of GAP‐43 correlates with
rapid, but not slow regrowth of injured dorsal root axons in the adult rat. Exp Neurol,
1999. 155(2): p. 157‐64.

120

115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.

Kanai, Y., et al., Involvement of an increased spinal TRPV1 sensitization through its up‐
regulation in mechanical allodynia of CCI rats. Neuropharmacology, 2005. 49(7): p.
977‐84.
Wheway, J., H. Herzog, and F. Mackay, The Y1 receptor for NPY: a key modulator of
the adaptive immune system. Peptides, 2007. 28(2): p. 453‐8.
Bedoui, S., S. von Horsten, and T. Gebhardt, A role for neuropeptide Y (NPY) in
phagocytosis: implications for innate and adaptive immunity. Peptides, 2007. 28(2):
p. 373‐6.
Ren, K. and R. Dubner, Interactions between the immune and nervous systems in pain.
Nat Med, 2010. 16(11): p. 1267‐76.
Eisenblatter, M., et al., In vivo optical imaging of cellular inflammatory response in
granuloma formation using fluorescence‐labeled macrophages. J Nucl Med, 2009.
50(10): p. 1676‐82.
Mayer‐Kuckuk, P. and A.L. Boskey, Molecular imaging promotes progress in
orthopedic research. Bone, 2006. 39(5): p. 965‐77.
Srinivas, M., et al., (19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol,
2010. 28(7): p. 363‐70.
Kadayakkara, D.K., et al., Assaying macrophage activity in a murine model of
inflammatory bowel disease using fluorine‐19 MRI. Lab Invest, 2012. 92(4): p. 636‐
45.
Moriwaki, K., et al., Neuropathic pain and prolonged regional inflammation as two
distinct symptomatological components in complex regional pain syndrome with
patchy osteoporosis‐‐a pilot study. Pain, 1997. 72(1‐2): p. 277‐82.
Suyama, H., et al., Osteoporosis following chronic constriction injury of sciatic nerve in
rats. J Bone Miner Metab, 2002. 20(2): p. 91‐7.
Lari, R., P.D. Kitchener, and J.A. Hamilton, The proliferative human monocyte
subpopulation contains osteoclast precursors. Arthritis Res Ther, 2009. 11(1): p. R23.
Calvo, M., J.M. Dawes, and D.L. Bennett, The role of the immune system in the
generation of neuropathic pain. Lancet Neurol, 2012. 11(7): p. 629‐42.
Ristoiu, V., Contribution of macrophages to peripheral neuropathic pain pathogenesis.
Life Sci, 2013. 93(23): p. 870‐81.
Vasudeva, K., et al., Imaging neuroinflammation in vivo in a neuropathic pain rat
model with near‐infrared fluorescence and (19)f magnetic resonance. PLoS One, 2014.
9(2): p. e90589.
Chaplan, S.R., et al., Quantitative assessment of tactile allodynia in the rat paw. J
Neurosci Methods, 1994. 53(1): p. 55‐63.
Ma, W., et al., Injured nerve‐derived COX2/PGE2 contributes to the maintenance of
neuropathic pain in aged rats. Neurobiol Aging, 2010. 31(7): p. 1227‐37.
Vanegas, H. and H.G. Schaible, Prostaglandins and cyclooxygenases [correction of
cycloxygenases] in the spinal cord. Prog Neurobiol, 2001. 64(4): p. 327‐63.
Natura, G., et al., Neuronal prostaglandin E2 receptor subtype EP3 mediates
antinociception during inflammation. Proc Natl Acad Sci U S A, 2013. 110(33): p.
13648‐53.
Latremoliere, A. and C.J. Woolf, Central sensitization: a generator of pain
hypersensitivity by central neural plasticity. J Pain, 2009. 10(9): p. 895‐926.

121

134.
135.

136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.

Basbaum, A.I., et al., Cellular and molecular mechanisms of pain. Cell, 2009. 139(2): p.
267‐84.
Pavlovic, S., et al., Targeting prostaglandin E2 receptors as an alternative strategy to
block cyclooxygenase‐2‐dependent extracellular matrix‐induced matrix
metalloproteinase‐9 expression by macrophages. J Biol Chem, 2006. 281(6): p. 3321‐
8.
Dubovy, P., I. Klusakova, and I. Hradilova Svizenska, Inflammatory profiling of
Schwann cells in contact with growing axons distal to nerve injury. Biomed Res Int,
2014. 2014: p. 691041.
Cui, J.G., et al., Possible role of inflammatory mediators in tactile hypersensitivity in rat
models of mononeuropathy. Pain, 2000. 88(3): p. 239‐48.
Ji, R.R., Z.Z. Xu, and Y.J. Gao, Emerging targets in neuroinflammation‐driven chronic
pain. Nat Rev Drug Discov, 2014. 13(7): p. 533‐48.
Costigan, M., J. Scholz, and C.J. Woolf, Neuropathic pain: a maladaptive response of the
nervous system to damage. Annu Rev Neurosci, 2009. 32: p. 1‐32.
White, F.A., S.K. Bhangoo, and R.J. Miller, Chemokines: integrators of pain and
inflammation. Nat Rev Drug Discov, 2005. 4(10): p. 834‐44.
Clark, A.K., E.A. Old, and M. Malcangio, Neuropathic pain and cytokines: current
perspectives. J Pain Res, 2013. 6: p. 803‐14.
Kiguchi, N., Y. Kobayashi, and S. Kishioka, Chemokines and cytokines in
neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol, 2012. 12(1):
p. 55‐61.
Barrette, B., et al., Requirement of myeloid cells for axon regeneration. J Neurosci,
2008. 28(38): p. 9363‐76.
Fu, S.Y. and T. Gordon, The cellular and molecular basis of peripheral nerve
regeneration. Mol Neurobiol, 1997. 14(1‐2): p. 67‐116.
Niemi, J.P., et al., A critical role for macrophages near axotomized neuronal cell bodies
in stimulating nerve regeneration. J Neurosci, 2013. 33(41): p. 16236‐48.
Kleinschnitz, C., et al., The extent of cytokine induction in peripheral nerve lesions
depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol, 2004.
149(1‐2): p. 77‐83.
Okamoto, K., et al., Pro‐ and anti‐inflammatory cytokine gene expression in rat sciatic
nerve chronic constriction injury model of neuropathic pain. Exp Neurol, 2001.
169(2): p. 386‐91.
Ramesh, G., A.G. MacLean, and M.T. Philipp, Cytokines and chemokines at the
crossroads of neuroinflammation, neurodegeneration, and neuropathic pain.
Mediators Inflamm, 2013. 2013: p. 480739.
Rittner, H.L., H. Machelska, and C. Stein, Leukocytes in the regulation of pain and
analgesia. J Leukoc Biol, 2005. 78(6): p. 1215‐22.
Azhar, N., et al., Analysis of serum inflammatory mediators identifies unique dynamic
networks associated with death and spontaneous survival in pediatric acute liver
failure. PLoS One, 2013. 8(11): p. e78202.
Emr, B., et al., Removal of inflammatory ascites is associated with dynamic
modification of local and systemic inflammation along with prevention of acute lung
injury: in vivo and in silico studies. Shock, 2014. 41(4): p. 317‐23.

122

152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.

165.
166.
167.
168.
169.

Zaaqoq, A.M., et al., Inducible Protein‐10, a potential driver of neurally controlled
Interleukin‐10 and morbidity in human blunt trauma. Crit Care Med, 2014.
Grzegorczyk, M. and D. Husmeier, Improvements in the reconstruction of time‐
varying gene regulatory networks: dynamic programming and regularization by
information sharing among genes. Bioinformatics, 2011. 27(5): p. 693‐9.
Aderhold, A., D. Husmeier, and M. Grzegorczyk, Statistical inference of regulatory
networks for circadian regulation. Stat Appl Genet Mol Biol, 2014. 13(3): p. 227‐73.
Franchi, L., et al., The inflammasome: a caspase‐1‐activation platform that regulates
immune responses and disease pathogenesis. Nat Immunol, 2009. 10(3): p. 241‐7.
Baron, R., A. Binder, and G. Wasner, Neuropathic pain: diagnosis, pathophysiological
mechanisms, and treatment. Lancet Neurol, 2010. 9(8): p. 807‐19.
Li, Q., et al., Involvement of the spinal NALP1 inflammasome in neuropathic pain and
aspirin‐triggered‐15‐epi‐lipoxin A4 induced analgesia. Neuroscience, 2013. 254: p.
230‐40.
Wang, S., et al., Xenobiotic receptor PXR regulates innate immunity via activation of
NLRP3 inflammasome in vascular endothelial cells. J Biol Chem, 2014.
Lechtenberg, B.C., P.D. Mace, and S.J. Riedl, Structural mechanisms in NLR
inflammasome signaling. Curr Opin Struct Biol, 2014. 29C: p. 17‐25.
Futani, H., et al., Relation between interleukin‐18 and PGE2 in synovial fluid of
osteoarthritis: a potential therapeutic target of cartilage degradation. J Immunother,
2002. 25 Suppl 1: p. S61‐4.
Kashiwamura, S., H. Ueda, and H. Okamura, Roles of interleukin‐18 in tissue
destruction and compensatory reactions. J Immunother, 2002. 25 Suppl 1: p. S4‐11.
Olee, T., et al., IL‐18 is produced by articular chondrocytes and induces
proinflammatory and catabolic responses. J Immunol, 1999. 162(2): p. 1096‐100.
Fiebich, B.L., et al., Interleukin‐1beta induces cyclooxygenase‐2 and prostaglandin
E(2) synthesis in human neuroblastoma cells: involvement of p38 mitogen‐activated
protein kinase and nuclear factor‐kappaB. J Neurochem, 2000. 75(5): p. 2020‐8.
Han, R., S. Tsui, and T.J. Smith, Up‐regulation of prostaglandin E2 synthesis by
interleukin‐1beta in human orbital fibroblasts involves coordinate induction of
prostaglandin‐endoperoxide H synthase‐2 and glutathione‐dependent prostaglandin
E2 synthase expression. J Biol Chem, 2002. 277(19): p. 16355‐64.
Schindler, H., et al., The production of IFN‐gamma by IL‐12/IL‐18‐activated
macrophages requires STAT4 signaling and is inhibited by IL‐4. J Immunol, 2001.
166(5): p. 3075‐82.
Tominaga, K., et al., IL‐12 synergizes with IL‐18 or IL‐1beta for IFN‐gamma
production from human T cells. Int Immunol, 2000. 12(2): p. 151‐60.
Yoshimoto, T., et al., IL‐12 up‐regulates IL‐18 receptor expression on T cells, Th1 cells,
and B cells: synergism with IL‐18 for IFN‐gamma production. J Immunol, 1998.
161(7): p. 3400‐7.
Munder, M., et al., Murine macrophages secrete interferon gamma upon combined
stimulation with interleukin (IL)‐12 and IL‐18: A novel pathway of autocrine
macrophage activation. J Exp Med, 1998. 187(12): p. 2103‐8.
Hao, S., et al., HSV‐mediated expression of interleukin‐4 in dorsal root ganglion
neurons reduces neuropathic pain. Mol Pain, 2006. 2: p. 6.

123

170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.

181.
182.
183.
184.
185.
186.
187.
188.
189.

Dinarello, C.A., et al., Overview of interleukin‐18: more than an interferon‐gamma
inducing factor. J Leukoc Biol, 1998. 63(6): p. 658‐64.
Abbadie, C., et al., Chemokines and pain mechanisms. Brain Res Rev, 2009. 60(1): p.
125‐34.
Li, W.W., et al., The NALP1 inflammasome controls cytokine production and
nociception in a rat fracture model of complex regional pain syndrome. Pain, 2009.
147(1‐3): p. 277‐86.
Vallat, J.M., B. Funalot, and L. Magy, Nerve biopsy: requirements for diagnosis and
clinical value. Acta Neuropathol, 2011. 121(3): p. 313‐26.
Himmelreich, U. and T. Dresselaers, Cell labeling and tracking for experimental
models using magnetic resonance imaging. Methods, 2009. 48(2): p. 112‐24.
Ahrens, E.T., et al., Clinical cell therapy imaging using a perfluorocarbon tracer and
fluorine‐19 MRI. Magn Reson Med, 2014. 72(6): p. 1‐6.
Flogel, U., et al., In vivo monitoring of inflammation after cardiac and cerebral
ischemia by fluorine magnetic resonance imaging. Circulation, 2008. 118(2): p. 140‐
8.
Ebner, B., et al., Early assessment of pulmonary inflammation by 19F MRI in vivo. Circ
Cardiovasc Imaging, 2010. 3(2): p. 202‐10.
Hertlein, T., et al., Visualization of abscess formation in a murine thigh infection model
of Staphylococcus aureus by 19F‐magnetic resonance imaging (MRI). PLoS One, 2011.
6(3): p. e18246.
Ye, Q., et al., In vivo detection of acute rat renal allograft rejection by MRI with USPIO
particles. Kidney Int, 2002. 61(3): p. 1124‐35.
Ye, Q., et al., Longitudinal tracking of recipient macrophages in a rat chronic cardiac
allograft rejection model with noninvasive magnetic resonance imaging using
micrometer‐sized paramagnetic iron oxide particles. Circulation, 2008. 118(2): p.
149‐56.
Ruiz‐Cabello, J., et al., Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed,
2011. 24(2): p. 114‐29.
Pogue, B.W., et al., Radiologic and near‐infrared/optical spectroscopic imaging: where
is the synergy? AJR Am J Roentgenol, 2010. 195(2): p. 321‐32.
Key, J. and J.F. Leary, Nanoparticles for multimodal in vivo imaging in nanomedicine.
Int J Nanomedicine, 2014. 9: p. 711‐26.
Kim, S.H. and J.M. Chung, An experimental model for peripheral neuropathy produced
by segmental spinal nerve ligation in the rat. Pain, 1992. 50(3): p. 355‐63.
Seltzer, Z., R. Dubner, and Y. Shir, A novel behavioral model of neuropathic pain
disorders produced in rats by partial sciatic nerve injury. Pain, 1990. 43(2): p. 205‐18.
De Vry, J., et al., Pharmacological characterization of the chronic constriction injury
model of neuropathic pain. Eur J Pharmacol, 2004. 491(2‐3): p. 137‐48.
Attama, A.A., SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat
Drug Deliv Formul, 2011. 5(3): p. 178‐87.
Ahrens, E.T. and J.W. Bulte, Tracking immune cells in vivo using magnetic resonance
imaging. Nat Rev Immunol, 2013. 13(10): p. 755‐63.
Ahrens, E.T., et al., In vivo imaging platform for tracking immunotherapeutic cells. Nat
Biotechnol, 2005. 23(8): p. 983‐7.

124

190.
191.
192.
193.
194.
195.
196.
197.
198.

Helfer, B.M., et al., Functional assessment of human dendritic cells labeled for in vivo
(19)F magnetic resonance imaging cell tracking. Cytotherapy, 2010. 12(2): p. 238‐50.
Ahrens, E.T. and J. Zhong, In vivo MRI cell tracking using perfluorocarbon probes and
fluorine‐19 detection. NMR Biomed, 2013. 26(7): p. 860‐71.
Wu, Y., et al., Human gamma delta T cells: a lymphoid lineage cell capable of
professional phagocytosis. J Immunol, 2009. 183(9): p. 5622‐9.
Johns, B.Z., TRPV1 mRNA is differenctially expressed in different vertebral levels of rat
dorsal root ganglia following sciatic nerve injury, in Bayer School of Natural and
Environmental Sciences2009, Duquesne University.
Colleoni, M. and P. Sacerdote, Murine models of human neuropathic pain. Biochim
Biophys Acta, 2010. 1802(10): p. 924‐33.
Lim, T.K., et al., Blood‐nerve barrier dysfunction contributes to the generation of
neuropathic pain and allows targeting of injured nerves for pain relief. Pain, 2014.
155(5): p. 954‐67.
Kisley, L.R., et al., Celecoxib reduces pulmonary inflammation but not lung
tumorigenesis in mice. Carcinogenesis, 2002. 23(10): p. 1653‐60.
Moalem, G. and D.J. Tracey, Immune and inflammatory mechanisms in neuropathic
pain. Brain Res Rev, 2006. 51(2): p. 240‐64.
Kotani, M., et al., Systemic circulation and bone recruitment of osteoclast precursors
tracked by using fluorescent imaging techniques. J Immunol, 2013. 190(2): p. 605‐12.

125

Appendix: Detailed Methods
A.1 Ethics Statement
The number of animals and the protocols used during the study were approved by the
Institutional Animal Care and Use Committee (IACUC), Duquesne University (Protocol number
#1109-10). Also, the study was carried out in strict accordance with the Guide for the care and
use of the Laboratory Animals of National Institute of Health and American Veterinary Medical
Association guidelines.

A.2 Animals
Male Sprague Dawley rats (Hilltop Lab Animals Inc., Scottdale, PA) weighing 250-350
grams were used in this study. Upon arrival at the animal care facility, Duquesne University, the
rats were acclimatized for at least one week, before performing any procedures on them. The rats
were maintained on regular corncob bedding and were fed regular rat chow during the
acclimation period. Upon commencement of the study procedures, the rats were shifted on paper
bedding and were fed purified diet (D10012G Research Diets, Inc. New Brunswick, NJ). Paper
bedding helps to reduce the discomfort during movement after the CCI surgery, as compared to
the coarser corncob bedding. Purified diet was preferred to the regular chow because it helps to
reduce the auto fluorescence during the LiCOR pearl imaging (LiCOR Biosciences). Rats were
maintained on routine 12:12 hour light dark cycle. Rats had unrestricted access to feed and water
throughout the study period.

A.3 Chronic Constriction Injury (CCI)
The rats were subjected to Chronic Constriction Injury (CCI) surgery as described by
Bennett and Xie in 1988 (Bennett and Xie, 1988). The surgery was performed under general
anesthesia using isoflurane. The rats were weighed before the surgery using the manual weigh
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machine. Immediately after that, the general anesthesia was induced with 5% isoflurane and
oxygen flow rate of 2 L/minute. The retraction of the eyeball and no response upon tapping of
the induction chamber were used as indicators of initial induction of anesthesia. Immediately
after the initial induction of the anesthesia, the rats were transferred to a heated-bed (~38 °C) and
the facemask was applied to maintain the general anesthesia. The infrared lamp was used at a
sufficient distance (~2 feet away from rat) to prevent hypothermia in the rats during anesthesia.
The anesthesia was maintained at ~1.5% isoflurane along with the oxygen flow rate of
2L/minute throughout the CCI/sham surgery. Rats were observed for the signs of surgical depth
of anesthesia by examining the retraction of eyeball, no tail flicking upon rolling the tail between
fingers and no leg withdrawal upon pinching the toe with the tissue forceps, to confirm the
appropriate depth of anesthesia before beginning the surgical procedures.

A.4 Rat Preparation Before Surgery
Rats were shaved at the right hind limb near the thigh region up to the knee joint along
with the right dorsal lumbar area of the back, using a clipper (Oster) with a size-40 clipper blade.
The shaving was performed first towards and then against the direction of the hair growth to
provide a smooth surface for the surgical preparation of the skin. After clipping, Nair hairremoving cream (for sensitive skin) was applied to the clipped area strictly for no more than 30
seconds and was wiped off using a gauze pad (2x2 inches) soaked with warm water (wringed
before use). Nair removing cream removed the fine hairs that were not removed by the clipper.
The hairless area was then dried with another gauze pad (2x2 inches). To prep of the area for
surgery, the thigh region was scrubbed with ready-to-use betadine and alcohol gauzes alternately,
at least three times each, to remove the microorganisms from the surgical area to prevent any
post-surgical infection.
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A.5 CCI Surgery
The surgical instruments were sterilized using the Germinator 500 dry sterilizer where
glass beads get heated up to 260 °C and the clean surgical instruments get sterilized when placed
in the beads for about 15 seconds. After wearing surgical gloves, the femur bone was palpated
(over the skin) with fingertips and a skin incision (~2 cm) was made parallel and right below the
femur bone, using a scalpel (#3) with a replaceable surgical blade (#10). Under the skin incision,
the junction between the two thigh muscles (i.e. gluteus superficialis and biceps femoris) was
seen as a shiny white fibrous tissue. This white fibrous tissue was incised using a scalpel or a
micro scissors and the two muscles get separated without any muscle tear or bleeding to neatly
expose the common sciatic nerve. The common sciatic nerve runs closer to the biceps femoris
muscle due to fascia attachments. Therefore, the common sciatic nerve was liberated from its
fascia attachments using a micro scissors under the microscope. Microscope must be used to
prevent any unintended injury to the sciatic nerve itself. When about 1 cm nerve was free from
its muscle attachments and was dangling in the space between the muscles, a sterile 4-0 chromic
gut suture was used to tie four square knots, about 1 mm apart on the common sciatic nerve and
this maneuver was performed under the microscope. Knots were tied with the help of a needle
holder. Utmost care was taken to ensure that the knots were neither too tight to constrict the
blood supply at the site of ligation nor too loose to allow the knots to freely move along the
nerve. The knots were tied in a way to stay put without being too tight or too loose. After the
CCI surgery, the separated muscles were sutured together using a 4-0 chromic gut suture and the
simple interrupted suture pattern. Finally, the incised skin was sutured back using 9 mm stainless
steel autoclips. Throughout the surgery, the rats were checked for peripheral perfusion (capillary
refill time) by pinching the toes (with the help of an assistant), regular breathing (thoracic
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movements) and heart rate (by placing the finger tips on ventral chest area, with the help of an
assistant).

A.6 Sham Surgery
Sham surgery was identical to the CCI surgery up to separating the nerve from its
attachment to the muscles. The common sciatic nerve in the sham rats was handled similar to the
one in the CCI rats except that no ligatures were placed around the nerve in the sham rats. The
muscle and skin were sutured back similar to the CCI surgery. Sham rats served as surgical
controls. Another control used during the study was naïve control where the rats did not
underwent any anesthesia or surgical protocols.

A.7 Behavioral Testing (Mechanical Allodynia Testing)
Mechanical allodynia testing was performed to test for the development of
hypersensitivity behavior in rats, which is indicative of evoked neuropathic pain post-CCI
surgery. The mechanical allodynia testing was performed a day before the surgery to obtain the
baseline levels in the right hind paw of the rats. The testing was repeated on day 11 post-surgery
to check for the development of hypersensitivity post-CCI or post-sham surgery. The testing was
performed using the calibrated von Frey filaments ranging from, 0.41 gram-force to 15 gramforce (Touch test sensory evaluator, size 3.61 to 5.18). The rats were placed into a perspex box
with a wire mesh bottom and were provided at least 10 minutes of acclimation period before the
test was started. The von Frey filaments were applied to the plantar surface of both the hind paws
of the rats through a wire mesh bottom of the cage. The filaments were applied at the plantar
surface of the hind paw region that is mostly innervated by the sciatic nerve. The filaments were
applied in an ascending order of their gram-forces (0.4, 0.6, 1, 1.4, 2, 4, 6, 8, 10, 15 g). Each
filament was applied for a total of ten times for each hind paw and the withdrawal responses
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were recorded for each application of each of the filaments. To begin with, the smallest gramforce filament was applied perpendicular to the paw surface for five times, until the filament
bends at an acute angle. Each application was separated by at least 2-3 seconds to clearly
distinguish between each response. A time lapse of at least 5 minutes was chosen between any
two filaments of different gram-forces. Same procedure was followed for all the filaments in the
ascending order and was repeated for both the hind paws. The testing was complete when either
all the filaments were tested or if the rat withdrew its hind paw on all ten applications of a given
filament.
To determine the gram-force causing 50% withdrawal responses in rats, a linear
regression analysis was performed with the number of withdrawal responses and the gram-forces
of the filaments used during the test. The linear regression was performed separately for both the
hind paws. The following formula was used to determine the normalized 50% withdrawal
threshold on day 11 post-surgery:
Normalized 50% withdrawal threshold (WT) = Post-Surgery (50% WT right paw – 50% WT left
paw) – Baseline (50% WT right paw – 50% WT left paw).
The normalized gram-force required for 50% withdrawal response was averaged
separately for the CCI, sham and naïve control groups and their mean values were compared
using the Kruskal-Wallis one-way ANOVA by Ranks Test in GraphPad PRSIM version 6.0e.
The values were considered significant at p ≤ 0.05.

A.8 Rat Tail-Vein Injection
The theranostic nanoemulsion (containing celecoxib) and the vehicle nanoemulsion
(without celecoxib) were injected intravenously through the right or left lateral tail-vein in the
rats. The injection (0.3 ml) was given under isoflurane anesthesia, on day 8 post-surgery using a
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1 ml syringe and a 25-gauge over-the-needle catheter. The anesthesia induction and maintenance
was performed as described earlier under the CCI surgery. At appropriate depth of anesthesia,
the tail was completely submerged in warm water (~38 º C) for about 1 minute to allow the
dilation and easy visualization of the lateral tail veins. Immediately after the dilation step, the tail
was wiped off with clean gauze to remove the moisture and any debris over the tail. Either of the
lateral tail veins was chosen for the injection based upon easy visualization of the vein. The
preferred site of the injection was the apical 1/3rd of the tail, about an inch away from the tip of
the tail. The tail was slightly rolled and held between the forefinger and thumb of the nondominant hand with a slight bend of the tail over the forefinger such that the lateral vein was
facing upwards. An alcohol swab was then used to clean the site of the injection. The needle was
positioned with its bevel facing upwards, and using the dominant hand, the tip of the needle was
inserted into the vein followed by rest of the needle. The successful placement into the vein was
confirmed by seeing blood at the hub of the needle. Immediately thereafter, the syringe
containing 0.3 ml of the nanoemulsion was attached to the needle, without displacing the needle
from the vein. The second most important confirmation of correct placement of the needle was
complete absence of resistance during the injection. The plunger of the syringe was pushed
slowly, and the nanoemulsion injection was completed in 30 seconds.

A.9 LiCOR Pearl Imaging
The in-vivo near-infrared fluorescence imaging was performed using a LiCOR Pearl
Impulse small animal imaging system (LiCOR Biosciences, Lincoln, NE). The LiCOR Pearl
imaging was performed at two time-points during a given experiment, one on day 8 post-surgery
(i.e. immediately after the nanoemulsion injection) to confirm the intravenous delivery of the
nanoemulsion and the second on day 11 post-surgery to image the site of injury. For the day 8
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imaging, the rats were imaged under isoflurane anesthesia due to a very short period of imaging
required, whereas on day 11 post-surgery, the rats were anesthetized with an injectable
anesthesia (xylazine, 7 mg/kg combined with ketamine, 80 mg/kg) given intraperitoneally to
maintain a longer duration of anesthesia (~ 20-30 minutes) required for comprehensive imaging.
Before capturing the rat images, the imager was set to a focus value of -1 where the rat
hairs were seen in-focus. All the in-vivo images were captured at a resolution of 170 um. All the
three wavelengths of light available on the LiCOR pearl imager (i.e. 785 nm, captured as pseudo
red fluorescence; 820 nm, captured as pseudo green fluorescence, and white light) were used
during imaging in this study.
As mentioned earlier, the nanoemulsion injection was given intravenously on day 8 postsurgery and the rats were maintained on ~1.5% isoflurane anesthesia during the tail vein
injection. Immediately after the injection and before the transfer of the rat to the LiCOR Pearl
imager, the anesthetic gas flow was increased to 5% for 1-2 minutes to transiently increase the
depth of the isoflurane anesthesia. Increase in the isoflurane gas flow was required to maintain
the anesthesia while taking a tail snapshot in the LiCOR pearl imager, with the site of injection
in-view. Upon completion of the imaging, the rats were transferred back to their respective
cages. On day 11 post-surgery, upon completion of the mechanical allodynia testing, the rats
were anesthetized with the injectable anesthesia mentioned above. At appropriate depth of the
anesthesia (i.e. absence of corneal reflex and no response to an external stimuli), the rat was
transferred to the LiCOR pearl imager. On day 11 post-surgery, four views (i.e. dorsal, ventral,
right lateral and left lateral) of the posterior half of each of the rats were captured and saved in
the computer for further image analysis. After the imaging was complete, the anesthesia was
reversed using yohimbine, 2 mg/kg body weight and the rats were monitored until fully
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awake. Yohimbine was not used if the rats exhibited a positive corneal reflex after the
completion of the imaging.

A.10 LiCOR Image Analysis
All the near-infrared images were analyzed using LiCOR Pearl Impulse software version
2.0. The dataset to be compared was imported and analyzed using linked look-up feature
provided in the software. An area was chosen over the right sciatic nerve region as a
representative of the site of injury (region of interest, ROI) and the same ROI was applied to
other images in a given dataset to obtain the normalized fluorescence intensity [i.e. total
fluorescence in ROI/area (pixels)]. The means of the normalized fluorescence intensities of the
three different conditions (i.e. CCI, sham and naïve control rats) were then compared by one-way
ANOVA using GraphPad PRISM version 6.0e. The differences were considered significant at p
< 0.05.

A.11 Euthanasia
On day 12 post-surgery, the rats were injected with ~2 ml of euthasol solution
(commercially available as fatal plus solution containing sodium pentobarbital, 390 mg/ml)
intraperitoneally under 1.5% isoflurane anesthesia. The death was confirmed by absence of a
heartbeat, respiration (thoracic movements), and changing of the eyeball color from pink to
transparent to opaque white.

A.12 Intracardiac Perfusion Fixation
Intracardiac perfusion fixation is mostly used to obtain whole body fixation and is
performed with 4% paraformaldehyde solution. The paraformaldehyde solution is carried to all
the body tissues via circulation and thus leads to whole body fixation. Therefore, perfusion
fixation is highly efficient when started immediately after the intraperitoneal injection of
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euthasol, when the heart is still functional. A functional circulatory system helps in efficient
delivery of the paraformaldehyde solution and thus allowing an excellent whole body fixation.
Immediately after the euthanasia injection, the isoflurane flow rate was increased to 5% and the
oxygen flow rate was reduced to 0.5 L/minute. The 4% paraformaldehyde solution was made
fresh (a day before the perfusion fixation) in buffered PBS (pH 7.4) and filtered using Nalgene
filters (1 L capacity) and stored at 4° C until used. The perfusion fixation apparatus was
borrowed from Dr. David A. Johnson’s laboratory in the department of Pharmaceutical Sciences
at Duquesne University.
The 60 ml perfusion syringe was filled with buffered PBS (pH 7.4) containing heparin
(10 U/ml) and was attached with Y tubing and to the perfusion pump. Similarly, another 60 ml
syringe was filled with 4% PFA solution and was also attached with the Y-tubing and to the
perfusion pump. The one-way valves, in the Y-tubing, for both the syringes were kept closed
until needed. The one-way valve for PBS/heparin was opened and the perfusion pump was
started to remove any air bubbles from the Y-tubing. Once the perfusion apparatus was ready to
be used, and the rat was injected with the euthasol, the thoracic cavity of the rat was opened. The
rat was in supine position with its ventral side facing upwards. To open the thoracic cavity, the
last rib of the rat was felt and a horizontal incision was made (using a scissors or a scalpel) in the
skin, muscles and the diaphragm separating the thoracic and the abdominal cavities. Two parallel
incisions were made on both the sides of the rib cage and the rib cage was reflected towards the
anterior side of the rat and clamped to keep in-place. The exposed functional heart (a beating
heart) in the thoracic cavity was grasped with a small artery forceps and a blunt perfusion needle
was inserted in the left ventricle of the heart and retained in-place with the help of an artery
forceps holding the needle through its jaws while clamped to the heart. Immediately thereafter, a
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snip in the right auricle was made with a small scissors, to make an outlet for the circulating fluid
in the closed circulation system. The perfusion with PBS/heparin was initiated @ 10ml/minute
and was later increased to 20 ml/minute. The perfusion with PBS/heparin was performed until
the blood in the circulatory system was replaced with the PBS/heparin solution and this was
confirmed with oozing of pale straw colored fluid from the auricle. After flushing out blood from
the circulatory system, the one-way valve for PBS/heparin tubing was closed and the valve for
4% PFA tubing was opened. Approximately 180 ml (60 ml syringe x 3) were used to perform the
whole body perfusion fixation of a rat weighing around 350 grams. At the end of the fixation
protocol, rats were stiff due to rigor mortis and tissue fixation. The surgical instruments used
during the perfusion fixation procedure were kept separate and never used during the survival rat
surgeries at any time and vice-versa.

A.13 Sciatic Nerve And Femur Bone Dissection
The sciatic nerve dissections were performed on day 12 post-surgery. The approach
towards the exposure of the common sciatic nerve either during the CCI/sham survival surgery
or during the dissection was identical. During the nerve dissection, the scar or incision marks
from the original CCI/sham surgery were followed as landmarks and re-incisions were made at
exact same sites again. For the naïve rats, the dissection protocol was identical to approaching
the sciatic nerve during a sham or CCI surgery. The ligations were easily discernible on day 12
post-surgery and ~1 cm of the common sciatic nerve was transected anterior and posterior to the
knot ligations using a micro scissors. The dissected nerve was stored overnight in 4% PFA (pH
7.4) at 4 °C and then transferred to 0.4% PFA solution next day and stored at 4 °C until further
processing. The sciatic nerves for both the hind limbs were dissected out from the CCI, sham and
naïve rats.
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The femur bone runs parallel and adjacent to the common sciatic nerve. To prevent any
damage to the sciatic nerve, the femur bone was always dissected out after the completion of the
sciatic nerve dissection. The femur bone was palpated with fingers and two parallel incisions
were made along the margins of the long axis of the bone using a scalpel (#3) with replaceable
surgical blade (#10). The ligaments joining the femur and tibia/fibula bones were transected and
the joint was carefully dislodged. Similarly, the ligaments joining the head of the femur and the
pelvic girdle were transected with circular motion of the blade to set free the femur bone. The
femur bone was then fixed and stored in 4% PFA (pH 7.4) overnight at 4°C and then transferred
to 0.4% PFA and stored at 4°C for later use. Both ipsilateral and contralateral femur bones were
collected from all the CCI, sham and naïve rats.

A.14 Sciatic Nerve Collection In Live Rats
The common sciatic nerve was transected under isoflurane anesthesia as the terminal
procedure and the rats were euthanized thereafter. The tissue collection was performed at four
time points spanned over a period of 18 days (i.e. 2-3 hours post-surgery and day 8, 11 and 18
post-surgery) for the CCI and sham rats along with the naïve non-surgical control rats. Four rats
were used for every given time-point. The common sciatic nerve collection protocol was same as
described earlier under sciatic nerve dissection. Immediately post-collection, the tissue was
preserved in RNA later solution (AM7024, Ambion) and stored at 4°C for 24 hours and
thereafter stored at -20 °C freezer until further processing. The ipsilateral sciatic nerves were
collected at the region of injury from all the CCI, sham and naïve rats.

A.15 Immunohistochemistry
The fixed ipsilateral and contralateral sciatic nerves from the CCI, sham and naive
control rats, stored in 0.4% PFA at 4° C were molded into a block using Optimal Cutting
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Temperature (OCT) compound (Sakura) at -20° C. Upon freezing, the block containing the
common sciatic nerve was mounted on the cryostat and was cryosectioned into 20 μm thick
longitudinal sections. The sections were placed on the superfrost plus gold slides (Fisher
Scientific, 15-188-48), which provide adequate adhesion of the fixed, frozen tissue section onto
the slide. The slides containing the cryosections were stored in the slide storage boxes and stored
at -20° C until used. To proceed with the immunofluorescence protocol, the slides were warmed
on a slide-warmer at 37 ° C for 30 minutes and then fixed in freshly made 4% 1X PFA (pH 7.4,
4° C) solution for 15 minutes. After fixation, four washes were performed in 1X PBS for 5
minutes each at room temperature. After washing, the sections were permeabilized by
submerging the slides in 0.3% buffered Triton X-100 (1X PBS, pH 7.4) for 30 minutes at room
temperature. Slides were washed again in 1X PBS for four times, five minutes each, at room
temperature. Followed by washing, blocking was performed with 50 µL normal donkey serum
(1:20 in 1X PBS, pH 7.4). The serum was placed covering the section and a coverslip was
placed over it and the slide was incubated for one hour at room temperature in a moisture
chamber. After incubation, the coverslip was removed by dipping the slide into 1X PBS solution.
Immediately after this step, the section was covered with 25 µL primary antibody (working
dilution) and a coverslip was placed over it and the slide was then incubated in a moisture
chamber over night at 4 °C. After the incubation, five washes were performed in 1X PBS (pH
7.4), five minutes each at room temperature. After the washing step, the sections were covered
with 25 µL secondary antibody (1:200) with a coverslip placed over it. The slide
was then incubated in the moisture chamber overnight at 4 °C. At the end of the incubation, final
washes were performed in 1X PBS (pH 7.4), five minutes each at room temperature. The
sections were mounted in Prolong Gold with DAPI (Molecular Probes) and were incubated over
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night at room temperature in dark. For the double immunofluorescence study, the two primary
antibodies to be used were diluted together and placed over the section. Similarly, the two
corresponding secondary antibodies were diluted together and placed over the section. Double
immunofluorescence studies were performed to examine the infiltration of macrophages (CD68)
along with the presence of caspase-1, IL-18, IL-1β and IL-1α using mouse anti-CD68, 1:100
(MCA341R, AbD Serotech), rabbit anti-caspse-1, 1:50 (caspse-1 p10 (M20) sc514, Santa Cruz
Biotechnology), rabbit anti-IL-18, 1:100 (R1186, Acris Antibodies), rabbit anti-IL-1β, 1:100
(ab9787, abcam) and goat anti-IL-1α, 1:100 (ab9875, abcam) primary antibodies. The double
immunofluorescence studies were also performed to study the expression of COX-2 and PGE2 in
the infiltrating macrophages using, rabbit anti-COX-2, 1:100 (ab15191, AbD Serotech) and
rabbit anti-prostaglandin E2 antibody, 1:100 (ab2318, AbD Serotech) along with mouse CD68,
1:100 (MCA341R, AbD Serotech) in treated and untreated rat groups. The secondary antibodies
used were Alexa fluor 488 donkey anti-mouse, 1:200 (A-21202, Invitrogen), Alexa fluor 546
donkey anti-goat, 1:200 (A-11056, Invitrogen) and Alexa fluor 647 donkey anti-rabbit, 1:200 (A31573, Invitrogen). All the antibody dilutions were prepared using 1:20 normal donkey serum in
1X PBS, pH 7.4. Antigen retrieval was performed during double immunofluorescence with
COX-2 and CD68 primary antibodies, using sodium citrate buffer (10 mM sodium citrate, 0.1%
Tween 20, pH 8.5). Antigen retrieval was also performed during double immunofluorescence
with caspase-1, IL-18, IL-1β, IL-1α, COX-2 and CD68 primary antibodies, using sodium citrate
buffer (10 mM sodium citrate, 0.1% Tween 20, pH 6 or pH 8.5). Antigen retrieval was not
required during double immunofluorescence with PGE2 and CD68 primary antibodies.
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A.16 Antigen Retrieval
As mentioned earlier, the antigen retrieval protocol was used for some of the antibodies
before the double immunofluorescence staining protocol. The protocol was identical to the
immunohistochemistry protocol described above except for the permeabilization step. The
permeabilization with Triton X-100 was replaced by a combined permeabilization and antigen
retrieval step using sodium citrate buffer and Tween-20 solution. For IL-1β and caspase staining,
the slides were incubated in sodium citrate and Tween-20, pH 6 for 5 minutes at 93°C for the
permeabilization and antigen retrieval step. For IL-1α staining, the slides were incubated in
sodium citrate and Tween-20, pH 6 for 3 minutes at 93°C for the permeabilization and antigen
retrieval step. For IL-18 and COX-2 staining, the slides were incubated in sodium citrate (10
mM) and Tween-20 (0.1%), pH 8.5 for 1 minute at 93°C for the permeabilization and antigen
retrieval step. After the permeabilization step, the slides were transferred to deionized water at
room temperature for 20 minutes and were allowed to cool down to the room temperature. After
this, the slides were rinsed in 1X buffered PBS (pH 7.4) five times and five minutes were given
for each rinse. After permeabilization and washing step, the blocking step and the rest of the
protocol was same as described under immunohistochemistry.

A.17 Confocal Microscopy and Quantification
Confocal microscopy was performed on a Leica SP2 spectral Laser Scanning Confocal
microscope and Leica SP2 spectral Laser Scanning Confocal microscope software was used to
analyze the confocal images. The quantification analysis was performed for the double
immunofluorescence slides stained with either COX-2 or PGE2 and CD68 antibodies, in the
three treated (with celecoxib) and three untreated (vehicle only) CCI rats. Confocal images for a
comparative set were acquired with the same instrument settings (laser power, PMT voltage, pin
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hole, etc.). To determine any changes in the relative number of macrophages in the treated and
untreated conditions, six regions of interest (ROIs) were chosen in each captured field-of-view of
the ipsilateral sciatic nerve sections stained for CD68 positive cells for the CCI treated and
untreated groups. At least two to three field of views (F) were used for each of the rat nerve
section to obtain ROIs between 12-18 for each of the rats. Since, we had three rats per condition,
there were between 36-54 ROIs for three rats per condition (i.e. CCI treated or untreated). Mean
fluorescence intensity (MFI) of CD68 stained sections was averaged from all the ROIs for the
CCI drug (n=54) and the CCI no drug (n=48) conditions (Table A1, Appendix). No significant
variation in the mean fluorescence intensity was found among individually identified
macrophages in the treated or untreated groups (Table A2, A3, Appendix). Therefore, the
differences in the average mean fluorescence intensity per unit area among treated and untreated
groups indicates differences in the relative number of macrophages between the two groups. The
relative expression of COX-2 and PGE2 in the macrophages was determined by finding the
ratios of the mean fluorescence intensity of COX-2 to the mean fluorescence intensity of CD68
in the same macrophage, and separately the ratios of the mean fluorescence intensity PGE2 in a
given macrophage in both cases in drug and no drug conditions (Table A2, A3, Appendix). The
CD68 fluorescence intensity in the macrophages did not change in the drug or no drug condition
and hence was used to normalize the COX-2 or PGE2 fluorescence intensity in the treated or
untreated CCI conditions. To analyze the COX-2 and PGE2 expression differences, a line was
drawn across individual macrophages (M) in the field-of-view (F) and mean fluorescence
intensity for either COX-2 or PGE2 was recorded in the individual cells. For the line analysis,
the images were captured at a total magnification of 80X (20X objective + 4X zoom). At least
five macrophages were chosen for each field-of-view and for three rats at least 40 macrophages
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were analyzed for any given condition. The changes in COX-2: macrophage or PGE2:
macrophage mean fluorescence intensity ratio in treated or untreated group was indicative of
relative changes in the COX-2 or PGE2 expression in the macrophages (Table A2, A3,
Appendix).

A.18 'Blinded' Experiments
Aspects of the studies described in this dissertation were carried out under ‘blinded
condition’. However, under certain circumstances it was not possible to do it as a blind study.
The nature of several aspect of the work performed would require at least two researchers
working together at all times to make it a blind study and at the time that these projects were
initiated that was not feasible. However, some of the experiments were analyzed in a semi-blind
fashion. For example, the NIR fluorescence image analysis was performed by an analyzer who
was blinded to the CCI, sham or naive conditions. Similarly, the histological data was collected
in a relatively blind fashion as well. The tissue samples collected during dissection were coded
and the confocal microscopy and image analysis were performed as per the codes which were
later matched with any given rat condition.
In the case of the behavioral data collection and analysis, it was not possible to stay blind
because the signs of a CCI surgery were very robust and the rat conditions were easily
discernible from the sham or naive rats.
The semi blind nature of the study would not change the interpretation of the data, due to
the fact that the behavioral differences, NIR fluorescence intensity differences and histological
differences observed between the CCI and control groups were robust and would be easily
distinguishable even if it was a completely blind study. However, for the future studies, when the
differences between the groups are subtle as may be the case with other experimental drug
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formulations, a blind study would be very useful and is highly recommended. This is feasible by
blinding the researcher for the type of nanoemulsion being used during the study. Furthermore,
when possible a working group of two should be employed. For example, one investigator could
recover the CCI tissue for histology and have a second investigator label the tissue samples for
their further analysis. There are other opportunities similar to this that can be employed.

A.19 Statistical Analysis
The statistical analysis was performed using GraphPad PRISM version 6.0e. as described
previously in chapter 2, 3 and 4.
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Table A‐1: Mean fluorescence intensity of CD68 positive stained slides from CCI rats
injected with either theranostic nanoemulsion or vehicle nanoemulsion.
CCI, with theranostic nanoemulsion
A1,F1, ROI 1
A1,F1, ROI 2
A1,F1, ROI 3
A1,F1, ROI 4
A1,F1, ROI 5
A1,F1, ROI 6
A1, F2, ROI 1
A1, F2, ROI 2
A1, F2, ROI 3
A1, F2, ROI 4
A1, F2, ROI 5
A1, F2, ROI 6
A1, F3, ROI 1
A1, F3, ROI 2
A1, F3, ROI 3
A1, F3, ROI 4
A1, F3, ROI 5
A1, F3, ROI 6
A3, F1, ROI 1
A3, F1, ROI 2
A3, F1, ROI 3
A3, F1, ROI 4
A3, F1, ROI 5
A3, F1, ROI 6
A3, F2, ROI 1
A3, F2, ROI 2
A3, F2, ROI 3
A3, F2, ROI 4
A3, F2, ROI 5
A3, F2, ROI 6
A3, F3, ROI 1
A3, F3, ROI 2
A3, F3, ROI 3
A3, F3, ROI 4
A3, F3, ROI 5
A3, F3, ROI 6
A5, F1, ROI 1
A5, F1, ROI 2
A5, F1, ROI 3
A5, F1, ROI 4
A5, F1, ROI 5
A5, F1, ROI 6
A5, F2, ROI 1
A5, F2, ROI 2
A5, F2, ROI 3
A5, F2, ROI 4
A5, F2, ROI 5
A5, F2, ROI 6
A5, F3, ROI 1
A5, F3, ROI 2
A5, F3, ROI 3
A5, F3, ROI 4
A5, F3, ROI 5
A5, F3, ROI 6
A1, A3, A5= three rats
F= Field of view
ROI = Region Of Interest
n = total number of ROIs

CD68 mean fluorescence intensity CCI, with vehicle nanoemulsion CD68 mean fluorescence intensity
9.68
C1, R1, 1
14.33
20.06
C1, R1, 2
14.45
10.44
C1, R1, 3
17.05
10.18
C1, R1, 4
12.8
15.06
C1, R1, 5
15.68
15.69
C1, R1, 6
11.68
6.73
C1, R2, 1
10.71
7.43
C1, R2, 2
14.44
7.87
C1, R2, 3
19.16
10.25
C1, R2, 4
14.18
5.42
C1, R2, 5
16.43
5.47
C1, R2, 6
13.52
1.57
C1, R3, 1
14.25
2.68
C1, R3, 2
13.33
2.48
C1, R3, 3
12.27
3.68
C1, R3, 4
14.35
4.18
C1, R3, 5
13.71
3.37
C1, R3, 6
14.05
11.09
C3, R1, 1
9.07
8.53
C3, R1, 2
10.1
8.18
C3, R1, 3
11.58
15.79
C3, R1, 4
9.75
10.74
C3, R1, 5
10.47
8.09
C3, R1, 6
12.47
6.22
C3, R2, 1
26.97
7.19
C3, R2, 2
17.75
4.6
C3, R2, 3
9.98
5.78
C3, R2, 4
7.76
10.93
C3, R2, 5
9.47
5.65
C3, R2, 6
12.75
7
C4, R1, 1
10.59
10.62
C4, R1, 2
8.22
7.1
C4, R1, 3
11.52
4.64
C4, R1, 4
13.78
7.17
C4, R1, 5
10.69
3.63
C4, R1, 6
9.36
5.59
C4, R2, 1
6.94
6.17
C4, R2, 2
5.09
5.93
C4, R2, 3
6.88
8.84
C4, R2, 4
6.89
3.92
C4, R2, 5
8.48
7.37
C4, R2, 6
1.27
4.98
C4, R3, 1
13.05
4.67
C4, R3, 2
4.34
3.27
C4, R3, 3
5.43
2.57
C4, R3, 4
4.43
2.64
C4, R3, 5
12.52
4.39
C4, R3, 6
4.19
1.59
1.35
1.28
4.46
1.85
2.37
n= 54

C1, C3, C4= three rats
F= Field of view
ROI = Region Of Interest
n = total number of ROIs
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n=48

Table A‐2: Mean fluorescence intensity of PGE2, CD68 and normalized PGE2 intensity (ratio
of PGE2 MFI and CD68 MFI) for CCI rats injected with theranostic and vehicle
nanoemulsion.
CCI, with theranostic nanoemulsion PGE2 MFI CD68 MFI Ratio of PGE2: CD68 MFI CCI, with vehicle nanoemulsion PGE2 MFI CD68 MFI Ratio of PGE2: CD68 MFI
33.56
33.41
1.004
C1, F1, M1
66.89
56.74
1.179
A1, F1, M1
A1, F1, M2
24.09
41.6
0.579
C1, F1, M2
61.79
49.52
1.248
55.12
22.24
2.478
C1, F1, M3
62.45
67.05
0.931
A1, F1, M3
31.75
78.03
0.407
C1, F1, M4
70.35
94.8
0.742
A1, F1, M4
46.58
34.45
1.352
C1, F1, M5
64.42
52.48
1.228
A1, F1, M5
A1, F2, M1
20.01
78.47
0.255
C1, F2, M1
55.43
46.52
1.192
61.5
101.7
0.605
C1, F2, M2
62.37
66.79
0.934
A1, F2, M2
48.25
65.81
0.733
C1, F2, M3
59.99
55.4
1.083
A1, F2, M3
68.82
39.96
1.722
C1, F2, M4
50.01
52.04
0.961
A1, F2, M4
36.26
75.11
0.483
C1, F2, M5
54.19
34.11
1.589
A1, F2, M5
A1, F3, M1
58.59
70.74
0.828
C1, F3, M1
52.1
32.44
1.606
48.84
40.07
1.219
C1, F3, M2
63.32
35.63
1.777
A1, F3, M2
37.98
38.66
0.982
C1, F3, M3
58.57
53.75
1.09
A1, F3, M3
28.94
41.3
0.701
C1, F3, M4
66.53
66.75
0.997
A1, F3, M4
A1, F3, M5
17.53
48.6
0.361
C1, F3, M5
46.95
44.6
1.053
13.38
38.73
0.345
C1, F4, M1
114.98
65.07
1.767
A3, F1, M1
21.86
31.55
0.693
C1, F4, M2
107.15
77.2
1.388
A3, F1, M2
29.75
80.61
0.369
C1, F4, M3
120.11
53
2.266
A3, F1, M3
19.48
37.12
0.525
C1, F4, M4
94.12
73.27
1.285
A3, F1, M4
A3, F1, M5
24.81
58.04
0.427
C1, F4, M5
148.45
94.59
1.569
24.63
26.64
0.925
C1, F5, M1
157.09
97.09
1.618
A3, F2, M1
16.33
48.88
0.334
C1, F5, M2
154.41
139.67
1.106
A3, F2, M2
24.26
58.55
0.414
C1, F5, M3
96.77
53.85
1.797
A3, F2, M3
A3, F2, M4
14.9
53.61
0.278
C1, F5, M4
89.34
52.17
1.712
11.34
23.97
0.473
C1, F5, M5
74.3
52.3
1.421
A3, F2, M5
19.83
41.05
0.483
C3, F1, M1
37.53
85.79
0.437
A3, F3, M1
29.81
69.71
0.428
C3, F1, M2
23.74
32.94
0.721
A3, F3, M2
28.64
39.15
0.732
C3, F1, M3
29.4
65.05
0.452
A3, F3, M3
A3, F3, M4
20.15
35.83
0.562
C3, F1, M4
24.23
103.76
0.234
21.75
54.77
0.397
C3, F1, M5
27.93
54.87
0.509
A3, F3, M5
15.83
29.61
0.535
C3, F2, M1
33.25
74.07
0.449
A5, F1, M1
23.68
38.14
0.621
C3, F2, M2
26.75
46.97
0.57
A5, F1, M2
A5, F1, M3
14.36
37.47
0.383
C3, F2, M3
31.8
60.44
0.526
35.1
102.9
0.341
C3, F2, M4
24.31
46.2
0.526
A5, F1, M4
21.48
38.07
0.564
C3, F2, M5
23.54
82.57
0.285
A5, F1, M5
22.01
25.59
0.86
C4, F1, M1
71.74
41.49
1.729
A5, F2, M1
20.18
45.42
0.444
C4, F1, M2
32.2
46.69
0.69
A5, F2, M2
A5, F2, M3
21.57
34.93
0.618
C4, F1, M3
53.69
93.62
0.573
16.51
37.32
0.442
C4, F1, M4
50.98
30.93
1.648
A5, F2, M4
15.13
47.61
0.318
C4, F1, M5
60.65
49.73
1.22
A5, F2, M5
16.46
62.38
0.264
C4, F2, M1
28.81
56.71
0.508
A5, F3, M1
A5, F3, M2
22.67
94.02
0.241
C4, F2, M2
30.79
42.21
0.729
16.48
36.5
0.452
C4, F2, M3
35.89
39.93
0.899
A5, F3, M3
16.13
42.16
0.383
C4, F2, M4
27.98
57.81
0.484
A5, F3, M4
13.64
27.75
0.492
C4, F2, M5
27.57
34.54
0.798
A5, F3, M5
53.25
54.96
0.969
C4, F3, M1
n = 45
C4, F3, M2
47.49
60.07
0.791
C4, F3, M3
52.09
51.01
1.021
A1, A3, A5 = Three rats
C4, F3, M4
49.72
32.51
1.529
F = Field of view
C4, F3, M5
39.42
42.21
0.934
M = Individual macrophages
n = total number of macrophages
n = 50
MFI= Mean fluorescence intensity
C1,C3, C4 = Three rats
F = Field of view
M = Individual macrophages
n = total number of macrophages
MFI= Mean fluorescence intensity
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Table A‐3: Mean fluorescence intensity of COX‐2, CD68 and normalized COX‐2 intensity
(ratio of COX‐2 MFI and CD68 MFI) for CCI rats injected with theranostic and vehicle
nanoemulsion.
CCI with theranostic nanoemulsion COX2 MFI CD68 MFI Ratio of COX2: CD68 MFI CCI with vehicle nanoemulsion COX2 MFI
22.57
28.68
0.787
C1, F1, M1
61.05
A1, F1, M1
20.23
65.39
0.309
C1, F1, M2
14.34
A1, F1, M2
14.28
40.89
0.349
C1, F1, M3
26.88
A1, F1, M3
12.42
49.18
0.253
C1, F1, M4
32.16
A1, F1, M4
12.03
71.58
0.168
C1, F1, M5
30.4
A1, F1, M5
11.41
48.5
0.235
C1, F2, M1
26.2
A1, F2, M1
5.8
25.75
0.225
C1, F2, M2
10.64
A1, F2, M2
6.15
52.43
0.117
C1, F2, M3
24.78
A1, F2, M3
11.61
53.33
0.218
C1, F2, M4
16.96
A1, F2, M4
6.14
32.28
0.19
C1, F2, M5
30.85
A1, F2, M5
7.09
16.28
0.436
C1, F3, M1
25.45
A1, F3, M1
4.74
76.85
0.062
C1, F3, M2
16.62
A1, F3, M2
5.72
42.04
0.136
C1, F3, M3
25.28
A1, F3, M3
7.71
50.32
0.153
C1, F3, M4
21.55
A1, F3, M4
3.62
16
0.226
C1, F3, M5
14.62
A1, F3, M5
9.63
64.16
0.15
C3, F2, M1
15.86
A3, F1, M1
25.69
48.26
0.532
C3, F2, M2
30.78
A3, F1, M2
17.78
59.18
0.3
C3, F2, M3
28.68
A3, F1, M3
15.73
128.92
0.122
C3, F2, M4
15.53
A3, F1, M4
18.23
98.06
0.186
C3, F2, M5
23.08
A3, F1, M5
11.05
39.6
0.279
C3, F1, M1
15.85
A3, F2, M1
11.73
37.32
0.314
C3, F1, M2
15.48
A3, F2, M2
11.04
35.86
0.308
C3, F1, M3
12.7
A3, F2, M3
5.9
33.64
0.175
C3, F1, M4
13.37
A3, F2, M4
8
27.82
0.288
C3, F1, M5
18.04
A3, F2, M5
4
39.29
0.102
C4, F1, M1
23.95
A3, F3, M1
5.73
74.04
0.077
C4, F1, M2
47.86
A3, F3, M2
6.27
34.74
0.18
C4, F1, M3
23.7
A3, F3, M3
10.4
24.66
0.422
C4, F1, M4
39.55
A3, F3, M4
10.77
51.67
0.208
C4, F1, M5
19.5
A3, F3, M5
14.95
23.92
0.625
C4, F2, M1
16.52
A5, F1, M1
11.09
77.96
0.142
C4, F2, M2
14.01
A5, F1, M2
12.78
47.58
0.269
C4, F2, M3
7.86
A5, F1, M3
9
57.41
0.157
C4, F2, M4
40.59
A5, F1, M4
11.88
38.12
0.312
C4, F2, M5
20.68
A5, F1, M5
7.03
41.48
0.169
C4, F3, M1
17.73
A5, F2, M1
3.98
26.34
0.151
C4, F3, M2
21.24
A5, F2, M2
4.88
46.09
0.106
C4, F3, M3
12.89
A5, F2, M3
4.77
20.7
0.23
C4, F3, M4
21.9
A5, F2, M4
7.31
35.07
0.208
C4, F3, M5
15.62
A5, F2, M5
4.18
20.52
0.204
A5, F3, M1
2.83
16.01
0.177
A5, F3, M2
2.28
19.83
0.115
A5, F3, M3
7.97
26.8
0.297
A5, F3, M4
5.14
35.42
0.145
A5, F3, M5
C1,C3, C4 = Three rats
n = 45
F = Field of view
A1, A3, A5 = Three rats
M = Individual macrophages
F = Field of view
n = total number of macrophages
M = Individual macrophages
MFI= Mean fluorescence intensity
n = total number of macrophages
MFI= Mean fluorescence intensity
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CD68 MFI
58.5
71.57
78.49
37.32
46.22
52.92
35.25
51.5
33.22
63.95
42.47
68.27
57.69
39.44
46.6
24.09
42.57
26.65
46.88
49.05
78.22
59.37
49.69
59.13
37.15
51.62
48.84
79.84
44.19
48.78
47.84
38.51
30.46
70.53
84.34
33.1
45.06
24.44
22.24
23.37

Ratio of COX2: CD68 MFI
1.044
0.2
0.342
0.862
0.658
0.495
0.302
0.481
0.511
0.482
0.599
0.243
0.438
0.546
0.314
0.658
0.723
1.076
0.331
0.471
0.203
0.261
0.256
0.226
0.486
0.464
0.98
0.297
0.895
0.4
0.345
0.364
0.258
0.575
0.245
0.536
0.471
0.527
0.985
0.668
n = 40

